NCT03653507: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
- State
- Under way
- Phase
- Phase 3
- People
- 507 taking part
- Started
- 28 Nov 2018
- Primary completion
- 25 Oct 2022
- Arms
- Zolbetuximab plus CAPOX
- Results
- Posted on the registry
- 31 Aug 2018: Trial registered
- 28 Nov 2018: Trial started
- 27 Jan 2025: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Progression Free Survival (PFS)
Primary outcome · Median, Months · From the date of randomization until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | 8.21 (95% Confidence Interval 7.26 to 8.84) |
| CAPOX+ Placebo | 253 | 6.80 (95% Confidence Interval 6.14 to 8.08) |
- p = 0.0005, Log Rank (superiority test); Hazard Ratio (HR) 0.689, 95% interval 0.552 to 0.860. Posted for: CAPOX+ Zolbetuximab
Overall Survival (OS)
Secondary outcome · Median, Months · From the date of randomization until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | 14.32 (95% Confidence Interval 12.09 to 16.39) |
| CAPOX+ Placebo | 253 | 12.16 (95% Confidence Interval 10.28 to 13.67) |
- p = 0.0047, Log Rank (superiority test); Hazard Ratio (HR) 0.763, 95% interval 0.622 to 0.936. Posted for: CAPOX+ Zolbetuximab
Time to Confirmed Deterioration (TTCD) Using Physical Functioning as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
Secondary outcome · Median, Months · From the date of randomization until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | 7.95 (95% Confidence Interval 5.88 to 19.78) |
| CAPOX+ Placebo | 253 | 7.92 (95% Confidence Interval 6.47 to 11.30) |
- p = 0.4654, Log Rank (superiority test); Hazard Ratio (HR) 1.012, 95% interval 0.772 to 1.328. Posted for: CAPOX+ Zolbetuximab
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale
Secondary outcome · Median, Months · From the date of randomization until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | NA (95% Confidence Interval 28.16 to NA) |
| CAPOX+ Placebo | 253 | 25.82 (95% Confidence Interval 18.46 to NA) |
- p = 0.4478, Log Rank (superiority test); Hazard Ratio (HR) 1.030, 95% interval 0.673 to 1.577. Posted for: CAPOX+ Zolbetuximab
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30
Secondary outcome · Median, Months · From the date of randomization until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | 9.40 (95% Confidence Interval 7.36 to 24.80) |
| CAPOX+ Placebo | 253 | 7.49 (95% Confidence Interval 6.11 to 9.86) |
- p = 0.1670, Log Rank (superiority test); Hazard Ratio (HR) 0.869, 95% interval 0.655 to 1.153. Posted for: CAPOX+ Zolbetuximab
Objective Response Rate (ORR)
Secondary outcome · Number, Percentage of Participants · From the date of randomization until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | 42.5 (95% Confidence Interval 36.36 to 48.85) |
| CAPOX+ Placebo | 253 | 39.1 (95% Confidence Interval 33.08 to 45.44) |
- p = 0.2219, Cochran-Mantel-Haenszel (superiority test). Posted for: CAPOX+ Zolbetuximab
Duration Of Response (DOR)
Secondary outcome · Median, Months · From first response (CR/PR) until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 108 | 6.28 (95% Confidence Interval 5.39 to 8.28) |
| CAPOX+ Placebo | 102 | 6.08 (95% Confidence Interval 4.44 to 6.34) |
- p = 0.0826, Log Rank (superiority test); Hazard Ratio (HR) 0.781, 95% interval 0.552 to 1.105. Posted for: CAPOX+ Zolbetuximab
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Secondary outcome · Number, Participants · From first dose until 61 months and 12 days
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab | 254 | 251 (NA to NA) |
| CAPOX+ Placebo | 249 | 244 (NA to NA) |
Number of Participant With Eastern Cooperative Oncology Group (ECOG) Performance Status
Secondary outcome · Number, Participants · Baseline, cycle (C) 1 day (D)1 through C60 D1
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab Baseline Score 0 | 253 | 108 |
| CAPOX+ Placebo Baseline Score 0 | 250 | 108 |
| CAPOX+ Zolbetuximab Baseline Score 1 | 253 | 145 |
| CAPOX+ Placebo Baseline Score 1 | 250 | 142 |
| CAPOX+ Zolbetuximab Baseline Score 2 | 253 | 0 |
| CAPOX+ Placebo Baseline Score 2 | 250 | 0 |
| CAPOX+ Zolbetuximab Baseline Score 3 | 253 | 0 |
| CAPOX+ Placebo Baseline Score 3 | 250 | 0 |
| CAPOX+ Zolbetuximab Baseline Score 4 | 253 | 0 |
| CAPOX+ Placebo Baseline Score 4 | 250 | 0 |
| CAPOX+ Zolbetuximab Baseline Score 5 | 253 | 0 |
| CAPOX+ Placebo Baseline Score 5 | 250 | 0 |
| CAPOX+ Zolbetuximab C2D1 Score 0 | 219 | 85 |
| CAPOX+ Placebo C2D1 Score 0 | 225 | 97 |
| CAPOX+ Zolbetuximab C2D1 Score 1 | 219 | 129 |
| CAPOX+ Placebo C2D1 Score 1 | 225 | 126 |
| CAPOX+ Zolbetuximab C2D1 Score 2 | 219 | 5 |
| CAPOX+ Placebo C2D1 Score 2 | 225 | 2 |
| CAPOX+ Zolbetuximab C2D1 Score 3 | 219 | 0 |
| CAPOX+ Placebo C2D1 Score 3 | 225 | 0 |
| CAPOX+ Zolbetuximab C2D1 Score 4 | 219 | 0 |
| CAPOX+ Placebo C2D1 Score 4 | 225 | 0 |
| CAPOX+ Zolbetuximab C2D1 Score 5 | 219 | 0 |
| CAPOX+ Placebo C2D1 Score 5 | 225 | 0 |
| CAPOX+ Zolbetuximab C3D1 Score 0 | 196 | 80 |
| CAPOX+ Placebo C3D1 Score 0 | 210 | 91 |
| CAPOX+ Zolbetuximab C3D1 Score 1 | 196 | 116 |
| CAPOX+ Placebo C3D1 Score 1 | 210 | 117 |
| CAPOX+ Zolbetuximab C3D1 Score 2 | 196 | 0 |
| CAPOX+ Placebo C3D1 Score 2 | 210 | 2 |
| CAPOX+ Zolbetuximab C3D1 Score 3 | 196 | 0 |
| CAPOX+ Placebo C3D1 Score 3 | 210 | 0 |
| CAPOX+ Zolbetuximab C3D1 Score 4 | 196 | 0 |
| CAPOX+ Placebo C3D1 Score 4 | 210 | 0 |
| CAPOX+ Zolbetuximab C3D1 Score 5 | 196 | 0 |
| CAPOX+ Placebo C3D1 Score 5 | 210 | 0 |
| CAPOX+ Zolbetuximab C4D1 Score 0 | 180 | 74 |
| CAPOX+ Placebo C4D1 Score 0 | 179 | 79 |
| CAPOX+ Zolbetuximab C4D1 Score 1 | 180 | 106 |
| CAPOX+ Placebo C4D1 Score 1 | 179 | 98 |
| CAPOX+ Zolbetuximab C4D1 Score 2 | 180 | 0 |
| CAPOX+ Placebo C4D1 Score 2 | 179 | 2 |
| CAPOX+ Zolbetuximab C4D1 Score 3 | 180 | 0 |
| CAPOX+ Placebo C4D1 Score 3 | 179 | 0 |
| CAPOX+ Zolbetuximab C4D1 Score 4 | 180 | 0 |
| CAPOX+ Placebo C4D1 Score 4 | 179 | 0 |
| CAPOX+ Zolbetuximab C4D1 Score 5 | 180 | 0 |
| CAPOX+ Placebo C4D1 Score 5 | 179 | 0 |
| CAPOX+ Zolbetuximab C5D1 Score 0 | 168 | 68 |
| CAPOX+ Placebo C5D1 Score 0 | 175 | 75 |
| CAPOX+ Zolbetuximab C5D1 Score 1 | 168 | 98 |
| CAPOX+ Placebo C5D1 Score 1 | 175 | 98 |
| CAPOX+ Zolbetuximab C5D1 Score 2 | 168 | 2 |
| CAPOX+ Placebo C5D1 Score 2 | 175 | 2 |
| CAPOX+ Zolbetuximab C5D1 Score 3 | 168 | 0 |
| CAPOX+ Placebo C5D1 Score 3 | 175 | 0 |
| CAPOX+ Zolbetuximab C5D1 Score 4 | 168 | 0 |
| CAPOX+ Placebo C5D1 Score 4 | 175 | 0 |
| CAPOX+ Zolbetuximab C5D1 Score 5 | 168 | 0 |
| CAPOX+ Placebo C5D1 Score 5 | 175 | 0 |
| CAPOX+ Zolbetuximab C6D1 Score 0 | 159 | 71 |
| CAPOX+ Placebo C6D1 Score 0 | 156 | 72 |
| CAPOX+ Zolbetuximab C6D1 Score 1 | 159 | 86 |
| CAPOX+ Placebo C6D1 Score 1 | 156 | 80 |
| CAPOX+ Zolbetuximab C6D1 Score 2 | 159 | 2 |
| CAPOX+ Placebo C6D1 Score 2 | 156 | 3 |
| CAPOX+ Zolbetuximab C6D1 Score 3 | 159 | 0 |
| CAPOX+ Placebo C6D1 Score 3 | 156 | 1 |
| CAPOX+ Zolbetuximab C6D1 Score 4 | 159 | 0 |
| CAPOX+ Placebo C6D1 Score 4 | 156 | 0 |
| CAPOX+ Zolbetuximab C6D1 Score 5 | 159 | 0 |
| CAPOX+ Placebo C6D1 Score 5 | 156 | 0 |
| CAPOX+ Zolbetuximab C7D1 Score 0 | 122 | 52 |
| CAPOX+ Placebo C7D1 Score 0 | 136 | 60 |
| CAPOX+ Zolbetuximab C7D1 Score 1 | 122 | 67 |
| CAPOX+ Placebo C7D1 Score 1 | 136 | 76 |
| CAPOX+ Zolbetuximab C7D1 Score 2 | 122 | 2 |
| CAPOX+ Placebo C7D1 Score 2 | 136 | 0 |
| CAPOX+ Zolbetuximab C7D1 Score 3 | 122 | 1 |
| CAPOX+ Placebo C7D1 Score 3 | 136 | 0 |
| CAPOX+ Zolbetuximab C7D1 Score 4 | 122 | 0 |
| CAPOX+ Placebo C7D1 Score 4 | 136 | 0 |
| CAPOX+ Zolbetuximab C7D1 Score 5 | 122 | 0 |
| CAPOX+ Placebo C7D1 Score 5 | 136 | 0 |
| CAPOX+ Zolbetuximab C8D1 Score 0 | 113 | 49 |
| CAPOX+ Placebo C8D1 Score 0 | 114 | 44 |
| CAPOX+ Zolbetuximab C8D1 Score 1 | 113 | 63 |
| CAPOX+ Placebo C8D1 Score 1 | 114 | 70 |
| CAPOX+ Zolbetuximab C8D1 Score 2 | 113 | 1 |
| CAPOX+ Placebo C8D1 Score 2 | 114 | 0 |
| CAPOX+ Zolbetuximab C8D1 Score 3 | 113 | 0 |
| CAPOX+ Placebo C8D1 Score 3 | 114 | 0 |
| CAPOX+ Zolbetuximab C8D1 Score 4 | 113 | 0 |
| CAPOX+ Placebo C8D1 Score 4 | 114 | 0 |
| CAPOX+ Zolbetuximab C8D1 Score 5 | 113 | 0 |
| CAPOX+ Placebo C8D1 Score 5 | 114 | 0 |
| CAPOX+ Zolbetuximab C9D1 Score 0 | 106 | 47 |
| CAPOX+ Placebo C9D1 Score 0 | 106 | 47 |
| CAPOX+ Zolbetuximab C9D1 Score 1 | 106 | 57 |
| CAPOX+ Placebo C9D1 Score 1 | 106 | 59 |
| CAPOX+ Zolbetuximab C9D1 Score 2 | 106 | 2 |
| CAPOX+ Placebo C9D1 Score 2 | 106 | 0 |
| CAPOX+ Zolbetuximab C9D1 Score 3 | 106 | 0 |
| CAPOX+ Placebo C9D1 Score 3 | 106 | 0 |
| CAPOX+ Zolbetuximab C9D1 Score 4 | 106 | 0 |
| CAPOX+ Placebo C9D1 Score 4 | 106 | 0 |
| CAPOX+ Zolbetuximab C9D1 Score 5 | 106 | 0 |
| CAPOX+ Placebo C9D1 Score 5 | 106 | 0 |
| CAPOX+ Zolbetuximab C10D1 Score 0 | 88 | 39 |
| CAPOX+ Placebo C10D1 Score 0 | 84 | 40 |
| CAPOX+ Zolbetuximab C10D1 Score 1 | 88 | 47 |
| CAPOX+ Placebo C10D1 Score 1 | 84 | 44 |
| CAPOX+ Zolbetuximab C10D1 Score 2 | 88 | 2 |
| CAPOX+ Placebo C10D1 Score 2 | 84 | 0 |
| CAPOX+ Zolbetuximab C10D1 Score 3 | 88 | 0 |
| CAPOX+ Placebo C10D1 Score 3 | 84 | 0 |
| CAPOX+ Zolbetuximab C10D1 Score 4 | 88 | 0 |
| CAPOX+ Placebo C10D1 Score 4 | 84 | 0 |
| CAPOX+ Zolbetuximab C10D1 Score 5 | 88 | 0 |
| CAPOX+ Placebo C10D1 Score 5 | 84 | 0 |
| CAPOX+ Zolbetuximab C11D1 Score 0 | 86 | 41 |
| CAPOX+ Placebo C11D1 Score 0 | 77 | 34 |
| CAPOX+ Zolbetuximab C11D1 Score 1 | 86 | 45 |
| CAPOX+ Placebo C11D1 Score 1 | 77 | 43 |
| CAPOX+ Zolbetuximab C11D1 Score 2 | 86 | 0 |
| CAPOX+ Placebo C11D1 Score 2 | 77 | 0 |
| CAPOX+ Zolbetuximab C11D1 Score 3 | 86 | 0 |
| CAPOX+ Placebo C11D1 Score 3 | 77 | 0 |
| CAPOX+ Zolbetuximab C11D1 Score 4 | 86 | 0 |
| CAPOX+ Placebo C11D1 Score 4 | 77 | 0 |
| CAPOX+ Zolbetuximab C11D1 Score 5 | 86 | 0 |
| CAPOX+ Placebo C11D1 Score 5 | 77 | 0 |
| CAPOX+ Zolbetuximab C12D1 Score 0 | 77 | 39 |
| CAPOX+ Placebo C12D1 Score 0 | 65 | 29 |
| CAPOX+ Zolbetuximab C12D1 Score 1 | 77 | 38 |
| CAPOX+ Placebo C12D1 Score 1 | 65 | 36 |
| CAPOX+ Zolbetuximab C12D1 Score 2 | 77 | 0 |
| CAPOX+ Placebo C12D1 Score 2 | 65 | 0 |
| CAPOX+ Zolbetuximab C12D1 Score 3 | 77 | 0 |
| CAPOX+ Placebo C12D1 Score 3 | 65 | 0 |
| CAPOX+ Zolbetuximab C12D1 Score 4 | 77 | 0 |
| CAPOX+ Placebo C12D1 Score 4 | 65 | 0 |
| CAPOX+ Zolbetuximab C12D1 Score 5 | 77 | 0 |
| CAPOX+ Placebo C12D1 Score 5 | 65 | 0 |
| CAPOX+ Zolbetuximab C13D1 Score 0 | 67 | 33 |
| CAPOX+ Placebo C13D1 Score 0 | 54 | 24 |
| CAPOX+ Zolbetuximab C13D1 Score 1 | 67 | 34 |
| CAPOX+ Placebo C13D1 Score 1 | 54 | 30 |
| CAPOX+ Zolbetuximab C13D1 Score 2 | 67 | 0 |
| CAPOX+ Placebo C13D1 Score 2 | 54 | 0 |
| CAPOX+ Zolbetuximab C13D1 Score 3 | 67 | 0 |
| CAPOX+ Placebo C13D1 Score 3 | 54 | 0 |
| CAPOX+ Zolbetuximab C13D1 Score 4 | 67 | 0 |
| CAPOX+ Placebo C13D1 Score 4 | 54 | 0 |
| CAPOX+ Zolbetuximab C13D1 Score 5 | 67 | 0 |
| CAPOX+ Placebo C13D1 Score 5 | 54 | 0 |
| CAPOX+ Zolbetuximab C14D1 Score 0 | 64 | 32 |
| CAPOX+ Placebo C14D1 Score 0 | 48 | 20 |
| CAPOX+ Zolbetuximab C14D1 Score 1 | 64 | 32 |
| CAPOX+ Placebo C14D1 Score 1 | 48 | 28 |
| CAPOX+ Zolbetuximab C14D1 Score 2 | 64 | 0 |
| CAPOX+ Placebo C14D1 Score 2 | 48 | 0 |
| CAPOX+ Zolbetuximab C14D1 Score 3 | 64 | 0 |
| CAPOX+ Placebo C14D1 Score 3 | 48 | 0 |
| CAPOX+ Zolbetuximab C14D1 Score 4 | 64 | 0 |
| CAPOX+ Placebo C14D1 Score 4 | 48 | 0 |
| CAPOX+ Zolbetuximab C14D1 Score 5 | 64 | 0 |
| CAPOX+ Placebo C14D1 Score 5 | 48 | 0 |
| CAPOX+ Zolbetuximab C15D1 Score 0 | 54 | 24 |
| CAPOX+ Placebo C15D1 Score 0 | 41 | 16 |
| CAPOX+ Zolbetuximab C15D1 Score 1 | 54 | 30 |
| CAPOX+ Placebo C15D1 Score 1 | 41 | 25 |
| CAPOX+ Zolbetuximab C15D1 Score 2 | 54 | 0 |
| CAPOX+ Placebo C15D1 Score 2 | 41 | 0 |
| CAPOX+ Zolbetuximab C15D1 Score 3 | 54 | 0 |
| CAPOX+ Placebo C15D1 Score 3 | 41 | 0 |
| CAPOX+ Zolbetuximab C15D1 Score 4 | 54 | 0 |
| CAPOX+ Placebo C15D1 Score 4 | 41 | 0 |
| CAPOX+ Zolbetuximab C15D1 Score 5 | 54 | 0 |
| CAPOX+ Placebo C15D1 Score 5 | 41 | 0 |
| CAPOX+ Zolbetuximab C16D1 Score 0 | 51 | 23 |
| CAPOX+ Placebo C16D1 Score 0 | 35 | 18 |
| CAPOX+ Zolbetuximab C16D1 Score 1 | 51 | 27 |
| CAPOX+ Placebo C16D1 Score 1 | 35 | 17 |
| CAPOX+ Zolbetuximab C16D1 Score 2 | 51 | 1 |
| CAPOX+ Placebo C16D1 Score 2 | 35 | 0 |
| CAPOX+ Zolbetuximab C16D1 Score 3 | 51 | 0 |
| CAPOX+ Placebo C16D1 Score 3 | 35 | 0 |
| CAPOX+ Zolbetuximab C16D1 Score 4 | 51 | 0 |
| CAPOX+ Placebo C16D1 Score 4 | 35 | 0 |
| CAPOX+ Zolbetuximab C16D1 Score 5 | 51 | 0 |
| CAPOX+ Placebo C16D1 Score 5 | 35 | 0 |
| CAPOX+ Zolbetuximab C17D1 Score 0 | 47 | 22 |
| CAPOX+ Placebo C17D1 Score 0 | 29 | 17 |
| CAPOX+ Zolbetuximab C17D1 Score 1 | 47 | 24 |
| CAPOX+ Placebo C17D1 Score 1 | 29 | 12 |
| CAPOX+ Zolbetuximab C17D1 Score 2 | 47 | 1 |
| CAPOX+ Placebo C17D1 Score 2 | 29 | 0 |
| CAPOX+ Zolbetuximab C17D1 Score 3 | 47 | 0 |
| CAPOX+ Placebo C17D1 Score 3 | 29 | 0 |
| CAPOX+ Zolbetuximab C17D1 Score 4 | 47 | 0 |
| CAPOX+ Placebo C17D1 Score 4 | 29 | 0 |
| CAPOX+ Zolbetuximab C17D1 Score 5 | 47 | 0 |
| CAPOX+ Placebo C17D1 Score 5 | 29 | 0 |
| CAPOX+ Zolbetuximab C18D1 Score 0 | 47 | 26 |
| CAPOX+ Placebo C18D1 Score 0 | 24 | 16 |
| CAPOX+ Zolbetuximab C18D1 Score 1 | 47 | 21 |
| CAPOX+ Placebo C18D1 Score 1 | 24 | 8 |
| CAPOX+ Zolbetuximab C18D1 Score 2 | 47 | 0 |
| CAPOX+ Placebo C18D1 Score 2 | 24 | 0 |
| CAPOX+ Zolbetuximab C18D1 Score 3 | 47 | 0 |
| CAPOX+ Placebo C18D1 Score 3 | 24 | 0 |
| CAPOX+ Zolbetuximab C18D1 Score 4 | 47 | 0 |
| CAPOX+ Placebo C18D1 Score 4 | 24 | 0 |
| CAPOX+ Zolbetuximab C18D1 Score 5 | 47 | 0 |
| CAPOX+ Placebo C18D1 Score 5 | 24 | 0 |
| CAPOX+ Zolbetuximab C19D1 Score 0 | 43 | 22 |
| CAPOX+ Placebo C19D1 Score 0 | 22 | 14 |
| CAPOX+ Zolbetuximab C19D1 Score 1 | 43 | 21 |
| CAPOX+ Placebo C19D1 Score 1 | 22 | 8 |
| CAPOX+ Zolbetuximab C19D1 Score 2 | 43 | 0 |
| CAPOX+ Placebo C19D1 Score 2 | 22 | 0 |
| CAPOX+ Zolbetuximab C19D1 Score 3 | 43 | 0 |
| CAPOX+ Placebo C19D1 Score 3 | 22 | 0 |
| CAPOX+ Zolbetuximab C19D1 Score 4 | 43 | 0 |
| CAPOX+ Placebo C19D1 Score 4 | 22 | 0 |
| CAPOX+ Zolbetuximab C19D1 Score 5 | 43 | 0 |
| CAPOX+ Placebo C19D1 Score 5 | 22 | 0 |
| CAPOX+ Zolbetuximab C20D1 Score 0 | 43 | 24 |
| CAPOX+ Placebo C20D1 Score 0 | 21 | 15 |
| CAPOX+ Zolbetuximab C20D1 Score 1 | 43 | 19 |
| CAPOX+ Placebo C20D1 Score 1 | 21 | 6 |
| CAPOX+ Zolbetuximab C20D1 Score 2 | 43 | 0 |
| CAPOX+ Placebo C20D1 Score 2 | 21 | 0 |
| CAPOX+ Zolbetuximab C20D1 Score 3 | 43 | 0 |
| CAPOX+ Placebo C20D1 Score 3 | 21 | 0 |
| CAPOX+ Zolbetuximab C20D1 Score 4 | 43 | 0 |
| CAPOX+ Placebo C20D1 Score 4 | 21 | 0 |
| CAPOX+ Zolbetuximab C20D1 Score 5 | 43 | 0 |
| CAPOX+ Placebo C20D1 Score 5 | 21 | 0 |
| CAPOX+ Zolbetuximab C21D1 Score 0 | 40 | 23 |
| CAPOX+ Placebo C21D1 Score 0 | 22 | 15 |
| CAPOX+ Zolbetuximab C21D1 Score 1 | 40 | 17 |
| CAPOX+ Placebo C21D1 Score 1 | 22 | 7 |
| CAPOX+ Zolbetuximab C21D1 Score 2 | 40 | 0 |
| CAPOX+ Placebo C21D1 Score 2 | 22 | 0 |
| CAPOX+ Zolbetuximab C21D1 Score 3 | 40 | 0 |
| CAPOX+ Placebo C21D1 Score 3 | 22 | 0 |
| CAPOX+ Zolbetuximab C21D1 Score 4 | 40 | 0 |
| CAPOX+ Placebo C21D1 Score 4 | 22 | 0 |
| CAPOX+ Zolbetuximab C21D1 Score 5 | 40 | 0 |
| CAPOX+ Placebo C21D1 Score 5 | 22 | 0 |
| CAPOX+ Zolbetuximab C22D1 Score 0 | 33 | 17 |
| CAPOX+ Placebo C22D1 Score 0 | 17 | 12 |
| CAPOX+ Zolbetuximab C22D1 Score 1 | 33 | 15 |
| CAPOX+ Placebo C22D1 Score 1 | 17 | 5 |
| CAPOX+ Zolbetuximab C22D1 Score 2 | 33 | 1 |
| CAPOX+ Placebo C22D1 Score 2 | 17 | 0 |
| CAPOX+ Zolbetuximab C22D1 Score 3 | 33 | 0 |
| CAPOX+ Placebo C22D1 Score 3 | 17 | 0 |
| CAPOX+ Zolbetuximab C22D1 Score 4 | 33 | 0 |
| CAPOX+ Placebo C22D1 Score 4 | 17 | 0 |
| CAPOX+ Zolbetuximab C22D1 Score 5 | 33 | 0 |
| CAPOX+ Placebo C22D1 Score 5 | 17 | 0 |
| CAPOX+ Zolbetuximab C23D1 Score 0 | 34 | 20 |
| CAPOX+ Placebo C23D1 Score 0 | 18 | 14 |
| CAPOX+ Zolbetuximab C23D1 Score 1 | 34 | 14 |
| CAPOX+ Placebo C23D1 Score 1 | 18 | 4 |
| CAPOX+ Zolbetuximab C23D1 Score 2 | 34 | 0 |
| CAPOX+ Placebo C23D1 Score 2 | 18 | 0 |
| CAPOX+ Zolbetuximab C23D1 Score 3 | 34 | 0 |
| CAPOX+ Placebo C23D1 Score 3 | 18 | 0 |
| CAPOX+ Zolbetuximab C23D1 Score 4 | 34 | 0 |
| CAPOX+ Placebo C23D1 Score 4 | 18 | 0 |
| CAPOX+ Zolbetuximab C23D1 Score 5 | 34 | 0 |
| CAPOX+ Placebo C23D1 Score 5 | 18 | 0 |
| CAPOX+ Zolbetuximab C24D1 Score 0 | 32 | 19 |
| CAPOX+ Placebo C24D1 Score 0 | 16 | 11 |
| CAPOX+ Zolbetuximab C24D1 Score 1 | 32 | 13 |
| CAPOX+ Placebo C24D1 Score 1 | 16 | 5 |
| CAPOX+ Zolbetuximab C24D1 Score 2 | 32 | 0 |
| CAPOX+ Placebo C24D1 Score 2 | 16 | 0 |
| CAPOX+ Zolbetuximab C24D1 Score 3 | 32 | 0 |
| CAPOX+ Placebo C24D1 Score 3 | 16 | 0 |
| CAPOX+ Zolbetuximab C24D1 Score 4 | 32 | 0 |
| CAPOX+ Placebo C24D1 Score 4 | 16 | 0 |
| CAPOX+ Zolbetuximab C24D1 Score 5 | 32 | 0 |
| CAPOX+ Placebo C24D1 Score 5 | 16 | 0 |
| CAPOX+ Zolbetuximab C25D1 Score 0 | 31 | 17 |
| CAPOX+ Placebo C25D1 Score 0 | 16 | 11 |
| CAPOX+ Zolbetuximab C25D1 Score 1 | 31 | 14 |
| CAPOX+ Placebo C25D1 Score 1 | 16 | 5 |
| CAPOX+ Zolbetuximab C25D1 Score 2 | 31 | 0 |
| CAPOX+ Placebo C25D1 Score 2 | 16 | 0 |
| CAPOX+ Zolbetuximab C25D1 Score 3 | 31 | 0 |
| CAPOX+ Placebo C25D1 Score 3 | 16 | 0 |
| CAPOX+ Zolbetuximab C25D1 Score 4 | 31 | 0 |
| CAPOX+ Placebo C25D1 Score 4 | 16 | 0 |
| CAPOX+ Zolbetuximab C25D1 Score 5 | 31 | 0 |
| CAPOX+ Placebo C25D1 Score 5 | 16 | 0 |
| CAPOX+ Zolbetuximab C26D1 Score 0 | 30 | 19 |
| CAPOX+ Placebo C26D1 Score 0 | 12 | 8 |
| CAPOX+ Zolbetuximab C26D1 Score 1 | 30 | 11 |
| CAPOX+ Placebo C26D1 Score 1 | 12 | 4 |
| CAPOX+ Zolbetuximab C26D1 Score 2 | 30 | 0 |
| CAPOX+ Placebo C26D1 Score 2 | 12 | 0 |
| CAPOX+ Zolbetuximab C26D1 Score 3 | 30 | 0 |
| CAPOX+ Placebo C26D1 Score 3 | 12 | 0 |
| CAPOX+ Zolbetuximab C26D1 Score 4 | 30 | 0 |
| CAPOX+ Placebo C26D1 Score 4 | 12 | 0 |
| CAPOX+ Zolbetuximab C26D1 Score 5 | 30 | 0 |
| CAPOX+ Placebo C26D1 Score 5 | 12 | 0 |
| CAPOX+ Zolbetuximab C27D1 Score 0 | 28 | 17 |
| CAPOX+ Placebo C27D1 Score 0 | 12 | 8 |
| CAPOX+ Zolbetuximab C27D1 Score 1 | 28 | 11 |
| CAPOX+ Placebo C27D1 Score 1 | 12 | 4 |
| CAPOX+ Zolbetuximab C27D1 Score 2 | 28 | 0 |
| CAPOX+ Placebo C27D1 Score 2 | 12 | 0 |
| CAPOX+ Zolbetuximab C27D1 Score 3 | 28 | 0 |
| CAPOX+ Placebo C27D1 Score 3 | 12 | 0 |
| CAPOX+ Zolbetuximab C27D1 Score 4 | 28 | 0 |
| CAPOX+ Placebo C27D1 Score 4 | 12 | 0 |
| CAPOX+ Zolbetuximab C27D1 Score 5 | 28 | 0 |
| CAPOX+ Placebo C27D1 Score 5 | 12 | 0 |
| CAPOX+ Zolbetuximab C28D1 Score 0 | 24 | 17 |
| CAPOX+ Placebo C28D1 Score 0 | 12 | 8 |
| CAPOX+ Zolbetuximab C28D1 Score 1 | 24 | 7 |
| CAPOX+ Placebo C28D1 Score 1 | 12 | 4 |
| CAPOX+ Zolbetuximab C28D1 Score 2 | 24 | 0 |
| CAPOX+ Placebo C28D1 Score 2 | 12 | 0 |
| CAPOX+ Zolbetuximab C28D1 Score 3 | 24 | 0 |
| CAPOX+ Placebo C28D1 Score 3 | 12 | 0 |
| CAPOX+ Zolbetuximab C28D1 Score 4 | 24 | 0 |
| CAPOX+ Placebo C28D1 Score 4 | 12 | 0 |
| CAPOX+ Zolbetuximab C28D1 Score 5 | 24 | 0 |
| CAPOX+ Placebo C28D1 Score 5 | 12 | 0 |
| CAPOX+ Zolbetuximab C29D1 Score 0 | 24 | 17 |
| CAPOX+ Placebo C29D1 Score 0 | 12 | 8 |
| CAPOX+ Zolbetuximab C29D1 Score 1 | 24 | 7 |
| CAPOX+ Placebo C29D1 Score 1 | 12 | 4 |
| CAPOX+ Zolbetuximab C29D1 Score 2 | 24 | 0 |
| CAPOX+ Placebo C29D1 Score 2 | 12 | 0 |
| CAPOX+ Zolbetuximab C29D1 Score 3 | 24 | 0 |
| CAPOX+ Placebo C29D1 Score 3 | 12 | 0 |
| CAPOX+ Zolbetuximab C29D1 Score 4 | 24 | 0 |
| CAPOX+ Placebo C29D1 Score 4 | 12 | 0 |
| CAPOX+ Zolbetuximab C29D1 Score 5 | 24 | 0 |
| CAPOX+ Placebo C29D1 Score 5 | 12 | 0 |
| CAPOX+ Zolbetuximab C30D1 Score 0 | 22 | 15 |
| CAPOX+ Placebo C30D1 Score 0 | 8 | 4 |
| CAPOX+ Zolbetuximab C30D1 Score 1 | 22 | 7 |
| CAPOX+ Placebo C30D1 Score 1 | 8 | 4 |
| CAPOX+ Zolbetuximab C30D1 Score 2 | 22 | 0 |
| CAPOX+ Placebo C30D1 Score 2 | 8 | 0 |
| CAPOX+ Zolbetuximab C30D1 Score 3 | 22 | 0 |
| CAPOX+ Placebo C30D1 Score 3 | 8 | 0 |
| CAPOX+ Zolbetuximab C30D1 Score 4 | 22 | 0 |
| CAPOX+ Placebo C30D1 Score 4 | 8 | 0 |
| CAPOX+ Zolbetuximab C30D1 Score 5 | 22 | 0 |
| CAPOX+ Placebo C30D1 Score 5 | 8 | 0 |
| CAPOX+ Zolbetuximab C31D1 Score 0 | 22 | 15 |
| CAPOX+ Placebo C31D1 Score 0 | 7 | 3 |
| CAPOX+ Zolbetuximab C31D1 Score 1 | 22 | 7 |
| CAPOX+ Placebo C31D1 Score 1 | 7 | 4 |
| CAPOX+ Zolbetuximab C31D1 Score 2 | 22 | 0 |
| CAPOX+ Placebo C31D1 Score 2 | 7 | 0 |
| CAPOX+ Zolbetuximab C31D1 Score 3 | 22 | 0 |
| CAPOX+ Placebo C31D1 Score 3 | 7 | 0 |
| CAPOX+ Zolbetuximab C31D1 Score 4 | 22 | 0 |
| CAPOX+ Placebo C31D1 Score 4 | 7 | 0 |
| CAPOX+ Zolbetuximab C31D1 Score 5 | 22 | 0 |
| CAPOX+ Placebo C31D1 Score 5 | 7 | 0 |
| CAPOX+ Zolbetuximab C32D1 Score 0 | 19 | 13 |
| CAPOX+ Placebo C32D1 Score 0 | 8 | 4 |
| CAPOX+ Zolbetuximab C32D1 Score 1 | 19 | 6 |
| CAPOX+ Placebo C32D1 Score 1 | 8 | 4 |
| CAPOX+ Zolbetuximab C32D1 Score 2 | 19 | 0 |
| CAPOX+ Placebo C32D1 Score 2 | 8 | 0 |
| CAPOX+ Zolbetuximab C32D1 Score 3 | 19 | 0 |
| CAPOX+ Placebo C32D1 Score 3 | 8 | 0 |
| CAPOX+ Zolbetuximab C32D1 Score 4 | 19 | 0 |
| CAPOX+ Placebo C32D1 Score 4 | 8 | 0 |
| CAPOX+ Zolbetuximab C32D1 Score 5 | 19 | 0 |
| CAPOX+ Placebo C32D1 Score 5 | 8 | 0 |
| CAPOX+ Zolbetuximab C33D1 Score 0 | 16 | 11 |
| CAPOX+ Placebo C33D1 Score 0 | 7 | 4 |
| CAPOX+ Zolbetuximab C33D1 Score 1 | 16 | 5 |
| CAPOX+ Placebo C33D1 Score 1 | 7 | 3 |
| CAPOX+ Zolbetuximab C33D1 Score 2 | 16 | 0 |
| CAPOX+ Placebo C33D1 Score 2 | 7 | 0 |
| CAPOX+ Zolbetuximab C33D1 Score 3 | 16 | 0 |
| CAPOX+ Placebo C33D1 Score 3 | 7 | 0 |
| CAPOX+ Zolbetuximab C33D1 Score 4 | 16 | 0 |
| CAPOX+ Placebo C33D1 Score 4 | 7 | 0 |
| CAPOX+ Zolbetuximab C33D1 Score 5 | 16 | 0 |
| CAPOX+ Placebo C33D1 Score 5 | 7 | 0 |
| CAPOX+ Zolbetuximab C34D1 Score 0 | 14 | 11 |
| CAPOX+ Placebo C34D1 Score 0 | 7 | 4 |
| CAPOX+ Zolbetuximab C34D1 Score 1 | 14 | 3 |
| CAPOX+ Placebo C34D1 Score 1 | 7 | 3 |
| CAPOX+ Zolbetuximab C34D1 Score 2 | 14 | 0 |
| CAPOX+ Placebo C34D1 Score 2 | 7 | 0 |
| CAPOX+ Zolbetuximab C34D1 Score 3 | 14 | 0 |
| CAPOX+ Placebo C34D1 Score 3 | 7 | 0 |
| CAPOX+ Zolbetuximab C34D1 Score 4 | 14 | 0 |
| CAPOX+ Placebo C34D1 Score 4 | 7 | 0 |
| CAPOX+ Zolbetuximab C34D1 Score 5 | 14 | 0 |
| CAPOX+ Placebo C34D1 Score 5 | 7 | 0 |
| CAPOX+ Zolbetuximab C35D1 Score 0 | 15 | 10 |
| CAPOX+ Placebo C35D1 Score 0 | 6 | 3 |
| CAPOX+ Zolbetuximab C35D1 Score 1 | 15 | 5 |
| CAPOX+ Placebo C35D1 Score 1 | 6 | 3 |
| CAPOX+ Zolbetuximab C35D1 Score 2 | 15 | 0 |
| CAPOX+ Placebo C35D1 Score 2 | 6 | 0 |
| CAPOX+ Zolbetuximab C35D1 Score 3 | 15 | 0 |
| CAPOX+ Placebo C35D1 Score 3 | 6 | 0 |
| CAPOX+ Zolbetuximab C35D1 Score 4 | 15 | 0 |
| CAPOX+ Placebo C35D1 Score 4 | 6 | 0 |
| CAPOX+ Zolbetuximab C35D1 Score 5 | 15 | 0 |
| CAPOX+ Placebo C35D1 Score 5 | 6 | 0 |
| CAPOX+ Zolbetuximab C36D1 Score 0 | 16 | 10 |
| CAPOX+ Placebo C36D1 Score 0 | 4 | 1 |
| CAPOX+ Zolbetuximab C36D1 Score 1 | 16 | 6 |
| CAPOX+ Placebo C36D1 Score 1 | 4 | 3 |
| CAPOX+ Zolbetuximab C36D1 Score 2 | 16 | 0 |
| CAPOX+ Placebo C36D1 Score 2 | 4 | 0 |
| CAPOX+ Zolbetuximab C36D1 Score 3 | 16 | 0 |
| CAPOX+ Placebo C36D1 Score 3 | 4 | 0 |
| CAPOX+ Zolbetuximab C36D1 Score 4 | 16 | 0 |
| CAPOX+ Placebo C36D1 Score 4 | 4 | 0 |
| CAPOX+ Zolbetuximab C36D1 Score 5 | 16 | 0 |
| CAPOX+ Placebo C36D1 Score 5 | 4 | 0 |
| CAPOX+ Zolbetuximab C37D1 Score 0 | 14 | 9 |
| CAPOX+ Placebo C37D1 Score 0 | 4 | 3 |
| CAPOX+ Zolbetuximab C37D1 Score 1 | 14 | 5 |
| CAPOX+ Placebo C37D1 Score 1 | 4 | 1 |
| CAPOX+ Zolbetuximab C37D1 Score 2 | 14 | 0 |
| CAPOX+ Placebo C37D1 Score 2 | 4 | 0 |
| CAPOX+ Zolbetuximab C37D1 Score 3 | 14 | 0 |
| CAPOX+ Placebo C37D1 Score 3 | 4 | 0 |
| CAPOX+ Zolbetuximab C37D1 Score 4 | 14 | 0 |
| CAPOX+ Placebo C37D1 Score 4 | 4 | 0 |
| CAPOX+ Zolbetuximab C37D1 Score 5 | 14 | 0 |
| CAPOX+ Placebo C37D1 Score 5 | 4 | 0 |
| CAPOX+ Zolbetuximab C38D1 Score 0 | 13 | 8 |
| CAPOX+ Placebo C38D1 Score 0 | 3 | 2 |
| CAPOX+ Zolbetuximab C38D1 Score 1 | 13 | 5 |
| CAPOX+ Placebo C38D1 Score 1 | 3 | 1 |
| CAPOX+ Zolbetuximab C38D1 Score 2 | 13 | 0 |
| CAPOX+ Placebo C38D1 Score 2 | 3 | 0 |
| CAPOX+ Zolbetuximab C38D1 Score 3 | 13 | 0 |
| CAPOX+ Placebo C38D1 Score 3 | 3 | 0 |
| CAPOX+ Zolbetuximab C38D1 Score 4 | 13 | 0 |
| CAPOX+ Placebo C38D1 Score 4 | 3 | 0 |
| CAPOX+ Zolbetuximab C38D1 Score 5 | 13 | 0 |
| CAPOX+ Placebo C38D1 Score 5 | 3 | 0 |
| CAPOX+ Zolbetuximab C39D1 Score 0 | 11 | 8 |
| CAPOX+ Placebo C39D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C39D1 Score 1 | 11 | 3 |
| CAPOX+ Placebo C39D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C39D1 Score 2 | 11 | 0 |
| CAPOX+ Placebo C39D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C39D1 Score 3 | 11 | 0 |
| CAPOX+ Placebo C39D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C39D1 Score 4 | 11 | 0 |
| CAPOX+ Placebo C39D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C39D1 Score 5 | 11 | 0 |
| CAPOX+ Placebo C39D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C40D1 Score 0 | 11 | 8 |
| CAPOX+ Placebo C40D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C40D1 Score 1 | 11 | 3 |
| CAPOX+ Placebo C40D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C40D1 Score 2 | 11 | 0 |
| CAPOX+ Placebo C40D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C40D1 Score 3 | 11 | 0 |
| CAPOX+ Placebo C40D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C40D1 Score 4 | 11 | 0 |
| CAPOX+ Placebo C40D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C40D1 Score 5 | 11 | 0 |
| CAPOX+ Placebo C40D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C41D1 Score 0 | 11 | 8 |
| CAPOX+ Placebo C41D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C41D1 Score 1 | 11 | 3 |
| CAPOX+ Placebo C41D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C41D1 Score 2 | 11 | 0 |
| CAPOX+ Placebo C41D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C41D1 Score 3 | 11 | 0 |
| CAPOX+ Placebo C41D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C41D1 Score 4 | 11 | 0 |
| CAPOX+ Placebo C41D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C41D1 Score 5 | 11 | 0 |
| CAPOX+ Placebo C41D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C42D1 Score 0 | 10 | 7 |
| CAPOX+ Placebo C42D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C42D1 Score 1 | 10 | 3 |
| CAPOX+ Placebo C42D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C42D1 Score 2 | 10 | 0 |
| CAPOX+ Placebo C42D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C42D1 Score 3 | 10 | 0 |
| CAPOX+ Placebo C42D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C42D1 Score 4 | 10 | 0 |
| CAPOX+ Placebo C42D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C42D1 Score 5 | 10 | 0 |
| CAPOX+ Placebo C42D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C43D1 Score 0 | 7 | 5 |
| CAPOX+ Placebo C43D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C43D1 Score 1 | 7 | 2 |
| CAPOX+ Placebo C43D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C43D1 Score 2 | 7 | 0 |
| CAPOX+ Placebo C43D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C43D1 Score 3 | 7 | 0 |
| CAPOX+ Placebo C43D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C43D1 Score 4 | 7 | 0 |
| CAPOX+ Placebo C43D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C43D1 Score 5 | 7 | 0 |
| CAPOX+ Placebo C43D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C44D1 Score 0 | 9 | 7 |
| CAPOX+ Placebo C44D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C44D1 Score 1 | 9 | 2 |
| CAPOX+ Placebo C44D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C44D1 Score 2 | 9 | 0 |
| CAPOX+ Placebo C44D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C44D1 Score 3 | 9 | 0 |
| CAPOX+ Placebo C44D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C44D1 Score 4 | 9 | 0 |
| CAPOX+ Placebo C44D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C44D1 Score 5 | 9 | 0 |
| CAPOX+ Placebo C44D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C45D1 Score 0 | 9 | 7 |
| CAPOX+ Placebo C45D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C45D1 Score 1 | 9 | 2 |
| CAPOX+ Placebo C45D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C45D1 Score 2 | 9 | 0 |
| CAPOX+ Placebo C45D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C45D1 Score 3 | 9 | 0 |
| CAPOX+ Placebo C45D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C45D1 Score 4 | 9 | 0 |
| CAPOX+ Placebo C45D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C45D1 Score 5 | 9 | 0 |
| CAPOX+ Placebo C45D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C46D1 Score 0 | 9 | 7 |
| CAPOX+ Zolbetuximab C46D1 Score 1 | 9 | 2 |
| CAPOX+ Zolbetuximab C46D1 Score 2 | 9 | 0 |
| CAPOX+ Zolbetuximab C46D1 Score 3 | 9 | 0 |
| CAPOX+ Zolbetuximab C46D1 Score 4 | 9 | 0 |
| CAPOX+ Zolbetuximab C46D1 Score 5 | 9 | 0 |
| CAPOX+ Zolbetuximab C47D1 Score 0 | 8 | 6 |
| CAPOX+ Zolbetuximab C47D1 Score 1 | 8 | 2 |
| CAPOX+ Zolbetuximab C47D1 Score 2 | 8 | 0 |
| CAPOX+ Zolbetuximab C47D1 Score 3 | 8 | 0 |
| CAPOX+ Zolbetuximab C47D1 Score 4 | 8 | 0 |
| CAPOX+ Zolbetuximab C47D1 Score 5 | 8 | 0 |
| CAPOX+ Zolbetuximab C48D1 Score 0 | 7 | 5 |
| CAPOX+ Zolbetuximab C48D1 Score 1 | 7 | 2 |
| CAPOX+ Zolbetuximab C48D1 Score 2 | 7 | 0 |
| CAPOX+ Zolbetuximab C48D1 Score 3 | 7 | 0 |
| CAPOX+ Zolbetuximab C48D1 Score 4 | 7 | 0 |
| CAPOX+ Zolbetuximab C48D1 Score 5 | 7 | 0 |
| CAPOX+ Zolbetuximab C49D1 Score 0 | 5 | 3 |
| CAPOX+ Zolbetuximab C49D1 Score 1 | 5 | 2 |
| CAPOX+ Zolbetuximab C49D1 Score 2 | 5 | 0 |
| CAPOX+ Zolbetuximab C49D1 Score 3 | 5 | 0 |
| CAPOX+ Zolbetuximab C49D1 Score 4 | 5 | 0 |
| CAPOX+ Zolbetuximab C49D1 Score 5 | 5 | 0 |
| CAPOX+ Zolbetuximab C50D1 Score 0 | 4 | 2 |
| CAPOX+ Zolbetuximab C50D1 Score 1 | 4 | 2 |
| CAPOX+ Zolbetuximab C50D1 Score 2 | 4 | 0 |
| CAPOX+ Zolbetuximab C50D1 Score 3 | 4 | 0 |
| CAPOX+ Zolbetuximab C50D1 Score 4 | 4 | 0 |
| CAPOX+ Zolbetuximab C50D1 Score 5 | 4 | 0 |
| CAPOX+ Zolbetuximab C51D1 Score 0 | 4 | 2 |
| CAPOX+ Zolbetuximab C51D1 Score 1 | 4 | 2 |
| CAPOX+ Zolbetuximab C51D1 Score 2 | 4 | 0 |
| CAPOX+ Zolbetuximab C51D1 Score 3 | 4 | 0 |
| CAPOX+ Zolbetuximab C51D1 Score 4 | 4 | 0 |
| CAPOX+ Zolbetuximab C51D1 Score 5 | 4 | 0 |
| CAPOX+ Zolbetuximab C52D1 Score 0 | 4 | 2 |
| CAPOX+ Zolbetuximab C52D1 Score 1 | 4 | 2 |
| CAPOX+ Zolbetuximab C52D1 Score 2 | 4 | 0 |
| CAPOX+ Zolbetuximab C52D1 Score 3 | 4 | 0 |
| CAPOX+ Zolbetuximab C52D1 Score 4 | 4 | 0 |
| CAPOX+ Zolbetuximab C52D1 Score 5 | 4 | 0 |
| CAPOX+ Zolbetuximab C53D1 Score 0 | 3 | 2 |
| CAPOX+ Zolbetuximab C53D1 Score 1 | 3 | 1 |
| CAPOX+ Zolbetuximab C53D1 Score 2 | 3 | 0 |
| CAPOX+ Zolbetuximab C53D1 Score 3 | 3 | 0 |
| CAPOX+ Zolbetuximab C53D1 Score 4 | 3 | 0 |
| CAPOX+ Zolbetuximab C53D1 Score 5 | 3 | 0 |
| CAPOX+ Zolbetuximab C54D1 Score 0 | 3 | 2 |
| CAPOX+ Zolbetuximab C54D1 Score 1 | 3 | 1 |
| CAPOX+ Zolbetuximab C54D1 Score 2 | 3 | 0 |
| CAPOX+ Zolbetuximab C54D1 Score 3 | 3 | 0 |
| CAPOX+ Zolbetuximab C54D1 Score 4 | 3 | 0 |
| CAPOX+ Zolbetuximab C54D1 Score 5 | 3 | 0 |
| CAPOX+ Zolbetuximab C55D1 Score 0 | 2 | 1 |
| CAPOX+ Zolbetuximab C55D1 Score 1 | 2 | 1 |
| CAPOX+ Zolbetuximab C55D1 Score 2 | 2 | 0 |
| CAPOX+ Zolbetuximab C55D1 Score 3 | 2 | 0 |
| CAPOX+ Zolbetuximab C55D1 Score 4 | 2 | 0 |
| CAPOX+ Zolbetuximab C55D1 Score 5 | 2 | 0 |
| CAPOX+ Zolbetuximab C56D1 Score 0 | 2 | 1 |
| CAPOX+ Zolbetuximab C56D1 Score 1 | 2 | 1 |
| CAPOX+ Zolbetuximab C56D1 Score 2 | 2 | 0 |
| CAPOX+ Zolbetuximab C56D1 Score 3 | 2 | 0 |
| CAPOX+ Zolbetuximab C56D1 Score 4 | 2 | 0 |
| CAPOX+ Zolbetuximab C56D1 Score 5 | 2 | 0 |
| CAPOX+ Zolbetuximab C57D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C57D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C57D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C57D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C57D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C57D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C58D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C58D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C58D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C58D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C58D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C58D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C59D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C59D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C59D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C59D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C59D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C59D1 Score 5 | 1 | 0 |
| CAPOX+ Zolbetuximab C60D1 Score 0 | 1 | 1 |
| CAPOX+ Zolbetuximab C60D1 Score 1 | 1 | 0 |
| CAPOX+ Zolbetuximab C60D1 Score 2 | 1 | 0 |
| CAPOX+ Zolbetuximab C60D1 Score 3 | 1 | 0 |
| CAPOX+ Zolbetuximab C60D1 Score 4 | 1 | 0 |
| CAPOX+ Zolbetuximab C60D1 Score 5 | 1 | 0 |
Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire
Secondary outcome · Mean, Unit on a scale · Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab Global Health Status Baseline | 243 | 68.83 (Standard Deviation 18.94) |
| CAPOX+ Placebo Global Health Status Baseline | 242 | 66.15 (Standard Deviation 19.40) |
| CAPOX+ Zolbetuximab Global Health Status C2D1 | 208 | 0.04 (Standard Deviation 17.35) |
| CAPOX+ Placebo Global Health Status C2D1 | 217 | 2.96 (Standard Deviation 18.89) |
| CAPOX+ Zolbetuximab Global Health Status C3D1 | 182 | 1.47 (Standard Deviation 17.15) |
| CAPOX+ Placebo Global Health Status C3D1 | 197 | 3.68 (Standard Deviation 20.69) |
| CAPOX+ Zolbetuximab Global Health Status C4D1 | 169 | 2.61 (Standard Deviation 18.79) |
| CAPOX+ Placebo Global Health Status C4D1 | 169 | 4.54 (Standard Deviation 20.59) |
| CAPOX+ Zolbetuximab Global Health Status C5D1 | 159 | 0.89 (Standard Deviation 20.96) |
| CAPOX+ Placebo Global Health Status C5D1 | 165 | 3.48 (Standard Deviation 19.57) |
| CAPOX+ Zolbetuximab Global Health Status C6D1 | 149 | 0.84 (Standard Deviation 19.32) |
| CAPOX+ Placebo Global Health Status C6D1 | 146 | 3.94 (Standard Deviation 20.51) |
| CAPOX+ Zolbetuximab Global Health Status C7D1 | 120 | 1.94 (Standard Deviation 18.29) |
| CAPOX+ Placebo Global Health Status C7D1 | 126 | 2.12 (Standard Deviation 19.69) |
| CAPOX+ Zolbetuximab Global Health Status C8D1 | 108 | 0.77 (Standard Deviation 16.96) |
| CAPOX+ Placebo Global Health Status C8D1 | 110 | 4.32 (Standard Deviation 20.31) |
| CAPOX+ Zolbetuximab Global Health Status C9D1 | 102 | 1.88 (Standard Deviation 20.91) |
| CAPOX+ Placebo Global Health Status C9D1 | 103 | 3.32 (Standard Deviation 20.89) |
| CAPOX+ Zolbetuximab Global Health Status C10D1 | 85 | 2.65 (Standard Deviation 20.38) |
| CAPOX+ Placebo Global Health Status C10D1 | 79 | 3.48 (Standard Deviation 22.23) |
| CAPOX+ Zolbetuximab Global Health Status C11D1 | 81 | 1.23 (Standard Deviation 21.89) |
| CAPOX+ Placebo Global Health Status C11D1 | 71 | 3.99 (Standard Deviation 23.18) |
| CAPOX+ Zolbetuximab Global Health Status C12D1 | 75 | 2.44 (Standard Deviation 23.44) |
| CAPOX+ Placebo Global Health Status C12D1 | 57 | 2.63 (Standard Deviation 22.06) |
| CAPOX+ Zolbetuximab Global Health Status C13D1 | 60 | 3.47 (Standard Deviation 24.22) |
| CAPOX+ Placebo Global Health Status C13D1 | 48 | 3.30 (Standard Deviation 20.82) |
| CAPOX+ Zolbetuximab Global Health Status C14D1 | 55 | 1.52 (Standard Deviation 18.08) |
| CAPOX+ Placebo Global Health Status C14D1 | 44 | 3.79 (Standard Deviation 21.15) |
| CAPOX+ Zolbetuximab Global Health Status C15D1 | 51 | 2.94 (Standard Deviation 22.78) |
| CAPOX+ Placebo Global Health Status C15D1 | 36 | 2.08 (Standard Deviation 21.02) |
| CAPOX+ Zolbetuximab Global Health Status C16D1 | 48 | 3.65 (Standard Deviation 22.67) |
| CAPOX+ Placebo Global Health Status C16D1 | 31 | 5.65 (Standard Deviation 17.40) |
| CAPOX+ Zolbetuximab Global Health Status C17D1 | 43 | 6.01 (Standard Deviation 19.36) |
| CAPOX+ Placebo Global Health Status C17D1 | 25 | 3.33 (Standard Deviation 20.41) |
| CAPOX+ Zolbetuximab Global Health Status C18D1 | 41 | 3.66 (Standard Deviation 21.33) |
| CAPOX+ Placebo Global Health Status C18D1 | 21 | 3.97 (Standard Deviation 31.36) |
| CAPOX+ Zolbetuximab Global Health Status C19D1 | 40 | 4.17 (Standard Deviation 17.50) |
| CAPOX+ Placebo Global Health Status C19D1 | 20 | 10.42 (Standard Deviation 15.97) |
| CAPOX+ Zolbetuximab Global Health Status C20D1 | 39 | 1.50 (Standard Deviation 17.72) |
| CAPOX+ Placebo Global Health Status C20D1 | 19 | 3.95 (Standard Deviation 19.71) |
| CAPOX+ Zolbetuximab Global Health Status C21D1 | 36 | 4.17 (Standard Deviation 18.53) |
| CAPOX+ Placebo Global Health Status C21D1 | 20 | 2.92 (Standard Deviation 18.98) |
| CAPOX+ Zolbetuximab Global Health Status C22D1 | 31 | 4.03 (Standard Deviation 19.71) |
| CAPOX+ Placebo Global Health Status C22D1 | 17 | 9.31 (Standard Deviation 22.99) |
| CAPOX+ Zolbetuximab Global Health Status C23D1 | 31 | 4.03 (Standard Deviation 16.92) |
| CAPOX+ Placebo Global Health Status C23D1 | 16 | 9.38 (Standard Deviation 19.69) |
| CAPOX+ Zolbetuximab Global Health Status C24D1 | 29 | 2.87 (Standard Deviation 19.32) |
| CAPOX+ Placebo Global Health Status C24D1 | 12 | 9.72 (Standard Deviation 21.86) |
| CAPOX+ Zolbetuximab Global Health Status C25D1 | 28 | 1.79 (Standard Deviation 18.75) |
| CAPOX+ Placebo Global Health Status C25D1 | 12 | 10.42 (Standard Deviation 24.39) |
| CAPOX+ Zolbetuximab Global Health Status C26D1 | 26 | 4.81 (Standard Deviation 16.36) |
| CAPOX+ Placebo Global Health Status C26D1 | 9 | 3.70 (Standard Deviation 19.59) |
| CAPOX+ Zolbetuximab Global Health Status C27D1 | 25 | 4.00 (Standard Deviation 18.18) |
| CAPOX+ Placebo Global Health Status C27D1 | 10 | 6.67 (Standard Deviation 11.65) |
| CAPOX+ Zolbetuximab Global Health Status C28D1 | 21 | 1.98 (Standard Deviation 18.62) |
| CAPOX+ Placebo Global Health Status C28D1 | 11 | 5.30 (Standard Deviation 14.08) |
| CAPOX+ Zolbetuximab Global Health Status C29D1 | 22 | 3.03 (Standard Deviation 14.21) |
| CAPOX+ Placebo Global Health Status C29D1 | 12 | 4.86 (Standard Deviation 14.42) |
| CAPOX+ Zolbetuximab Global Health Status C30D1 | 20 | 2.92 (Standard Deviation 14.12) |
| CAPOX+ Zolbetuximab Global Health Status C31D1 | 20 | 2.08 (Standard Deviation 19.28) |
| CAPOX+ Zolbetuximab Global Health Status C32D1 | 18 | 2.78 (Standard Deviation 16.17) |
| CAPOX+ Zolbetuximab Global Health Status C33D1 | 15 | 5.56 (Standard Deviation 17.72) |
| CAPOX+ Zolbetuximab Global Health Status C34D1 | 12 | 8.33 (Standard Deviation 20.72) |
| CAPOX+ Zolbetuximab Global Health Status C35D1 | 13 | 4.49 (Standard Deviation 17.88) |
| CAPOX+ Zolbetuximab Global Health Status C36D1 | 12 | 2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Global Health Status C37D1 | 11 | 10.61 (Standard Deviation 15.85) |
| CAPOX+ Zolbetuximab Global Health Status C38D1 | 10 | 8.33 (Standard Deviation 21.15) |
| CAPOX+ Zolbetuximab Global Health Status C39D1 | 9 | 3.70 (Standard Deviation 13.89) |
| CAPOX+ Zolbetuximab Global Health Status 30 day follow up | 57 | -8.63 (Standard Deviation 25.10) |
| CAPOX+ Placebo Global Health Status 30 day follow up | 78 | -10.68 (Standard Deviation 24.65) |
| CAPOX+ Zolbetuximab Global Health Status 90 day follow up | 61 | -5.46 (Standard Deviation 21.19) |
| CAPOX+ Placebo Global Health Status 90 day follow up | 79 | -4.96 (Standard Deviation 22.86) |
| CAPOX+ Zolbetuximab Physical Functioning Baseline | 243 | 83.79 (Standard Deviation 16.85) |
| CAPOX+ Placebo Physical Functioning Baseline | 242 | 83.55 (Standard Deviation 17.22) |
| CAPOX+ Zolbetuximab Physical Functioning C2D1 | 208 | -0.93 (Standard Deviation 14.62) |
| CAPOX+ Placebo Physical Functioning C2D1 | 217 | -0.77 (Standard Deviation 13.70) |
| CAPOX+ Zolbetuximab Physical Functioning C3D1 | 182 | -1.76 (Standard Deviation 14.13) |
| CAPOX+ Placebo Physical Functioning C3D1 | 197 | -0.07 (Standard Deviation 14.94) |
| CAPOX+ Zolbetuximab Physical Functioning C4D1 | 169 | -0.16 (Standard Deviation 14.25) |
| CAPOX+ Placebo Physical Functioning C4D1 | 169 | 1.07 (Standard Deviation 15.38) |
| CAPOX+ Zolbetuximab Physical Functioning C5D1 | 159 | -0.67 (Standard Deviation 15.32) |
| CAPOX+ Placebo Physical Functioning C5D1 | 165 | 0.24 (Standard Deviation 16.29) |
| CAPOX+ Zolbetuximab Physical Functioning C6D1 | 149 | -0.89 (Standard Deviation 15.47) |
| CAPOX+ Placebo Physical Functioning C6D1 | 146 | -0.96 (Standard Deviation 17.94) |
| CAPOX+ Zolbetuximab Physical Functioning C7D1 | 120 | -1.78 (Standard Deviation 16.05) |
| CAPOX+ Placebo Physical Functioning C7D1 | 126 | 0.21 (Standard Deviation 17.69) |
| CAPOX+ Zolbetuximab Physical Functioning C8D1 | 108 | -3.27 (Standard Deviation 15.51) |
| CAPOX+ Placebo Physical Functioning C8D1 | 110 | -1.33 (Standard Deviation 17.08) |
| CAPOX+ Zolbetuximab Physical Functioning C9D1 | 102 | -3.20 (Standard Deviation 17.84) |
| CAPOX+ Placebo Physical Functioning C9D1 | 103 | -0.84 (Standard Deviation 18.26) |
| CAPOX+ Zolbetuximab Physical Functioning C10D1 | 85 | -2.75 (Standard Deviation 17.13) |
| CAPOX+ Placebo Physical Functioning C10D1 | 79 | -2.28 (Standard Deviation 18.76) |
| CAPOX+ Zolbetuximab Physical Functioning C11D1 | 81 | -0.82 (Standard Deviation 15.00) |
| CAPOX+ Placebo Physical Functioning C11D1 | 71 | -0.09 (Standard Deviation 17.11) |
| CAPOX+ Zolbetuximab Physical Functioning C12D1 | 75 | -0.89 (Standard Deviation 17.31) |
| CAPOX+ Placebo Physical Functioning C12D1 | 57 | -0.70 (Standard Deviation 19.18) |
| CAPOX+ Zolbetuximab Physical Functioning C13D1 | 60 | -0.56 (Standard Deviation 18.59) |
| CAPOX+ Placebo Physical Functioning C13D1 | 48 | 0.97 (Standard Deviation 13.89) |
| CAPOX+ Zolbetuximab Physical Functioning C14D1 | 55 | 0.12 (Standard Deviation 15.95) |
| CAPOX+ Placebo Physical Functioning C14D1 | 44 | 1.21 (Standard Deviation 13.04) |
| CAPOX+ Zolbetuximab Physical Functioning C15D1 | 51 | 0.39 (Standard Deviation 14.20) |
| CAPOX+ Placebo Physical Functioning C15D1 | 36 | 0.00 (Standard Deviation 13.62) |
| CAPOX+ Zolbetuximab Physical Functioning C16D1 | 48 | -0.42 (Standard Deviation 14.77) |
| CAPOX+ Placebo Physical Functioning C16D1 | 31 | 0.86 (Standard Deviation 12.14) |
| CAPOX+ Zolbetuximab Physical Functioning C17D1 | 43 | 2.33 (Standard Deviation 14.61) |
| CAPOX+ Placebo Physical Functioning C17D1 | 25 | 2.13 (Standard Deviation 16.75) |
| CAPOX+ Zolbetuximab Physical Functioning C18D1 | 41 | -2.93 (Standard Deviation 17.32) |
| CAPOX+ Placebo Physical Functioning C18D1 | 21 | 3.49 (Standard Deviation 15.44) |
| CAPOX+ Zolbetuximab Physical Functioning C19D1 | 40 | 1.33 (Standard Deviation 10.48) |
| CAPOX+ Placebo Physical Functioning C19D1 | 20 | 4.00 (Standard Deviation 13.40) |
| CAPOX+ Zolbetuximab Physical Functioning C20D1 | 39 | -0.85 (Standard Deviation 11.96) |
| CAPOX+ Placebo Physical Functioning C20D1 | 19 | 2.81 (Standard Deviation 16.68) |
| CAPOX+ Zolbetuximab Physical Functioning C21D1 | 36 | -0.74 (Standard Deviation 13.31) |
| CAPOX+ Placebo Physical Functioning C21D1 | 20 | 3.33 (Standard Deviation 12.89) |
| CAPOX+ Zolbetuximab Physical Functioning C22D1 | 31 | -0.22 (Standard Deviation 12.11) |
| CAPOX+ Placebo Physical Functioning C22D1 | 17 | 5.49 (Standard Deviation 17.52) |
| CAPOX+ Zolbetuximab Physical Functioning C23D1 | 31 | -0.22 (Standard Deviation 14.35) |
| CAPOX+ Placebo Physical Functioning C23D1 | 16 | 5.83 (Standard Deviation 19.30) |
| CAPOX+ Zolbetuximab Physical Functioning C24D1 | 29 | 2.30 (Standard Deviation 14.61) |
| CAPOX+ Placebo Physical Functioning C24D1 | 12 | 5.56 (Standard Deviation 17.71) |
| CAPOX+ Zolbetuximab Physical Functioning C25D1 | 28 | 0.48 (Standard Deviation 17.40) |
| CAPOX+ Placebo Physical Functioning C25D1 | 12 | 3.89 (Standard Deviation 23.35) |
| CAPOX+ Zolbetuximab Physical Functioning C26D1 | 26 | 1.28 (Standard Deviation 17.28) |
| CAPOX+ Placebo Physical Functioning C26D1 | 9 | 2.96 (Standard Deviation 17.36) |
| CAPOX+ Zolbetuximab Physical Functioning C27D1 | 25 | 1.07 (Standard Deviation 16.52) |
| CAPOX+ Placebo Physical Functioning C27D1 | 10 | 2.00 (Standard Deviation 13.72) |
| CAPOX+ Zolbetuximab Physical Functioning C28D1 | 21 | -1.27 (Standard Deviation 16.55) |
| CAPOX+ Placebo Physical Functioning C28D1 | 11 | -1.82 (Standard Deviation 19.80) |
| CAPOX+ Zolbetuximab Physical Functioning C29D1 | 22 | -3.33 (Standard Deviation 23.25) |
| CAPOX+ Placebo Physical Functioning C29D1 | 12 | 1.11 (Standard Deviation 18.16) |
| CAPOX+ Zolbetuximab Physical Functioning C30D1 | 20 | 1.67 (Standard Deviation 16.17) |
| CAPOX+ Zolbetuximab Physical Functioning C31D1 | 20 | 2.00 (Standard Deviation 16.91) |
| CAPOX+ Zolbetuximab Physical Functioning C32D1 | 18 | -1.11 (Standard Deviation 19.97) |
| CAPOX+ Zolbetuximab Physical Functioning C33D1 | 15 | 2.22 (Standard Deviation 18.11) |
| CAPOX+ Zolbetuximab Physical Functioning C34D1 | 12 | 6.67 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Physical Functioning C35D1 | 13 | 7.18 (Standard Deviation 18.55) |
| CAPOX+ Zolbetuximab Physical Functioning C36D1 | 12 | 6.67 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Physical Functioning C37D1 | 11 | 7.27 (Standard Deviation 17.24) |
| CAPOX+ Zolbetuximab Physical Functioning C38D1 | 10 | 6.67 (Standard Deviation 21.55) |
| CAPOX+ Zolbetuximab Physical Functioning C39D1 | 9 | 2.96 (Standard Deviation 10.06) |
| CAPOX+ Zolbetuximab Physical Functioning 30 day follow up | 57 | -8.65 (Standard Deviation 22.36) |
| CAPOX+ Placebo Physical Functioning 30 day follow up | 78 | -9.91 (Standard Deviation 20.29) |
| CAPOX+ Zolbetuximab Physical Functioning 90 day follow up | 61 | -10.16 (Standard Deviation 20.28) |
| CAPOX+ Placebo Physical Functioning 90 day follow up | 79 | -10.63 (Standard Deviation 22.28) |
| CAPOX+ Zolbetuximab Role Functioning Baseline | 243 | 83.20 (Standard Deviation 22.52) |
| CAPOX+ Placebo Role Functioning Baseline | 242 | 82.23 (Standard Deviation 23.59) |
| CAPOX+ Zolbetuximab Role Functioning C2D1 | 208 | -2.64 (Standard Deviation 20.52) |
| CAPOX+ Placebo Role Functioning C2D1 | 217 | -1.92 (Standard Deviation 19.97) |
| CAPOX+ Zolbetuximab Role Functioning C3D1 | 182 | -2.38 (Standard Deviation 21.82) |
| CAPOX+ Placebo Role Functioning C3D1 | 197 | -2.28 (Standard Deviation 24.38) |
| CAPOX+ Zolbetuximab Role Functioning C4D1 | 169 | -2.37 (Standard Deviation 20.36) |
| CAPOX+ Placebo Role Functioning C4D1 | 169 | -0.79 (Standard Deviation 24.65) |
| CAPOX+ Zolbetuximab Role Functioning C5D1 | 159 | -0.94 (Standard Deviation 20.73) |
| CAPOX+ Placebo Role Functioning C5D1 | 165 | -0.40 (Standard Deviation 25.03) |
| CAPOX+ Zolbetuximab Role Functioning C6D1 | 149 | -3.69 (Standard Deviation 22.91) |
| CAPOX+ Placebo Role Functioning C6D1 | 146 | -3.08 (Standard Deviation 24.68) |
| CAPOX+ Zolbetuximab Role Functioning C7D1 | 120 | -2.08 (Standard Deviation 20.68) |
| CAPOX+ Placebo Role Functioning C7D1 | 126 | -0.79 (Standard Deviation 23.74) |
| CAPOX+ Zolbetuximab Role Functioning C8D1 | 108 | -5.25 (Standard Deviation 21.57) |
| CAPOX+ Placebo Role Functioning C8D1 | 110 | -5.61 (Standard Deviation 26.16) |
| CAPOX+ Zolbetuximab Role Functioning C9D1 | 102 | -5.39 (Standard Deviation 23.71) |
| CAPOX+ Placebo Role Functioning C9D1 | 103 | -2.59 (Standard Deviation 23.89) |
| CAPOX+ Zolbetuximab Role Functioning C10D1 | 85 | -3.92 (Standard Deviation 24.89) |
| CAPOX+ Placebo Role Functioning C10D1 | 79 | -3.59 (Standard Deviation 26.91) |
| CAPOX+ Zolbetuximab Role Functioning C11D1 | 81 | -3.50 (Standard Deviation 19.31) |
| CAPOX+ Placebo Role Functioning C11D1 | 71 | -3.29 (Standard Deviation 28.40) |
| CAPOX+ Zolbetuximab Role Functioning C12D1 | 75 | -3.33 (Standard Deviation 23.89) |
| CAPOX+ Placebo Role Functioning C12D1 | 57 | -2.63 (Standard Deviation 26.69) |
| CAPOX+ Zolbetuximab Role Functioning C13D1 | 60 | -0.83 (Standard Deviation 24.44) |
| CAPOX+ Placebo Role Functioning C13D1 | 48 | -0.35 (Standard Deviation 27.39) |
| CAPOX+ Zolbetuximab Role Functioning C14D1 | 55 | -1.21 (Standard Deviation 21.48) |
| CAPOX+ Placebo Role Functioning C14D1 | 44 | 0.76 (Standard Deviation 21.25) |
| CAPOX+ Zolbetuximab Role Functioning C15D1 | 51 | -0.65 (Standard Deviation 21.07) |
| CAPOX+ Placebo Role Functioning C15D1 | 36 | -0.46 (Standard Deviation 24.72) |
| CAPOX+ Zolbetuximab Role Functioning C16D1 | 48 | 1.74 (Standard Deviation 23.12) |
| CAPOX+ Placebo Role Functioning C16D1 | 31 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Role Functioning C17D1 | 43 | 3.10 (Standard Deviation 22.50) |
| CAPOX+ Placebo Role Functioning C17D1 | 25 | 2.67 (Standard Deviation 28.74) |
| CAPOX+ Zolbetuximab Role Functioning C18D1 | 41 | -3.25 (Standard Deviation 20.49) |
| CAPOX+ Placebo Role Functioning C18D1 | 21 | 6.35 (Standard Deviation 21.39) |
| CAPOX+ Zolbetuximab Role Functioning C19D1 | 40 | -0.42 (Standard Deviation 20.50) |
| CAPOX+ Placebo Role Functioning C19D1 | 20 | 6.67 (Standard Deviation 17.44) |
| CAPOX+ Zolbetuximab Role Functioning C20D1 | 39 | 1.28 (Standard Deviation 20.37) |
| CAPOX+ Placebo Role Functioning C20D1 | 19 | 10.53 (Standard Deviation 22.37) |
| CAPOX+ Zolbetuximab Role Functioning C21D1 | 36 | -0.93 (Standard Deviation 20.29) |
| CAPOX+ Placebo Role Functioning C21D1 | 20 | 6.67 (Standard Deviation 23.82) |
| CAPOX+ Zolbetuximab Role Functioning C22D1 | 31 | 0.54 (Standard Deviation 19.48) |
| CAPOX+ Placebo Role Functioning C22D1 | 17 | 8.82 (Standard Deviation 24.38) |
| CAPOX+ Zolbetuximab Role Functioning C23D1 | 31 | 0.00 (Standard Deviation 18.76) |
| CAPOX+ Placebo Role Functioning C23D1 | 16 | 9.37 (Standard Deviation 30.41) |
| CAPOX+ Zolbetuximab Role Functioning C24D1 | 29 | 0.00 (Standard Deviation 18.37) |
| CAPOX+ Placebo Role Functioning C24D1 | 12 | 6.94 (Standard Deviation 27.02) |
| CAPOX+ Zolbetuximab Role Functioning C25D1 | 28 | 1.79 (Standard Deviation 20.95) |
| CAPOX+ Placebo Role Functioning C25D1 | 12 | 8.33 (Standard Deviation 28.87) |
| CAPOX+ Zolbetuximab Role Functioning C26D1 | 26 | -0.64 (Standard Deviation 20.81) |
| CAPOX+ Placebo Role Functioning C26D1 | 9 | -3.70 (Standard Deviation 27.36) |
| CAPOX+ Zolbetuximab Role Functioning C27D1 | 25 | 0.00 (Standard Deviation 17.35) |
| CAPOX+ Placebo Role Functioning C27D1 | 10 | -3.33 (Standard Deviation 23.31) |
| CAPOX+ Zolbetuximab Role Functioning C28D1 | 21 | 1.59 (Standard Deviation 18.18) |
| CAPOX+ Placebo Role Functioning C28D1 | 11 | -4.55 (Standard Deviation 21.20) |
| CAPOX+ Zolbetuximab Role Functioning C29D1 | 22 | -1.52 (Standard Deviation 24.62) |
| CAPOX+ Placebo Role Functioning C29D1 | 12 | 2.78 (Standard Deviation 19.89) |
| CAPOX+ Zolbetuximab Role Functioning C30D1 | 20 | 3.33 (Standard Deviation 19.19) |
| CAPOX+ Zolbetuximab Role Functioning C31D1 | 20 | 7.50 (Standard Deviation 21.27) |
| CAPOX+ Zolbetuximab Role Functioning C32D1 | 18 | 5.56 (Standard Deviation 23.57) |
| CAPOX+ Zolbetuximab Role Functioning C33D1 | 15 | 6.67 (Standard Deviation 20.70) |
| CAPOX+ Zolbetuximab Role Functioning C34D1 | 12 | 9.72 (Standard Deviation 24.06) |
| CAPOX+ Zolbetuximab Role Functioning C35D1 | 13 | 7.69 (Standard Deviation 21.10) |
| CAPOX+ Zolbetuximab Role Functioning C36D1 | 12 | 9.72 (Standard Deviation 21.86) |
| CAPOX+ Zolbetuximab Role Functioning C37D1 | 11 | 12.12 (Standard Deviation 23.68) |
| CAPOX+ Zolbetuximab Role Functioning C38D1 | 10 | 13.33 (Standard Deviation 21.94) |
| CAPOX+ Zolbetuximab Role Functioning C39D1 | 9 | 7.41 (Standard Deviation 22.22) |
| CAPOX+ Zolbetuximab Role Functioning 30 day follow up | 57 | -13.16 (Standard Deviation 27.95) |
| CAPOX+ Placebo Role Functioning 30 day follow up | 78 | -16.88 (Standard Deviation 31.38) |
| CAPOX+ Zolbetuximab Role Functioning 90 day follow up | 61 | -10.93 (Standard Deviation 27.03) |
| CAPOX+ Placebo Role Functioning 90 day follow up | 79 | -9.49 (Standard Deviation 30.39) |
| CAPOX+ Zolbetuximab Emotional Functioning Baseline | 243 | 80.42 (Standard Deviation 19.13) |
| CAPOX+ Placebo Emotional Functioning Baseline | 242 | 78.79 (Standard Deviation 19.41) |
| CAPOX+ Zolbetuximab Emotional Functioning C2D1 | 208 | 1.32 (Standard Deviation 15.92) |
| CAPOX+ Placebo Emotional Functioning C2D1 | 217 | 4.42 (Standard Deviation 16.49) |
| CAPOX+ Zolbetuximab Emotional Functioning C3D1 | 182 | 0.05 (Standard Deviation 16.21) |
| CAPOX+ Placebo Emotional Functioning C3D1 | 197 | 3.00 (Standard Deviation 18.84) |
| CAPOX+ Zolbetuximab Emotional Functioning C4D1 | 169 | 2.42 (Standard Deviation 15.52) |
| CAPOX+ Placebo Emotional Functioning C4D1 | 169 | 2.51 (Standard Deviation 19.52) |
| CAPOX+ Zolbetuximab Emotional Functioning C5D1 | 159 | 2.46 (Standard Deviation 17.35) |
| CAPOX+ Placebo Emotional Functioning C5D1 | 165 | 3.69 (Standard Deviation 17.81) |
| CAPOX+ Zolbetuximab Emotional Functioning C6D1 | 149 | 1.79 (Standard Deviation 15.96) |
| CAPOX+ Placebo Emotional Functioning C6D1 | 146 | 3.77 (Standard Deviation 19.18) |
| CAPOX+ Zolbetuximab Emotional Functioning C7D1 | 120 | 3.54 (Standard Deviation 17.90) |
| CAPOX+ Placebo Emotional Functioning C7D1 | 126 | 2.12 (Standard Deviation 21.24) |
| CAPOX+ Zolbetuximab Emotional Functioning C8D1 | 108 | 0.77 (Standard Deviation 19.15) |
| CAPOX+ Placebo Emotional Functioning C8D1 | 110 | 2.20 (Standard Deviation 18.08) |
| CAPOX+ Zolbetuximab Emotional Functioning C9D1 | 102 | 2.53 (Standard Deviation 19.19) |
| CAPOX+ Placebo Emotional Functioning C9D1 | 103 | 2.59 (Standard Deviation 19.07) |
| CAPOX+ Zolbetuximab Emotional Functioning C10D1 | 85 | 5.20 (Standard Deviation 21.13) |
| CAPOX+ Placebo Emotional Functioning C10D1 | 79 | 1.79 (Standard Deviation 20.62) |
| CAPOX+ Zolbetuximab Emotional Functioning C11D1 | 81 | 5.35 (Standard Deviation 20.47) |
| CAPOX+ Placebo Emotional Functioning C11D1 | 71 | 2.58 (Standard Deviation 20.97) |
| CAPOX+ Zolbetuximab Emotional Functioning C12D1 | 75 | 6.44 (Standard Deviation 19.93) |
| CAPOX+ Placebo Emotional Functioning C12D1 | 57 | 2.05 (Standard Deviation 21.49) |
| CAPOX+ Zolbetuximab Emotional Functioning C13D1 | 60 | 6.11 (Standard Deviation 20.40) |
| CAPOX+ Placebo Emotional Functioning C13D1 | 48 | 1.91 (Standard Deviation 21.42) |
| CAPOX+ Zolbetuximab Emotional Functioning C14D1 | 55 | 3.94 (Standard Deviation 19.96) |
| CAPOX+ Placebo Emotional Functioning C14D1 | 44 | -1.33 (Standard Deviation 18.76) |
| CAPOX+ Zolbetuximab Emotional Functioning C15D1 | 51 | 4.25 (Standard Deviation 16.61) |
| CAPOX+ Placebo Emotional Functioning C15D1 | 36 | -1.85 (Standard Deviation 21.19) |
| CAPOX+ Zolbetuximab Emotional Functioning C16D1 | 48 | 3.99 (Standard Deviation 15.75) |
| CAPOX+ Placebo Emotional Functioning C16D1 | 31 | -0.27 (Standard Deviation 23.22) |
| CAPOX+ Zolbetuximab Emotional Functioning C17D1 | 43 | 5.81 (Standard Deviation 15.16) |
| CAPOX+ Placebo Emotional Functioning C17D1 | 25 | 5.33 (Standard Deviation 16.12) |
| CAPOX+ Zolbetuximab Emotional Functioning C18D1 | 41 | 2.24 (Standard Deviation 15.59) |
| CAPOX+ Placebo Emotional Functioning C18D1 | 21 | 3.97 (Standard Deviation 19.65) |
| CAPOX+ Zolbetuximab Emotional Functioning C19D1 | 40 | 5.00 (Standard Deviation 15.07) |
| CAPOX+ Placebo Emotional Functioning C19D1 | 20 | 4.58 (Standard Deviation 13.10) |
| CAPOX+ Zolbetuximab Emotional Functioning C20D1 | 39 | 3.85 (Standard Deviation 15.40) |
| CAPOX+ Placebo Emotional Functioning C20D1 | 19 | 1.75 (Standard Deviation 19.95) |
| CAPOX+ Zolbetuximab Emotional Functioning C21D1 | 36 | 3.94 (Standard Deviation 18.31) |
| CAPOX+ Placebo Emotional Functioning C21D1 | 20 | 5.00 (Standard Deviation 18.22) |
| CAPOX+ Zolbetuximab Emotional Functioning C22D1 | 31 | 4.30 (Standard Deviation 14.25) |
| CAPOX+ Placebo Emotional Functioning C22D1 | 17 | 2.45 (Standard Deviation 18.58) |
| CAPOX+ Zolbetuximab Emotional Functioning C23D1 | 31 | 2.42 (Standard Deviation 11.42) |
| CAPOX+ Placebo Emotional Functioning C23D1 | 16 | 3.65 (Standard Deviation 23.56) |
| CAPOX+ Zolbetuximab Emotional Functioning C24D1 | 29 | 2.59 (Standard Deviation 14.79) |
| CAPOX+ Placebo Emotional Functioning C24D1 | 12 | -0.69 (Standard Deviation 23.96) |
| CAPOX+ Zolbetuximab Emotional Functioning C25D1 | 28 | 2.68 (Standard Deviation 16.36) |
| CAPOX+ Placebo Emotional Functioning C25D1 | 12 | -0.69 (Standard Deviation 20.24) |
| CAPOX+ Zolbetuximab Emotional Functioning C26D1 | 26 | 4.17 (Standard Deviation 16.37) |
| CAPOX+ Placebo Emotional Functioning C26D1 | 9 | -3.70 (Standard Deviation 18.69) |
| CAPOX+ Zolbetuximab Emotional Functioning C27D1 | 25 | 3.00 (Standard Deviation 18.30) |
| CAPOX+ Placebo Emotional Functioning C27D1 | 10 | -5.83 (Standard Deviation 19.66) |
| CAPOX+ Zolbetuximab Emotional Functioning C28D1 | 21 | 0.79 (Standard Deviation 19.53) |
| CAPOX+ Placebo Emotional Functioning C28D1 | 11 | -3.79 (Standard Deviation 19.85) |
| CAPOX+ Zolbetuximab Emotional Functioning C29D1 | 22 | 2.65 (Standard Deviation 17.33) |
| CAPOX+ Placebo Emotional Functioning C29D1 | 12 | -3.47 (Standard Deviation 27.17) |
| CAPOX+ Zolbetuximab Emotional Functioning C30D1 | 20 | -0.42 (Standard Deviation 17.41) |
| CAPOX+ Zolbetuximab Emotional Functioning C31D1 | 20 | 1.25 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Emotional Functioning C32D1 | 18 | 3.70 (Standard Deviation 16.96) |
| CAPOX+ Zolbetuximab Emotional Functioning C33D1 | 15 | 5.56 (Standard Deviation 18.81) |
| CAPOX+ Zolbetuximab Emotional Functioning C34D1 | 12 | 11.81 (Standard Deviation 12.03) |
| CAPOX+ Zolbetuximab Emotional Functioning C35D1 | 13 | 5.13 (Standard Deviation 15.79) |
| CAPOX+ Zolbetuximab Emotional Functioning C36D1 | 12 | 9.03 (Standard Deviation 15.27) |
| CAPOX+ Zolbetuximab Emotional Functioning C37D1 | 11 | 11.36 (Standard Deviation 15.93) |
| CAPOX+ Zolbetuximab Emotional Functioning C38D1 | 10 | 10.83 (Standard Deviation 14.72) |
| CAPOX+ Zolbetuximab Emotional Functioning C39D1 | 9 | -1.85 (Standard Deviation 21.15) |
| CAPOX+ Zolbetuximab Emotional Functioning 30 day follow up | 57 | -5.99 (Standard Deviation 26.01) |
| CAPOX+ Placebo Emotional Functioning 30 day follow up | 78 | -5.02 (Standard Deviation 24.15) |
| CAPOX+ Zolbetuximab Emotional Functioning 90 day follow up | 61 | -4.37 (Standard Deviation 15.34) |
| CAPOX+ Placebo Emotional Functioning 90 day follow up | 79 | 0.21 (Standard Deviation 21.88) |
| CAPOX+ Zolbetuximab Cognitive Functioning Baseline | 243 | 90.95 (Standard Deviation 14.86) |
| CAPOX+ Placebo Cognitive Functioning Baseline | 242 | 87.81 (Standard Deviation 18.01) |
| CAPOX+ Zolbetuximab Cognitive Functioning C2D1 | 208 | -0.24 (Standard Deviation 13.36) |
| CAPOX+ Placebo Cognitive Functioning C2D1 | 217 | 0.54 (Standard Deviation 15.50) |
| CAPOX+ Zolbetuximab Cognitive Functioning C3D1 | 182 | -1.47 (Standard Deviation 14.90) |
| CAPOX+ Placebo Cognitive Functioning C3D1 | 197 | 0.51 (Standard Deviation 15.51) |
| CAPOX+ Zolbetuximab Cognitive Functioning C4D1 | 169 | -0.59 (Standard Deviation 13.47) |
| CAPOX+ Placebo Cognitive Functioning C4D1 | 169 | 1.87 (Standard Deviation 15.58) |
| CAPOX+ Zolbetuximab Cognitive Functioning C5D1 | 159 | -1.89 (Standard Deviation 15.80) |
| CAPOX+ Placebo Cognitive Functioning C5D1 | 165 | 2.22 (Standard Deviation 15.13) |
| CAPOX+ Zolbetuximab Cognitive Functioning C6D1 | 149 | -1.45 (Standard Deviation 14.87) |
| CAPOX+ Placebo Cognitive Functioning C6D1 | 146 | 0.91 (Standard Deviation 16.81) |
| CAPOX+ Zolbetuximab Cognitive Functioning C7D1 | 120 | 0.00 (Standard Deviation 16.31) |
| CAPOX+ Placebo Cognitive Functioning C7D1 | 126 | -1.19 (Standard Deviation 17.02) |
| CAPOX+ Zolbetuximab Cognitive Functioning C8D1 | 108 | -2.16 (Standard Deviation 15.13) |
| CAPOX+ Placebo Cognitive Functioning C8D1 | 110 | 0.15 (Standard Deviation 18.27) |
| CAPOX+ Zolbetuximab Cognitive Functioning C9D1 | 102 | -1.96 (Standard Deviation 14.70) |
| CAPOX+ Placebo Cognitive Functioning C9D1 | 103 | 0.97 (Standard Deviation 18.05) |
| CAPOX+ Zolbetuximab Cognitive Functioning C10D1 | 85 | -0.59 (Standard Deviation 17.15) |
| CAPOX+ Placebo Cognitive Functioning C10D1 | 79 | -0.42 (Standard Deviation 19.61) |
| CAPOX+ Zolbetuximab Cognitive Functioning C11D1 | 81 | -1.23 (Standard Deviation 14.86) |
| CAPOX+ Placebo Cognitive Functioning C11D1 | 71 | -1.41 (Standard Deviation 18.42) |
| CAPOX+ Zolbetuximab Cognitive Functioning C12D1 | 75 | -0.22 (Standard Deviation 13.83) |
| CAPOX+ Placebo Cognitive Functioning C12D1 | 57 | 1.17 (Standard Deviation 16.62) |
| CAPOX+ Zolbetuximab Cognitive Functioning C13D1 | 60 | -0.28 (Standard Deviation 15.19) |
| CAPOX+ Placebo Cognitive Functioning C13D1 | 48 | 0.69 (Standard Deviation 22.00) |
| CAPOX+ Zolbetuximab Cognitive Functioning C14D1 | 55 | 0.61 (Standard Deviation 15.70) |
| CAPOX+ Placebo Cognitive Functioning C14D1 | 44 | 0.00 (Standard Deviation 19.02) |
| CAPOX+ Zolbetuximab Cognitive Functioning C15D1 | 51 | -0.98 (Standard Deviation 15.06) |
| CAPOX+ Placebo Cognitive Functioning C15D1 | 36 | -1.39 (Standard Deviation 19.67) |
| CAPOX+ Zolbetuximab Cognitive Functioning C16D1 | 48 | 1.39 (Standard Deviation 16.43) |
| CAPOX+ Placebo Cognitive Functioning C16D1 | 31 | -2.69 (Standard Deviation 20.68) |
| CAPOX+ Zolbetuximab Cognitive Functioning C17D1 | 43 | 0.78 (Standard Deviation 12.57) |
| CAPOX+ Placebo Cognitive Functioning C17D1 | 25 | 2.67 (Standard Deviation 14.97) |
| CAPOX+ Zolbetuximab Cognitive Functioning C18D1 | 41 | 1.63 (Standard Deviation 13.85) |
| CAPOX+ Placebo Cognitive Functioning C18D1 | 21 | 2.38 (Standard Deviation 16.06) |
| CAPOX+ Zolbetuximab Cognitive Functioning C19D1 | 40 | 0.42 (Standard Deviation 16.66) |
| CAPOX+ Placebo Cognitive Functioning C19D1 | 20 | 3.33 (Standard Deviation 11.60) |
| CAPOX+ Zolbetuximab Cognitive Functioning C20D1 | 39 | 0.85 (Standard Deviation 17.91) |
| CAPOX+ Placebo Cognitive Functioning C20D1 | 19 | 1.75 (Standard Deviation 21.44) |
| CAPOX+ Zolbetuximab Cognitive Functioning C21D1 | 36 | 0.93 (Standard Deviation 19.08) |
| CAPOX+ Placebo Cognitive Functioning C21D1 | 20 | 6.67 (Standard Deviation 18.26) |
| CAPOX+ Zolbetuximab Cognitive Functioning C22D1 | 31 | 2.69 (Standard Deviation 18.31) |
| CAPOX+ Placebo Cognitive Functioning C22D1 | 17 | 4.90 (Standard Deviation 20.21) |
| CAPOX+ Zolbetuximab Cognitive Functioning C23D1 | 31 | 1.61 (Standard Deviation 17.93) |
| CAPOX+ Placebo Cognitive Functioning C23D1 | 16 | 6.25 (Standard Deviation 17.08) |
| CAPOX+ Zolbetuximab Cognitive Functioning C24D1 | 29 | 2.30 (Standard Deviation 18.75) |
| CAPOX+ Placebo Cognitive Functioning C24D1 | 12 | 0.00 (Standard Deviation 15.89) |
| CAPOX+ Zolbetuximab Cognitive Functioning C25D1 | 28 | 1.79 (Standard Deviation 18.89) |
| CAPOX+ Placebo Cognitive Functioning C25D1 | 12 | 1.39 (Standard Deviation 19.41) |
| CAPOX+ Zolbetuximab Cognitive Functioning C26D1 | 26 | 1.92 (Standard Deviation 19.05) |
| CAPOX+ Placebo Cognitive Functioning C26D1 | 9 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Cognitive Functioning C27D1 | 25 | 2.67 (Standard Deviation 17.13) |
| CAPOX+ Placebo Cognitive Functioning C27D1 | 10 | -1.67 (Standard Deviation 14.59) |
| CAPOX+ Zolbetuximab Cognitive Functioning C28D1 | 21 | 3.17 (Standard Deviation 18.72) |
| CAPOX+ Placebo Cognitive Functioning C28D1 | 11 | -3.03 (Standard Deviation 14.56) |
| CAPOX+ Zolbetuximab Cognitive Functioning C29D1 | 22 | 0.76 (Standard Deviation 21.50) |
| CAPOX+ Placebo Cognitive Functioning C29D1 | 12 | 0.00 (Standard Deviation 14.21) |
| CAPOX+ Zolbetuximab Cognitive Functioning C30D1 | 20 | 0.00 (Standard Deviation 18.73) |
| CAPOX+ Zolbetuximab Cognitive Functioning C31D1 | 20 | 0.00 (Standard Deviation 18.73) |
| CAPOX+ Zolbetuximab Cognitive Functioning C32D1 | 18 | 2.78 (Standard Deviation 21.58) |
| CAPOX+ Zolbetuximab Cognitive Functioning C33D1 | 15 | 5.56 (Standard Deviation 20.57) |
| CAPOX+ Zolbetuximab Cognitive Functioning C34D1 | 12 | 6.94 (Standard Deviation 21.86) |
| CAPOX+ Zolbetuximab Cognitive Functioning C35D1 | 13 | 6.41 (Standard Deviation 24.09) |
| CAPOX+ Zolbetuximab Cognitive Functioning C36D1 | 12 | 8.33 (Standard Deviation 19.46) |
| CAPOX+ Zolbetuximab Cognitive Functioning C37D1 | 11 | 9.09 (Standard Deviation 21.56) |
| CAPOX+ Zolbetuximab Cognitive Functioning C38D1 | 10 | 8.33 (Standard Deviation 23.90) |
| CAPOX+ Zolbetuximab Cognitive Functioning C39D1 | 9 | 1.85 (Standard Deviation 13.03) |
| CAPOX+ Zolbetuximab Cognitive Functioning 30 day follow up | 57 | -2.63 (Standard Deviation 18.84) |
| CAPOX+ Placebo Cognitive Functioning 30 day follow up | 78 | -4.27 (Standard Deviation 20.18) |
| CAPOX+ Zolbetuximab Cognitive Functioning 90 day follow up | 61 | -7.65 (Standard Deviation 17.37) |
| CAPOX+ Placebo Cognitive Functioning 90 day follow up | 79 | -2.32 (Standard Deviation 20.28) |
| CAPOX+ Zolbetuximab Social Functioning Baseline | 243 | 79.42 (Standard Deviation 22.16) |
| CAPOX+ Placebo Social Functioning Baseline | 242 | 79.55 (Standard Deviation 23.48) |
| CAPOX+ Zolbetuximab Social Functioning C2D1 | 208 | 0.88 (Standard Deviation 21.31) |
| CAPOX+ Placebo Social Functioning C2D1 | 217 | -1.61 (Standard Deviation 20.88) |
| CAPOX+ Zolbetuximab Social Functioning C3D1 | 182 | -1.47 (Standard Deviation 23.65) |
| CAPOX+ Placebo Social Functioning C3D1 | 197 | -1.44 (Standard Deviation 22.70) |
| CAPOX+ Zolbetuximab Social Functioning C4D1 | 169 | 0.79 (Standard Deviation 23.77) |
| CAPOX+ Placebo Social Functioning C4D1 | 169 | 1.97 (Standard Deviation 21.73) |
| CAPOX+ Zolbetuximab Social Functioning C5D1 | 159 | 2.20 (Standard Deviation 25.58) |
| CAPOX+ Placebo Social Functioning C5D1 | 165 | 0.20 (Standard Deviation 22.31) |
| CAPOX+ Zolbetuximab Social Functioning C6D1 | 149 | -0.78 (Standard Deviation 25.29) |
| CAPOX+ Placebo Social Functioning C6D1 | 146 | -1.37 (Standard Deviation 22.53) |
| CAPOX+ Zolbetuximab Social Functioning C7D1 | 120 | -0.97 (Standard Deviation 26.22) |
| CAPOX+ Placebo Social Functioning C7D1 | 126 | -0.66 (Standard Deviation 24.71) |
| CAPOX+ Zolbetuximab Social Functioning C8D1 | 108 | -0.93 (Standard Deviation 27.33) |
| CAPOX+ Placebo Social Functioning C8D1 | 110 | -2.12 (Standard Deviation 23.58) |
| CAPOX+ Zolbetuximab Social Functioning C9D1 | 102 | -0.98 (Standard Deviation 24.01) |
| CAPOX+ Placebo Social Functioning C9D1 | 103 | -0.32 (Standard Deviation 24.47) |
| CAPOX+ Zolbetuximab Social Functioning C10D1 | 85 | 2.55 (Standard Deviation 25.39) |
| CAPOX+ Placebo Social Functioning C10D1 | 79 | -0.84 (Standard Deviation 27.20) |
| CAPOX+ Zolbetuximab Social Functioning C11D1 | 81 | 3.29 (Standard Deviation 23.19) |
| CAPOX+ Placebo Social Functioning C11D1 | 71 | -2.58 (Standard Deviation 25.14) |
| CAPOX+ Zolbetuximab Social Functioning C12D1 | 75 | 3.33 (Standard Deviation 23.09) |
| CAPOX+ Placebo Social Functioning C12D1 | 57 | -1.75 (Standard Deviation 28.12) |
| CAPOX+ Zolbetuximab Social Functioning C13D1 | 60 | 3.89 (Standard Deviation 24.43) |
| CAPOX+ Placebo Social Functioning C13D1 | 48 | -0.35 (Standard Deviation 23.19) |
| CAPOX+ Zolbetuximab Social Functioning C14D1 | 55 | 2.12 (Standard Deviation 20.80) |
| CAPOX+ Placebo Social Functioning C14D1 | 44 | 1.52 (Standard Deviation 24.86) |
| CAPOX+ Zolbetuximab Social Functioning C15D1 | 51 | 1.63 (Standard Deviation 22.42) |
| CAPOX+ Placebo Social Functioning C15D1 | 36 | -2.78 (Standard Deviation 23.06) |
| CAPOX+ Zolbetuximab Social Functioning C16D1 | 48 | 4.86 (Standard Deviation 20.03) |
| CAPOX+ Placebo Social Functioning C16D1 | 31 | 1.08 (Standard Deviation 19.21) |
| CAPOX+ Zolbetuximab Social Functioning C17D1 | 43 | 5.43 (Standard Deviation 18.45) |
| CAPOX+ Placebo Social Functioning C17D1 | 25 | 3.33 (Standard Deviation 15.96) |
| CAPOX+ Zolbetuximab Social Functioning C18D1 | 41 | 0.81 (Standard Deviation 22.96) |
| CAPOX+ Placebo Social Functioning C18D1 | 21 | 2.38 (Standard Deviation 16.90) |
| CAPOX+ Zolbetuximab Social Functioning C19D1 | 40 | 5.42 (Standard Deviation 19.02) |
| CAPOX+ Placebo Social Functioning C19D1 | 20 | 8.33 (Standard Deviation 20.59) |
| CAPOX+ Zolbetuximab Social Functioning C20D1 | 39 | 2.56 (Standard Deviation 21.81) |
| CAPOX+ Placebo Social Functioning C20D1 | 19 | 7.02 (Standard Deviation 20.27) |
| CAPOX+ Zolbetuximab Social Functioning C21D1 | 36 | 2.31 (Standard Deviation 21.88) |
| CAPOX+ Placebo Social Functioning C21D1 | 20 | 4.17 (Standard Deviation 17.83) |
| CAPOX+ Zolbetuximab Social Functioning C22D1 | 31 | 5.91 (Standard Deviation 21.32) |
| CAPOX+ Placebo Social Functioning C22D1 | 17 | 4.90 (Standard Deviation 15.33) |
| CAPOX+ Zolbetuximab Social Functioning C23D1 | 31 | 4.30 (Standard Deviation 24.33) |
| CAPOX+ Placebo Social Functioning C23D1 | 16 | 8.33 (Standard Deviation 18.26) |
| CAPOX+ Zolbetuximab Social Functioning C24D1 | 29 | 4.02 (Standard Deviation 23.84) |
| CAPOX+ Placebo Social Functioning C24D1 | 12 | -1.39 (Standard Deviation 15.01) |
| CAPOX+ Zolbetuximab Social Functioning C25D1 | 28 | 4.76 (Standard Deviation 21.21) |
| CAPOX+ Placebo Social Functioning C25D1 | 12 | -2.78 (Standard Deviation 15.62) |
| CAPOX+ Zolbetuximab Social Functioning C26D1 | 26 | 5.77 (Standard Deviation 23.54) |
| CAPOX+ Placebo Social Functioning C26D1 | 9 | 3.70 (Standard Deviation 24.69) |
| CAPOX+ Zolbetuximab Social Functioning C27D1 | 25 | 4.00 (Standard Deviation 25.59) |
| CAPOX+ Placebo Social Functioning C27D1 | 10 | 5.00 (Standard Deviation 15.81) |
| CAPOX+ Zolbetuximab Social Functioning C28D1 | 21 | 4.76 (Standard Deviation 29.88) |
| CAPOX+ Placebo Social Functioning C28D1 | 11 | 3.03 (Standard Deviation 16.36) |
| CAPOX+ Zolbetuximab Social Functioning C29D1 | 22 | 3.03 (Standard Deviation 26.55) |
| CAPOX+ Placebo Social Functioning C29D1 | 12 | 0.00 (Standard Deviation 21.32) |
| CAPOX+ Zolbetuximab Social Functioning C30D1 | 20 | 3.33 (Standard Deviation 28.41) |
| CAPOX+ Zolbetuximab Social Functioning C31D1 | 20 | 3.33 (Standard Deviation 27.36) |
| CAPOX+ Zolbetuximab Social Functioning C32D1 | 18 | 0.93 (Standard Deviation 29.41) |
| CAPOX+ Zolbetuximab Social Functioning C33D1 | 15 | 3.33 (Standard Deviation 34.04) |
| CAPOX+ Zolbetuximab Social Functioning C34D1 | 12 | 5.56 (Standard Deviation 35.06) |
| CAPOX+ Zolbetuximab Social Functioning C35D1 | 13 | 2.56 (Standard Deviation 32.52) |
| CAPOX+ Zolbetuximab Social Functioning C36D1 | 12 | 5.56 (Standard Deviation 33.58) |
| CAPOX+ Zolbetuximab Social Functioning C37D1 | 11 | 6.06 (Standard Deviation 36.72) |
| CAPOX+ Zolbetuximab Social Functioning C38D1 | 10 | 13.33 (Standard Deviation 31.23) |
| CAPOX+ Zolbetuximab Social Functioning C39D1 | 9 | 0.00 (Standard Deviation 33.33) |
| CAPOX+ Zolbetuximab Social Functioning 30 day follow up | 57 | -4.09 (Standard Deviation 28.22) |
| CAPOX+ Placebo Social Functioning 30 day follow up | 78 | -12.82 (Standard Deviation 26.03) |
| CAPOX+ Zolbetuximab Social Functioning 90 day follow up | 61 | 0.27 (Standard Deviation 24.05) |
| CAPOX+ Placebo Social Functioning 90 day follow up | 79 | -8.23 (Standard Deviation 26.40) |
| CAPOX+ Zolbetuximab Fatigue Baseline | 243 | 26.29 (Standard Deviation 22.00) |
| CAPOX+ Placebo Fatigue Baseline | 242 | 27.55 (Standard Deviation 22.43) |
| CAPOX+ Zolbetuximab Fatigue C2D1 | 208 | 1.66 (Standard Deviation 19.69) |
| CAPOX+ Placebo Fatigue C2D1 | 217 | 0.15 (Standard Deviation 19.11) |
| CAPOX+ Zolbetuximab Fatigue C3D1 | 182 | 3.17 (Standard Deviation 21.71) |
| CAPOX+ Placebo Fatigue C3D1 | 197 | 0.96 (Standard Deviation 21.26) |
| CAPOX+ Zolbetuximab Fatigue C4D1 | 169 | 1.05 (Standard Deviation 21.93) |
| CAPOX+ Placebo Fatigue C4D1 | 169 | -0.46 (Standard Deviation 22.03) |
| CAPOX+ Zolbetuximab Fatigue C5D1 | 159 | 1.40 (Standard Deviation 23.21) |
| CAPOX+ Placebo Fatigue C5D1 | 165 | -0.81 (Standard Deviation 23.52) |
| CAPOX+ Zolbetuximab Fatigue C6D1 | 149 | 2.83 (Standard Deviation 21.07) |
| CAPOX+ Placebo Fatigue C6D1 | 146 | 0.91 (Standard Deviation 25.25) |
| CAPOX+ Zolbetuximab Fatigue C7D1 | 120 | 1.11 (Standard Deviation 20.99) |
| CAPOX+ Placebo Fatigue C7D1 | 126 | -1.06 (Standard Deviation 23.11) |
| CAPOX+ Zolbetuximab Fatigue C8D1 | 108 | 4.94 (Standard Deviation 20.34) |
| CAPOX+ Placebo Fatigue C8D1 | 110 | 0.10 (Standard Deviation 23.05) |
| CAPOX+ Zolbetuximab Fatigue C9D1 | 102 | 1.96 (Standard Deviation 24.94) |
| CAPOX+ Placebo Fatigue C9D1 | 103 | -0.86 (Standard Deviation 23.06) |
| CAPOX+ Zolbetuximab Fatigue C10D1 | 85 | 1.57 (Standard Deviation 25.67) |
| CAPOX+ Placebo Fatigue C10D1 | 79 | -0.42 (Standard Deviation 24.81) |
| CAPOX+ Zolbetuximab Fatigue C11D1 | 81 | -0.14 (Standard Deviation 22.53) |
| CAPOX+ Placebo Fatigue C11D1 | 71 | -0.31 (Standard Deviation 24.34) |
| CAPOX+ Zolbetuximab Fatigue C12D1 | 75 | -0.89 (Standard Deviation 24.08) |
| CAPOX+ Placebo Fatigue C12D1 | 57 | 0.00 (Standard Deviation 23.19) |
| CAPOX+ Zolbetuximab Fatigue C13D1 | 60 | -3.70 (Standard Deviation 25.03) |
| CAPOX+ Placebo Fatigue C13D1 | 48 | 0.00 (Standard Deviation 20.76) |
| CAPOX+ Zolbetuximab Fatigue C14D1 | 55 | -2.22 (Standard Deviation 19.99) |
| CAPOX+ Placebo Fatigue C14D1 | 44 | -0.76 (Standard Deviation 19.82) |
| CAPOX+ Zolbetuximab Fatigue C15D1 | 51 | -3.27 (Standard Deviation 21.12) |
| CAPOX+ Placebo Fatigue C15D1 | 36 | -0.62 (Standard Deviation 17.20) |
| CAPOX+ Zolbetuximab Fatigue C16D1 | 48 | -4.63 (Standard Deviation 21.60) |
| CAPOX+ Placebo Fatigue C16D1 | 31 | -2.15 (Standard Deviation 17.55) |
| CAPOX+ Zolbetuximab Fatigue C17D1 | 43 | -2.07 (Standard Deviation 18.98) |
| CAPOX+ Placebo Fatigue C17D1 | 25 | -1.78 (Standard Deviation 18.61) |
| CAPOX+ Zolbetuximab Fatigue C18D1 | 41 | -0.81 (Standard Deviation 17.10) |
| CAPOX+ Placebo Fatigue C18D1 | 21 | -7.94 (Standard Deviation 17.26) |
| CAPOX+ Zolbetuximab Fatigue C19D1 | 40 | -1.11 (Standard Deviation 17.93) |
| CAPOX+ Placebo Fatigue C19D1 | 20 | -4.44 (Standard Deviation 15.46) |
| CAPOX+ Zolbetuximab Fatigue C20D1 | 39 | 0.57 (Standard Deviation 16.51) |
| CAPOX+ Placebo Fatigue C20D1 | 19 | -4.68 (Standard Deviation 18.64) |
| CAPOX+ Zolbetuximab Fatigue C21D1 | 36 | 1.23 (Standard Deviation 16.75) |
| CAPOX+ Placebo Fatigue C21D1 | 20 | -3.33 (Standard Deviation 18.77) |
| CAPOX+ Zolbetuximab Fatigue C22D1 | 31 | -2.87 (Standard Deviation 19.02) |
| CAPOX+ Placebo Fatigue C22D1 | 17 | -3.27 (Standard Deviation 18.33) |
| CAPOX+ Zolbetuximab Fatigue C23D1 | 31 | -1.43 (Standard Deviation 17.62) |
| CAPOX+ Placebo Fatigue C23D1 | 16 | -4.17 (Standard Deviation 22.18) |
| CAPOX+ Zolbetuximab Fatigue C24D1 | 29 | -1.15 (Standard Deviation 17.65) |
| CAPOX+ Placebo Fatigue C24D1 | 12 | -3.70 (Standard Deviation 19.73) |
| CAPOX+ Zolbetuximab Fatigue C25D1 | 28 | -3.17 (Standard Deviation 18.36) |
| CAPOX+ Placebo Fatigue C25D1 | 12 | -0.93 (Standard Deviation 17.38) |
| CAPOX+ Zolbetuximab Fatigue C26D1 | 26 | -1.71 (Standard Deviation 21.70) |
| CAPOX+ Placebo Fatigue C26D1 | 9 | 0.00 (Standard Deviation 11.11) |
| CAPOX+ Zolbetuximab Fatigue C27D1 | 25 | -3.11 (Standard Deviation 14.17) |
| CAPOX+ Placebo Fatigue C27D1 | 10 | 2.22 (Standard Deviation 15.54) |
| CAPOX+ Zolbetuximab Fatigue C28D1 | 21 | -2.65 (Standard Deviation 16.06) |
| CAPOX+ Placebo Fatigue C28D1 | 11 | 8.08 (Standard Deviation 13.23) |
| CAPOX+ Zolbetuximab Fatigue C29D1 | 22 | -3.54 (Standard Deviation 14.70) |
| CAPOX+ Placebo Fatigue C29D1 | 12 | 5.56 (Standard Deviation 18.65) |
| CAPOX+ Zolbetuximab Fatigue C30D1 | 20 | -2.78 (Standard Deviation 13.90) |
| CAPOX+ Zolbetuximab Fatigue C31D1 | 20 | -2.22 (Standard Deviation 17.14) |
| CAPOX+ Zolbetuximab Fatigue C32D1 | 18 | -5.56 (Standard Deviation 18.77) |
| CAPOX+ Zolbetuximab Fatigue C33D1 | 15 | -8.15 (Standard Deviation 19.91) |
| CAPOX+ Zolbetuximab Fatigue C34D1 | 12 | -12.04 (Standard Deviation 18.63) |
| CAPOX+ Zolbetuximab Fatigue C35D1 | 13 | -10.26 (Standard Deviation 12.39) |
| CAPOX+ Zolbetuximab Fatigue C36D1 | 12 | -12.04 (Standard Deviation 10.00) |
| CAPOX+ Zolbetuximab Fatigue C37D1 | 11 | -12.12 (Standard Deviation 14.45) |
| CAPOX+ Zolbetuximab Fatigue C38D1 | 10 | -12.22 (Standard Deviation 21.24) |
| CAPOX+ Zolbetuximab Fatigue C39D1 | 9 | -7.41 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Fatigue 30 day follow up | 57 | 11.50 (Standard Deviation 23.09) |
| CAPOX+ Placebo Fatigue 30 day follow up | 78 | 13.68 (Standard Deviation 27.15) |
| CAPOX+ Zolbetuximab Fatigue 90 day follow up | 61 | 11.84 (Standard Deviation 21.55) |
| CAPOX+ Placebo Fatigue 90 day follow up | 79 | 7.31 (Standard Deviation 22.00) |
| CAPOX+ Zolbetuximab Nausea and Vomiting Baseline | 243 | 10.49 (Standard Deviation 18.08) |
| CAPOX+ Placebo Nausea and Vomiting Baseline | 242 | 15.08 (Standard Deviation 23.20) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C2D1 | 208 | 6.41 (Standard Deviation 19.77) |
| CAPOX+ Placebo Nausea and Vomiting C2D1 | 217 | -0.92 (Standard Deviation 20.77) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C3D1 | 182 | 5.86 (Standard Deviation 19.88) |
| CAPOX+ Placebo Nausea and Vomiting C3D1 | 197 | 0.17 (Standard Deviation 22.21) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C4D1 | 169 | 4.73 (Standard Deviation 20.67) |
| CAPOX+ Placebo Nausea and Vomiting C4D1 | 169 | -2.76 (Standard Deviation 22.98) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C5D1 | 159 | 4.93 (Standard Deviation 21.01) |
| CAPOX+ Placebo Nausea and Vomiting C5D1 | 165 | -3.74 (Standard Deviation 25.06) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C6D1 | 149 | 6.04 (Standard Deviation 20.25) |
| CAPOX+ Placebo Nausea and Vomiting C6D1 | 146 | -1.60 (Standard Deviation 24.71) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C7D1 | 120 | 1.25 (Standard Deviation 19.94) |
| CAPOX+ Placebo Nausea and Vomiting C7D1 | 126 | -2.91 (Standard Deviation 24.59) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C8D1 | 108 | 3.09 (Standard Deviation 20.14) |
| CAPOX+ Placebo Nausea and Vomiting C8D1 | 110 | -6.97 (Standard Deviation 23.83) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C9D1 | 102 | 1.80 (Standard Deviation 20.83) |
| CAPOX+ Placebo Nausea and Vomiting C9D1 | 103 | -6.15 (Standard Deviation 20.74) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C10D1 | 85 | 0.39 (Standard Deviation 20.25) |
| CAPOX+ Placebo Nausea and Vomiting C10D1 | 79 | -7.17 (Standard Deviation 24.99) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C11D1 | 81 | -1.65 (Standard Deviation 19.65) |
| CAPOX+ Placebo Nausea and Vomiting C11D1 | 71 | -6.81 (Standard Deviation 24.17) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C12D1 | 75 | -1.11 (Standard Deviation 19.82) |
| CAPOX+ Placebo Nausea and Vomiting C12D1 | 57 | -2.34 (Standard Deviation 25.48) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C13D1 | 60 | -3.33 (Standard Deviation 20.54) |
| CAPOX+ Placebo Nausea and Vomiting C13D1 | 48 | -7.99 (Standard Deviation 23.82) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C14D1 | 55 | -1.21 (Standard Deviation 19.73) |
| CAPOX+ Placebo Nausea and Vomiting C14D1 | 44 | -4.17 (Standard Deviation 21.00) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C15D1 | 51 | -2.94 (Standard Deviation 18.17) |
| CAPOX+ Placebo Nausea and Vomiting C15D1 | 36 | -5.56 (Standard Deviation 20.31) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C16D1 | 48 | -1.04 (Standard Deviation 20.17) |
| CAPOX+ Placebo Nausea and Vomiting C16D1 | 31 | -5.91 (Standard Deviation 20.43) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C17D1 | 43 | -1.94 (Standard Deviation 18.62) |
| CAPOX+ Placebo Nausea and Vomiting C17D1 | 25 | 2.67 (Standard Deviation 13.33) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C18D1 | 41 | 0.81 (Standard Deviation 20.40) |
| CAPOX+ Placebo Nausea and Vomiting C18D1 | 21 | -4.76 (Standard Deviation 11.95) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C19D1 | 40 | 0.00 (Standard Deviation 20.32) |
| CAPOX+ Placebo Nausea and Vomiting C19D1 | 20 | -4.17 (Standard Deviation 11.94) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C20D1 | 39 | -0.85 (Standard Deviation 19.10) |
| CAPOX+ Placebo Nausea and Vomiting C20D1 | 19 | -4.39 (Standard Deviation 12.22) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C21D1 | 36 | 0.00 (Standard Deviation 19.92) |
| CAPOX+ Placebo Nausea and Vomiting C21D1 | 20 | -3.33 (Standard Deviation 11.60) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C22D1 | 31 | -2.69 (Standard Deviation 20.23) |
| CAPOX+ Placebo Nausea and Vomiting C22D1 | 17 | -5.88 (Standard Deviation 13.10) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C23D1 | 31 | -3.76 (Standard Deviation 21.39) |
| CAPOX+ Placebo Nausea and Vomiting C23D1 | 16 | -7.29 (Standard Deviation 12.12) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C24D1 | 29 | -3.45 (Standard Deviation 20.11) |
| CAPOX+ Placebo Nausea and Vomiting C24D1 | 12 | -1.39 (Standard Deviation 11.14) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C25D1 | 28 | -4.17 (Standard Deviation 20.60) |
| CAPOX+ Placebo Nausea and Vomiting C25D1 | 12 | -6.94 (Standard Deviation 13.22) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C26D1 | 26 | -4.49 (Standard Deviation 20.85) |
| CAPOX+ Placebo Nausea and Vomiting C26D1 | 9 | -1.85 (Standard Deviation 24.22) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C27D1 | 25 | -4.67 (Standard Deviation 20.14) |
| CAPOX+ Placebo Nausea and Vomiting C27D1 | 10 | -5.00 (Standard Deviation 15.81) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C28D1 | 21 | -0.79 (Standard Deviation 23.85) |
| CAPOX+ Placebo Nausea and Vomiting C28D1 | 11 | -3.03 (Standard Deviation 14.56) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C29D1 | 22 | -3.79 (Standard Deviation 21.78) |
| CAPOX+ Placebo Nausea and Vomiting C29D1 | 12 | -9.72 (Standard Deviation 13.22) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C30D1 | 20 | -3.33 (Standard Deviation 21.36) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C31D1 | 20 | -4.17 (Standard Deviation 23.49) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C32D1 | 18 | -2.78 (Standard Deviation 25.72) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C33D1 | 15 | -8.89 (Standard Deviation 21.70) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C34D1 | 12 | -8.33 (Standard Deviation 25.13) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C35D1 | 13 | -6.41 (Standard Deviation 25.04) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C36D1 | 12 | -6.94 (Standard Deviation 25.08) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C37D1 | 11 | -9.09 (Standard Deviation 20.23) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C38D1 | 10 | -6.67 (Standard Deviation 14.05) |
| CAPOX+ Zolbetuximab Nausea and Vomiting C39D1 | 9 | -5.56 (Standard Deviation 8.33) |
| CAPOX+ Zolbetuximab Nausea and Vomiting 30 day follow up | 57 | 4.39 (Standard Deviation 19.80) |
| CAPOX+ Placebo Nausea and Vomiting 30 day follow up | 78 | 0.21 (Standard Deviation 24.25) |
| CAPOX+ Zolbetuximab Nausea and Vomiting 90 day follow up | 61 | 7.38 (Standard Deviation 21.20) |
| CAPOX+ Placebo Nausea and Vomiting 90 day follow up | 79 | -1.05 (Standard Deviation 26.06) |
| CAPOX+ Zolbetuximab Pain Baseline | 243 | 21.67 (Standard Deviation 22.14) |
| CAPOX+ Placebo Pain Baseline | 242 | 24.10 (Standard Deviation 23.71) |
| CAPOX+ Zolbetuximab Pain C2D1 | 208 | -4.17 (Standard Deviation 22.43) |
| CAPOX+ Placebo Pain C2D1 | 217 | -4.61 (Standard Deviation 20.08) |
| CAPOX+ Zolbetuximab Pain C3D1 | 182 | -5.40 (Standard Deviation 21.16) |
| CAPOX+ Placebo Pain C3D1 | 197 | -3.38 (Standard Deviation 22.77) |
| CAPOX+ Zolbetuximab Pain C4D1 | 169 | -7.10 (Standard Deviation 21.18) |
| CAPOX+ Placebo Pain C4D1 | 169 | -7.40 (Standard Deviation 22.41) |
| CAPOX+ Zolbetuximab Pain C5D1 | 159 | -4.82 (Standard Deviation 22.06) |
| CAPOX+ Placebo Pain C5D1 | 165 | -6.26 (Standard Deviation 26.05) |
| CAPOX+ Zolbetuximab Pain C6D1 | 149 | -3.13 (Standard Deviation 19.79) |
| CAPOX+ Placebo Pain C6D1 | 146 | -6.85 (Standard Deviation 26.09) |
| CAPOX+ Zolbetuximab Pain C7D1 | 120 | -6.39 (Standard Deviation 22.16) |
| CAPOX+ Placebo Pain C7D1 | 126 | -7.67 (Standard Deviation 22.57) |
| CAPOX+ Zolbetuximab Pain C8D1 | 108 | -4.17 (Standard Deviation 22.22) |
| CAPOX+ Placebo Pain C8D1 | 110 | -5.61 (Standard Deviation 24.96) |
| CAPOX+ Zolbetuximab Pain C9D1 | 102 | -5.07 (Standard Deviation 21.72) |
| CAPOX+ Placebo Pain C9D1 | 103 | -8.09 (Standard Deviation 24.46) |
| CAPOX+ Zolbetuximab Pain C10D1 | 85 | -4.12 (Standard Deviation 22.11) |
| CAPOX+ Placebo Pain C10D1 | 79 | -6.33 (Standard Deviation 25.50) |
| CAPOX+ Zolbetuximab Pain C11D1 | 81 | -6.38 (Standard Deviation 21.01) |
| CAPOX+ Placebo Pain C11D1 | 71 | -6.34 (Standard Deviation 26.78) |
| CAPOX+ Zolbetuximab Pain C12D1 | 75 | -4.44 (Standard Deviation 22.48) |
| CAPOX+ Placebo Pain C12D1 | 57 | -7.02 (Standard Deviation 24.99) |
| CAPOX+ Zolbetuximab Pain C13D1 | 60 | -6.39 (Standard Deviation 23.98) |
| CAPOX+ Placebo Pain C13D1 | 48 | -7.64 (Standard Deviation 24.54) |
| CAPOX+ Zolbetuximab Pain C14D1 | 55 | -5.76 (Standard Deviation 22.27) |
| CAPOX+ Placebo Pain C14D1 | 44 | -6.06 (Standard Deviation 24.14) |
| CAPOX+ Zolbetuximab Pain C15D1 | 51 | -6.54 (Standard Deviation 19.17) |
| CAPOX+ Placebo Pain C15D1 | 36 | -7.41 (Standard Deviation 21.25) |
| CAPOX+ Zolbetuximab Pain C16D1 | 48 | -6.25 (Standard Deviation 19.64) |
| CAPOX+ Placebo Pain C16D1 | 31 | -6.45 (Standard Deviation 23.04) |
| CAPOX+ Zolbetuximab Pain C17D1 | 43 | -5.04 (Standard Deviation 19.43) |
| CAPOX+ Placebo Pain C17D1 | 25 | -7.33 (Standard Deviation 25.95) |
| CAPOX+ Zolbetuximab Pain C18D1 | 41 | -1.63 (Standard Deviation 18.18) |
| CAPOX+ Placebo Pain C18D1 | 21 | -11.90 (Standard Deviation 27.96) |
| CAPOX+ Zolbetuximab Pain C19D1 | 40 | -2.50 (Standard Deviation 18.32) |
| CAPOX+ Placebo Pain C19D1 | 20 | -7.50 (Standard Deviation 26.20) |
| CAPOX+ Zolbetuximab Pain C20D1 | 39 | -0.85 (Standard Deviation 16.64) |
| CAPOX+ Placebo Pain C20D1 | 19 | -8.77 (Standard Deviation 30.11) |
| CAPOX+ Zolbetuximab Pain C21D1 | 36 | -2.31 (Standard Deviation 19.58) |
| CAPOX+ Placebo Pain C21D1 | 20 | -11.67 (Standard Deviation 29.17) |
| CAPOX+ Zolbetuximab Pain C22D1 | 31 | -2.69 (Standard Deviation 18.31) |
| CAPOX+ Placebo Pain C22D1 | 17 | -12.75 (Standard Deviation 30.35) |
| CAPOX+ Zolbetuximab Pain C23D1 | 31 | -3.76 (Standard Deviation 18.11) |
| CAPOX+ Placebo Pain C23D1 | 16 | -15.63 (Standard Deviation 30.10) |
| CAPOX+ Zolbetuximab Pain C24D1 | 29 | -4.02 (Standard Deviation 18.18) |
| CAPOX+ Placebo Pain C24D1 | 12 | -8.33 (Standard Deviation 29.73) |
| CAPOX+ Zolbetuximab Pain C25D1 | 28 | -1.19 (Standard Deviation 21.24) |
| CAPOX+ Placebo Pain C25D1 | 12 | -11.11 (Standard Deviation 29.59) |
| CAPOX+ Zolbetuximab Pain C26D1 | 26 | -3.85 (Standard Deviation 19.61) |
| CAPOX+ Placebo Pain C26D1 | 9 | -9.26 (Standard Deviation 18.84) |
| CAPOX+ Zolbetuximab Pain C27D1 | 25 | -4.00 (Standard Deviation 20.57) |
| CAPOX+ Placebo Pain C27D1 | 10 | -6.67 (Standard Deviation 23.83) |
| CAPOX+ Zolbetuximab Pain C28D1 | 21 | -4.76 (Standard Deviation 21.18) |
| CAPOX+ Placebo Pain C28D1 | 11 | -3.03 (Standard Deviation 19.46) |
| CAPOX+ Zolbetuximab Pain C29D1 | 22 | -3.79 (Standard Deviation 21.16) |
| CAPOX+ Placebo Pain C29D1 | 12 | -11.11 (Standard Deviation 23.92) |
| CAPOX+ Zolbetuximab Pain C30D1 | 20 | -6.67 (Standard Deviation 19.79) |
| CAPOX+ Zolbetuximab Pain C31D1 | 20 | -6.67 (Standard Deviation 21.90) |
| CAPOX+ Zolbetuximab Pain C32D1 | 18 | -6.48 (Standard Deviation 22.97) |
| CAPOX+ Zolbetuximab Pain C33D1 | 15 | -10.00 (Standard Deviation 22.54) |
| CAPOX+ Zolbetuximab Pain C34D1 | 12 | -13.89 (Standard Deviation 21.12) |
| CAPOX+ Zolbetuximab Pain C35D1 | 13 | -10.26 (Standard Deviation 22.09) |
| CAPOX+ Zolbetuximab Pain C36D1 | 12 | -12.50 (Standard Deviation 21.47) |
| CAPOX+ Zolbetuximab Pain C37D1 | 11 | -12.12 (Standard Deviation 23.68) |
| CAPOX+ Zolbetuximab Pain C38D1 | 10 | -5.00 (Standard Deviation 24.91) |
| CAPOX+ Zolbetuximab Pain C39D1 | 9 | -9.26 (Standard Deviation 16.90) |
| CAPOX+ Zolbetuximab Pain 30 day follow up | 57 | 4.97 (Standard Deviation 27.45) |
| CAPOX+ Placebo Pain 30 day follow up | 78 | 8.76 (Standard Deviation 26.42) |
| CAPOX+ Zolbetuximab Pain 90 day follow up | 61 | 4.37 (Standard Deviation 22.55) |
| CAPOX+ Placebo Pain 90 day follow up | 79 | 2.11 (Standard Deviation 22.70) |
| CAPOX+ Zolbetuximab Dyspnoea Baseline | 243 | 9.74 (Standard Deviation 17.96) |
| CAPOX+ Placebo Dyspnoea Baseline | 242 | 10.88 (Standard Deviation 19.35) |
| CAPOX+ Zolbetuximab Dyspnoea C2D1 | 208 | 2.24 (Standard Deviation 15.89) |
| CAPOX+ Placebo Dyspnoea C2D1 | 217 | -0.77 (Standard Deviation 17.99) |
| CAPOX+ Zolbetuximab Dyspnoea C3D1 | 182 | -0.37 (Standard Deviation 16.80) |
| CAPOX+ Placebo Dyspnoea C3D1 | 197 | 0.51 (Standard Deviation 22.20) |
| CAPOX+ Zolbetuximab Dyspnoea C4D1 | 169 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Placebo Dyspnoea C4D1 | 169 | -0.39 (Standard Deviation 23.28) |
| CAPOX+ Zolbetuximab Dyspnoea C5D1 | 159 | -0.42 (Standard Deviation 19.48) |
| CAPOX+ Placebo Dyspnoea C5D1 | 165 | -2.22 (Standard Deviation 23.03) |
| CAPOX+ Zolbetuximab Dyspnoea C6D1 | 149 | 1.12 (Standard Deviation 19.54) |
| CAPOX+ Placebo Dyspnoea C6D1 | 146 | 0.00 (Standard Deviation 21.80) |
| CAPOX+ Zolbetuximab Dyspnoea C7D1 | 120 | 1.67 (Standard Deviation 20.20) |
| CAPOX+ Placebo Dyspnoea C7D1 | 126 | -0.53 (Standard Deviation 22.70) |
| CAPOX+ Zolbetuximab Dyspnoea C8D1 | 108 | 1.85 (Standard Deviation 19.25) |
| CAPOX+ Placebo Dyspnoea C8D1 | 110 | 2.12 (Standard Deviation 23.58) |
| CAPOX+ Zolbetuximab Dyspnoea C9D1 | 102 | 0.65 (Standard Deviation 18.15) |
| CAPOX+ Placebo Dyspnoea C9D1 | 103 | -2.27 (Standard Deviation 20.49) |
| CAPOX+ Zolbetuximab Dyspnoea C10D1 | 85 | 1.18 (Standard Deviation 20.86) |
| CAPOX+ Placebo Dyspnoea C10D1 | 79 | -0.42 (Standard Deviation 24.16) |
| CAPOX+ Zolbetuximab Dyspnoea C11D1 | 81 | 0.41 (Standard Deviation 20.07) |
| CAPOX+ Placebo Dyspnoea C11D1 | 71 | -3.29 (Standard Deviation 21.20) |
| CAPOX+ Zolbetuximab Dyspnoea C12D1 | 75 | -1.33 (Standard Deviation 20.09) |
| CAPOX+ Placebo Dyspnoea C12D1 | 57 | -2.92 (Standard Deviation 19.19) |
| CAPOX+ Zolbetuximab Dyspnoea C13D1 | 60 | -0.56 (Standard Deviation 23.36) |
| CAPOX+ Placebo Dyspnoea C13D1 | 48 | -2.78 (Standard Deviation 21.56) |
| CAPOX+ Zolbetuximab Dyspnoea C14D1 | 55 | -0.61 (Standard Deviation 20.78) |
| CAPOX+ Placebo Dyspnoea C14D1 | 44 | -4.55 (Standard Deviation 19.81) |
| CAPOX+ Zolbetuximab Dyspnoea C15D1 | 51 | 0.00 (Standard Deviation 17.64) |
| CAPOX+ Placebo Dyspnoea C15D1 | 36 | -4.63 (Standard Deviation 16.24) |
| CAPOX+ Zolbetuximab Dyspnoea C16D1 | 48 | -0.69 (Standard Deviation 16.11) |
| CAPOX+ Placebo Dyspnoea C16D1 | 31 | -3.23 (Standard Deviation 21.70) |
| CAPOX+ Zolbetuximab Dyspnoea C17D1 | 43 | 0.00 (Standard Deviation 16.27) |
| CAPOX+ Placebo Dyspnoea C17D1 | 25 | -6.67 (Standard Deviation 21.52) |
| CAPOX+ Zolbetuximab Dyspnoea C18D1 | 41 | 1.63 (Standard Deviation 16.59) |
| CAPOX+ Placebo Dyspnoea C18D1 | 21 | -9.52 (Standard Deviation 18.69) |
| CAPOX+ Zolbetuximab Dyspnoea C19D1 | 40 | 0.00 (Standard Deviation 16.88) |
| CAPOX+ Placebo Dyspnoea C19D1 | 20 | -11.67 (Standard Deviation 19.57) |
| CAPOX+ Zolbetuximab Dyspnoea C20D1 | 39 | 2.56 (Standard Deviation 19.32) |
| CAPOX+ Placebo Dyspnoea C20D1 | 19 | -10.53 (Standard Deviation 22.37) |
| CAPOX+ Zolbetuximab Dyspnoea C21D1 | 36 | 0.93 (Standard Deviation 16.88) |
| CAPOX+ Placebo Dyspnoea C21D1 | 20 | -10.00 (Standard Deviation 19.04) |
| CAPOX+ Zolbetuximab Dyspnoea C22D1 | 31 | 1.08 (Standard Deviation 20.15) |
| CAPOX+ Placebo Dyspnoea C22D1 | 17 | -9.80 (Standard Deviation 22.87) |
| CAPOX+ Zolbetuximab Dyspnoea C23D1 | 31 | 0.00 (Standard Deviation 14.91) |
| CAPOX+ Placebo Dyspnoea C23D1 | 16 | -8.33 (Standard Deviation 22.77) |
| CAPOX+ Zolbetuximab Dyspnoea C24D1 | 29 | 0.00 (Standard Deviation 17.82) |
| CAPOX+ Placebo Dyspnoea C24D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Dyspnoea C25D1 | 28 | 0.00 (Standard Deviation 20.29) |
| CAPOX+ Placebo Dyspnoea C25D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Dyspnoea C26D1 | 26 | -3.85 (Standard Deviation 14.38) |
| CAPOX+ Placebo Dyspnoea C26D1 | 9 | -7.41 (Standard Deviation 14.70) |
| CAPOX+ Zolbetuximab Dyspnoea C27D1 | 25 | 2.67 (Standard Deviation 16.44) |
| CAPOX+ Placebo Dyspnoea C27D1 | 10 | -6.67 (Standard Deviation 14.05) |
| CAPOX+ Zolbetuximab Dyspnoea C28D1 | 21 | -1.59 (Standard Deviation 16.59) |
| CAPOX+ Placebo Dyspnoea C28D1 | 11 | -9.09 (Standard Deviation 21.56) |
| CAPOX+ Zolbetuximab Dyspnoea C29D1 | 22 | 7.58 (Standard Deviation 27.08) |
| CAPOX+ Placebo Dyspnoea C29D1 | 12 | -11.11 (Standard Deviation 21.71) |
| CAPOX+ Zolbetuximab Dyspnoea C30D1 | 20 | 0.00 (Standard Deviation 18.73) |
| CAPOX+ Zolbetuximab Dyspnoea C31D1 | 20 | -1.67 (Standard Deviation 22.88) |
| CAPOX+ Zolbetuximab Dyspnoea C32D1 | 18 | 0.00 (Standard Deviation 22.87) |
| CAPOX+ Zolbetuximab Dyspnoea C33D1 | 15 | 2.22 (Standard Deviation 23.46) |
| CAPOX+ Zolbetuximab Dyspnoea C34D1 | 12 | -8.33 (Standard Deviation 20.72) |
| CAPOX+ Zolbetuximab Dyspnoea C35D1 | 13 | -2.56 (Standard Deviation 21.35) |
| CAPOX+ Zolbetuximab Dyspnoea C36D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Dyspnoea C37D1 | 11 | -9.09 (Standard Deviation 21.56) |
| CAPOX+ Zolbetuximab Dyspnoea C38D1 | 10 | -3.33 (Standard Deviation 18.92) |
| CAPOX+ Zolbetuximab Dyspnoea C39D1 | 9 | -3.70 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Dyspnoea 30 day follow up | 57 | 3.51 (Standard Deviation 16.29) |
| CAPOX+ Placebo Dyspnoea 30 day follow up | 78 | 4.27 (Standard Deviation 23.02) |
| CAPOX+ Zolbetuximab Dyspnoea 90 day follow up | 61 | 2.73 (Standard Deviation 15.27) |
| CAPOX+ Placebo Dyspnoea 90 day follow up | 79 | 2.53 (Standard Deviation 24.33) |
| CAPOX+ Zolbetuximab Insomnia Baseline | 243 | 20.99 (Standard Deviation 27.16) |
| CAPOX+ Placebo Insomnia Baseline | 242 | 24.79 (Standard Deviation 26.66) |
| CAPOX+ Zolbetuximab Insomnia C2D1 | 208 | -1.44 (Standard Deviation 27.47) |
| CAPOX+ Placebo Insomnia C2D1 | 217 | -1.54 (Standard Deviation 27.55) |
| CAPOX+ Zolbetuximab Insomnia C3D1 | 182 | -0.55 (Standard Deviation 28.14) |
| CAPOX+ Placebo Insomnia C3D1 | 197 | -2.54 (Standard Deviation 28.56) |
| CAPOX+ Zolbetuximab Insomnia C4D1 | 169 | -4.73 (Standard Deviation 28.47) |
| CAPOX+ Placebo Insomnia C4D1 | 169 | -5.13 (Standard Deviation 27.94) |
| CAPOX+ Zolbetuximab Insomnia C5D1 | 159 | -2.73 (Standard Deviation 28.06) |
| CAPOX+ Placebo Insomnia C5D1 | 165 | -4.44 (Standard Deviation 28.16) |
| CAPOX+ Zolbetuximab Insomnia C6D1 | 149 | -5.15 (Standard Deviation 28.40) |
| CAPOX+ Placebo Insomnia C6D1 | 146 | -2.51 (Standard Deviation 30.35) |
| CAPOX+ Zolbetuximab Insomnia C7D1 | 120 | -5.28 (Standard Deviation 28.34) |
| CAPOX+ Placebo Insomnia C7D1 | 126 | -2.91 (Standard Deviation 31.28) |
| CAPOX+ Zolbetuximab Insomnia C8D1 | 108 | 0.31 (Standard Deviation 29.00) |
| CAPOX+ Placebo Insomnia C8D1 | 110 | -4.85 (Standard Deviation 25.48) |
| CAPOX+ Zolbetuximab Insomnia C9D1 | 102 | -4.90 (Standard Deviation 29.44) |
| CAPOX+ Placebo Insomnia C9D1 | 103 | -4.21 (Standard Deviation 27.88) |
| CAPOX+ Zolbetuximab Insomnia C10D1 | 85 | -5.49 (Standard Deviation 29.48) |
| CAPOX+ Placebo Insomnia C10D1 | 79 | -0.42 (Standard Deviation 28.49) |
| CAPOX+ Zolbetuximab Insomnia C11D1 | 81 | -2.47 (Standard Deviation 29.71) |
| CAPOX+ Placebo Insomnia C11D1 | 71 | 0.94 (Standard Deviation 30.33) |
| CAPOX+ Zolbetuximab Insomnia C12D1 | 75 | -0.89 (Standard Deviation 27.39) |
| CAPOX+ Placebo Insomnia C12D1 | 57 | -0.58 (Standard Deviation 29.87) |
| CAPOX+ Zolbetuximab Insomnia C13D1 | 60 | -3.33 (Standard Deviation 24.32) |
| CAPOX+ Placebo Insomnia C13D1 | 48 | 1.39 (Standard Deviation 33.66) |
| CAPOX+ Zolbetuximab Insomnia C14D1 | 55 | 0.61 (Standard Deviation 27.59) |
| CAPOX+ Placebo Insomnia C14D1 | 44 | -0.76 (Standard Deviation 33.32) |
| CAPOX+ Zolbetuximab Insomnia C15D1 | 51 | 5.23 (Standard Deviation 23.45) |
| CAPOX+ Placebo Insomnia C15D1 | 36 | 1.85 (Standard Deviation 30.80) |
| CAPOX+ Zolbetuximab Insomnia C16D1 | 48 | 0.00 (Standard Deviation 25.73) |
| CAPOX+ Placebo Insomnia C16D1 | 31 | 6.45 (Standard Deviation 24.97) |
| CAPOX+ Zolbetuximab Insomnia C17D1 | 43 | 1.55 (Standard Deviation 25.15) |
| CAPOX+ Placebo Insomnia C17D1 | 25 | 12.00 (Standard Deviation 31.74) |
| CAPOX+ Zolbetuximab Insomnia C18D1 | 41 | 0.00 (Standard Deviation 24.72) |
| CAPOX+ Placebo Insomnia C18D1 | 21 | 4.76 (Standard Deviation 24.23) |
| CAPOX+ Zolbetuximab Insomnia C19D1 | 40 | 0.00 (Standard Deviation 21.35) |
| CAPOX+ Placebo Insomnia C19D1 | 20 | 6.67 (Standard Deviation 38.39) |
| CAPOX+ Zolbetuximab Insomnia C20D1 | 39 | -0.85 (Standard Deviation 17.91) |
| CAPOX+ Placebo Insomnia C20D1 | 19 | 7.02 (Standard Deviation 23.78) |
| CAPOX+ Zolbetuximab Insomnia C21D1 | 36 | 0.00 (Standard Deviation 19.52) |
| CAPOX+ Placebo Insomnia C21D1 | 20 | 8.33 (Standard Deviation 30.35) |
| CAPOX+ Zolbetuximab Insomnia C22D1 | 31 | -5.38 (Standard Deviation 17.42) |
| CAPOX+ Placebo Insomnia C22D1 | 17 | 9.80 (Standard Deviation 34.89) |
| CAPOX+ Zolbetuximab Insomnia C23D1 | 31 | -3.23 (Standard Deviation 15.76) |
| CAPOX+ Placebo Insomnia C23D1 | 16 | 4.17 (Standard Deviation 34.16) |
| CAPOX+ Zolbetuximab Insomnia C24D1 | 29 | 0.00 (Standard Deviation 17.82) |
| CAPOX+ Placebo Insomnia C24D1 | 12 | 0.00 (Standard Deviation 24.62) |
| CAPOX+ Zolbetuximab Insomnia C25D1 | 28 | -2.38 (Standard Deviation 20.14) |
| CAPOX+ Placebo Insomnia C25D1 | 12 | 2.78 (Standard Deviation 22.29) |
| CAPOX+ Zolbetuximab Insomnia C26D1 | 26 | -2.56 (Standard Deviation 18.67) |
| CAPOX+ Placebo Insomnia C26D1 | 9 | 3.70 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Insomnia C27D1 | 25 | -4.00 (Standard Deviation 17.53) |
| CAPOX+ Placebo Insomnia C27D1 | 10 | 6.67 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Insomnia C28D1 | 21 | -1.59 (Standard Deviation 19.65) |
| CAPOX+ Placebo Insomnia C28D1 | 11 | 15.15 (Standard Deviation 27.34) |
| CAPOX+ Zolbetuximab Insomnia C29D1 | 22 | 1.52 (Standard Deviation 21.77) |
| CAPOX+ Placebo Insomnia C29D1 | 12 | 8.33 (Standard Deviation 25.13) |
| CAPOX+ Zolbetuximab Insomnia C30D1 | 20 | -1.67 (Standard Deviation 17.01) |
| CAPOX+ Zolbetuximab Insomnia C31D1 | 20 | 1.67 (Standard Deviation 17.01) |
| CAPOX+ Zolbetuximab Insomnia C32D1 | 18 | 0.00 (Standard Deviation 22.87) |
| CAPOX+ Zolbetuximab Insomnia C33D1 | 15 | -2.22 (Standard Deviation 19.79) |
| CAPOX+ Zolbetuximab Insomnia C34D1 | 12 | -2.78 (Standard Deviation 22.29) |
| CAPOX+ Zolbetuximab Insomnia C35D1 | 13 | 0.00 (Standard Deviation 23.57) |
| CAPOX+ Zolbetuximab Insomnia C36D1 | 12 | -2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Insomnia C37D1 | 11 | 3.03 (Standard Deviation 23.35) |
| CAPOX+ Zolbetuximab Insomnia C38D1 | 10 | 6.67 (Standard Deviation 34.43) |
| CAPOX+ Zolbetuximab Insomnia C39D1 | 9 | 7.41 (Standard Deviation 22.22) |
| CAPOX+ Zolbetuximab Insomnia 30 day follow up | 57 | 6.43 (Standard Deviation 30.50) |
| CAPOX+ Placebo Insomnia 30 day follow up | 78 | 8.55 (Standard Deviation 36.21) |
| CAPOX+ Zolbetuximab Insomnia 90 day follow up | 61 | 6.56 (Standard Deviation 22.62) |
| CAPOX+ Placebo Insomnia 90 day follow up | 79 | 0.42 (Standard Deviation 28.99) |
| CAPOX+ Zolbetuximab Appetite Loss Baseline | 243 | 26.20 (Standard Deviation 29.91) |
| CAPOX+ Placebo Appetite Loss Baseline | 242 | 24.66 (Standard Deviation 29.17) |
| CAPOX+ Zolbetuximab Appetite Loss C2D1 | 208 | 3.69 (Standard Deviation 31.97) |
| CAPOX+ Placebo Appetite Loss C2D1 | 217 | -2.61 (Standard Deviation 27.37) |
| CAPOX+ Zolbetuximab Appetite Loss C3D1 | 182 | 0.73 (Standard Deviation 34.86) |
| CAPOX+ Placebo Appetite Loss C3D1 | 197 | -2.71 (Standard Deviation 27.43) |
| CAPOX+ Zolbetuximab Appetite Loss C4D1 | 169 | -3.55 (Standard Deviation 34.32) |
| CAPOX+ Placebo Appetite Loss C4D1 | 169 | -5.13 (Standard Deviation 33.13) |
| CAPOX+ Zolbetuximab Appetite Loss C5D1 | 159 | -2.94 (Standard Deviation 36.24) |
| CAPOX+ Placebo Appetite Loss C5D1 | 165 | -4.44 (Standard Deviation 33.03) |
| CAPOX+ Zolbetuximab Appetite Loss C6D1 | 149 | -0.22 (Standard Deviation 34.55) |
| CAPOX+ Placebo Appetite Loss C6D1 | 146 | -2.51 (Standard Deviation 33.47) |
| CAPOX+ Zolbetuximab Appetite Loss C7D1 | 120 | -4.44 (Standard Deviation 37.41) |
| CAPOX+ Placebo Appetite Loss C7D1 | 126 | -6.88 (Standard Deviation 31.36) |
| CAPOX+ Zolbetuximab Appetite Loss C8D1 | 108 | -1.23 (Standard Deviation 31.55) |
| CAPOX+ Placebo Appetite Loss C8D1 | 110 | -6.36 (Standard Deviation 32.71) |
| CAPOX+ Zolbetuximab Appetite Loss C9D1 | 102 | -3.92 (Standard Deviation 36.72) |
| CAPOX+ Placebo Appetite Loss C9D1 | 103 | -7.12 (Standard Deviation 34.51) |
| CAPOX+ Zolbetuximab Appetite Loss C10D1 | 85 | -3.92 (Standard Deviation 31.04) |
| CAPOX+ Placebo Appetite Loss C10D1 | 79 | -10.13 (Standard Deviation 32.62) |
| CAPOX+ Zolbetuximab Appetite Loss C11D1 | 81 | -7.82 (Standard Deviation 31.30) |
| CAPOX+ Placebo Appetite Loss C11D1 | 71 | -12.21 (Standard Deviation 33.92) |
| CAPOX+ Zolbetuximab Appetite Loss C12D1 | 75 | -8.00 (Standard Deviation 31.40) |
| CAPOX+ Placebo Appetite Loss C12D1 | 57 | -11.11 (Standard Deviation 30.43) |
| CAPOX+ Zolbetuximab Appetite Loss C13D1 | 60 | -9.44 (Standard Deviation 36.36) |
| CAPOX+ Placebo Appetite Loss C13D1 | 48 | -12.50 (Standard Deviation 31.23) |
| CAPOX+ Zolbetuximab Appetite Loss C14D1 | 55 | -12.12 (Standard Deviation 31.01) |
| CAPOX+ Placebo Appetite Loss C14D1 | 44 | -11.36 (Standard Deviation 30.45) |
| CAPOX+ Zolbetuximab Appetite Loss C15D1 | 51 | -9.80 (Standard Deviation 30.03) |
| CAPOX+ Placebo Appetite Loss C15D1 | 36 | -11.11 (Standard Deviation 29.81) |
| CAPOX+ Zolbetuximab Appetite Loss C16D1 | 48 | -9.72 (Standard Deviation 32.22) |
| CAPOX+ Placebo Appetite Loss C16D1 | 31 | -8.60 (Standard Deviation 32.17) |
| CAPOX+ Zolbetuximab Appetite Loss C17D1 | 43 | -8.53 (Standard Deviation 32.61) |
| CAPOX+ Placebo Appetite Loss C17D1 | 25 | -6.67 (Standard Deviation 36.00) |
| CAPOX+ Zolbetuximab Appetite Loss C18D1 | 41 | -12.20 (Standard Deviation 32.28) |
| CAPOX+ Placebo Appetite Loss C18D1 | 21 | -9.52 (Standard Deviation 35.19) |
| CAPOX+ Zolbetuximab Appetite Loss C19D1 | 40 | -14.17 (Standard Deviation 30.09) |
| CAPOX+ Placebo Appetite Loss C19D1 | 20 | -15.00 (Standard Deviation 20.16) |
| CAPOX+ Zolbetuximab Appetite Loss C20D1 | 39 | -7.69 (Standard Deviation 33.74) |
| CAPOX+ Placebo Appetite Loss C20D1 | 19 | -15.79 (Standard Deviation 30.16) |
| CAPOX+ Zolbetuximab Appetite Loss C21D1 | 36 | -4.63 (Standard Deviation 33.00) |
| CAPOX+ Placebo Appetite Loss C21D1 | 20 | -10.00 (Standard Deviation 34.37) |
| CAPOX+ Zolbetuximab Appetite Loss C22D1 | 31 | -10.75 (Standard Deviation 32.65) |
| CAPOX+ Placebo Appetite Loss C22D1 | 17 | -17.65 (Standard Deviation 31.44) |
| CAPOX+ Zolbetuximab Appetite Loss C23D1 | 31 | -10.75 (Standard Deviation 30.29) |
| CAPOX+ Placebo Appetite Loss C23D1 | 16 | -14.58 (Standard Deviation 40.31) |
| CAPOX+ Zolbetuximab Appetite Loss C24D1 | 29 | -13.79 (Standard Deviation 28.89) |
| CAPOX+ Placebo Appetite Loss C24D1 | 12 | -16.67 (Standard Deviation 33.33) |
| CAPOX+ Zolbetuximab Appetite Loss C25D1 | 28 | -10.71 (Standard Deviation 30.16) |
| CAPOX+ Placebo Appetite Loss C25D1 | 12 | -16.67 (Standard Deviation 33.33) |
| CAPOX+ Zolbetuximab Appetite Loss C26D1 | 26 | -12.82 (Standard Deviation 35.37) |
| CAPOX+ Placebo Appetite Loss C26D1 | 9 | -14.81 (Standard Deviation 17.57) |
| CAPOX+ Zolbetuximab Appetite Loss C27D1 | 25 | -8.00 (Standard Deviation 30.85) |
| CAPOX+ Placebo Appetite Loss C27D1 | 10 | -10.00 (Standard Deviation 31.62) |
| CAPOX+ Zolbetuximab Appetite Loss C28D1 | 21 | -14.29 (Standard Deviation 32.61) |
| CAPOX+ Placebo Appetite Loss C28D1 | 11 | 0.00 (Standard Deviation 29.81) |
| CAPOX+ Zolbetuximab Appetite Loss C29D1 | 22 | -16.67 (Standard Deviation 28.64) |
| CAPOX+ Placebo Appetite Loss C29D1 | 12 | -11.11 (Standard Deviation 29.59) |
| CAPOX+ Zolbetuximab Appetite Loss C30D1 | 20 | -10.00 (Standard Deviation 32.62) |
| CAPOX+ Zolbetuximab Appetite Loss C31D1 | 20 | -16.67 (Standard Deviation 31.53) |
| CAPOX+ Zolbetuximab Appetite Loss C32D1 | 18 | -14.81 (Standard Deviation 36.55) |
| CAPOX+ Zolbetuximab Appetite Loss C33D1 | 15 | -17.78 (Standard Deviation 37.52) |
| CAPOX+ Zolbetuximab Appetite Loss C34D1 | 12 | -27.78 (Standard Deviation 34.33) |
| CAPOX+ Zolbetuximab Appetite Loss C35D1 | 13 | -17.95 (Standard Deviation 35.00) |
| CAPOX+ Zolbetuximab Appetite Loss C36D1 | 12 | -19.44 (Standard Deviation 36.12) |
| CAPOX+ Zolbetuximab Appetite Loss C37D1 | 11 | -18.18 (Standard Deviation 37.61) |
| CAPOX+ Zolbetuximab Appetite Loss C38D1 | 10 | -23.33 (Standard Deviation 41.72) |
| CAPOX+ Zolbetuximab Appetite Loss C39D1 | 9 | -18.52 (Standard Deviation 37.68) |
| CAPOX+ Zolbetuximab Appetite Loss 30 day follow up | 57 | 4.68 (Standard Deviation 38.03) |
| CAPOX+ Placebo Appetite Loss 30 day follow up | 78 | 6.41 (Standard Deviation 29.94) |
| CAPOX+ Zolbetuximab Appetite Loss 90 day follow up | 61 | 3.28 (Standard Deviation 38.83) |
| CAPOX+ Placebo Appetite Loss 90 day follow up | 79 | 0.84 (Standard Deviation 32.46) |
| CAPOX+ Zolbetuximab Constipation Baseline | 243 | 18.11 (Standard Deviation 26.09) |
| CAPOX+ Placebo Constipation Baseline | 242 | 17.63 (Standard Deviation 27.02) |
| CAPOX+ Zolbetuximab Constipation C2D1 | 208 | -0.64 (Standard Deviation 24.94) |
| CAPOX+ Placebo Constipation C2D1 | 217 | -2.76 (Standard Deviation 25.10) |
| CAPOX+ Zolbetuximab Constipation C3D1 | 182 | -2.38 (Standard Deviation 26.23) |
| CAPOX+ Placebo Constipation C3D1 | 197 | -5.25 (Standard Deviation 23.58) |
| CAPOX+ Zolbetuximab Constipation C4D1 | 169 | -4.73 (Standard Deviation 26.30) |
| CAPOX+ Placebo Constipation C4D1 | 169 | -6.90 (Standard Deviation 29.07) |
| CAPOX+ Zolbetuximab Constipation C5D1 | 159 | -2.73 (Standard Deviation 25.97) |
| CAPOX+ Placebo Constipation C5D1 | 165 | -4.65 (Standard Deviation 26.77) |
| CAPOX+ Zolbetuximab Constipation C6D1 | 149 | -5.82 (Standard Deviation 26.77) |
| CAPOX+ Placebo Constipation C6D1 | 146 | -4.34 (Standard Deviation 29.36) |
| CAPOX+ Zolbetuximab Constipation C7D1 | 120 | -7.78 (Standard Deviation 26.19) |
| CAPOX+ Placebo Constipation C7D1 | 126 | -2.12 (Standard Deviation 32.32) |
| CAPOX+ Zolbetuximab Constipation C8D1 | 108 | -4.63 (Standard Deviation 27.14) |
| CAPOX+ Placebo Constipation C8D1 | 110 | -3.03 (Standard Deviation 31.13) |
| CAPOX+ Zolbetuximab Constipation C9D1 | 102 | -4.25 (Standard Deviation 22.82) |
| CAPOX+ Placebo Constipation C9D1 | 103 | -5.50 (Standard Deviation 29.19) |
| CAPOX+ Zolbetuximab Constipation C10D1 | 85 | -6.27 (Standard Deviation 26.97) |
| CAPOX+ Placebo Constipation C10D1 | 79 | -7.17 (Standard Deviation 30.97) |
| CAPOX+ Zolbetuximab Constipation C11D1 | 81 | -4.94 (Standard Deviation 28.44) |
| CAPOX+ Placebo Constipation C11D1 | 71 | -3.29 (Standard Deviation 33.88) |
| CAPOX+ Zolbetuximab Constipation C12D1 | 75 | -6.22 (Standard Deviation 25.52) |
| CAPOX+ Placebo Constipation C12D1 | 57 | -1.17 (Standard Deviation 26.70) |
| CAPOX+ Zolbetuximab Constipation C13D1 | 60 | -7.78 (Standard Deviation 25.58) |
| CAPOX+ Placebo Constipation C13D1 | 48 | -3.47 (Standard Deviation 33.85) |
| CAPOX+ Zolbetuximab Constipation C14D1 | 55 | -6.06 (Standard Deviation 25.73) |
| CAPOX+ Placebo Constipation C14D1 | 44 | -2.27 (Standard Deviation 28.21) |
| CAPOX+ Zolbetuximab Constipation C15D1 | 51 | -4.58 (Standard Deviation 27.50) |
| CAPOX+ Placebo Constipation C15D1 | 36 | -3.70 (Standard Deviation 32.64) |
| CAPOX+ Zolbetuximab Constipation C16D1 | 48 | -2.78 (Standard Deviation 26.48) |
| CAPOX+ Placebo Constipation C16D1 | 31 | -2.15 (Standard Deviation 33.26) |
| CAPOX+ Zolbetuximab Constipation C17D1 | 43 | -3.88 (Standard Deviation 27.42) |
| CAPOX+ Placebo Constipation C17D1 | 25 | -1.33 (Standard Deviation 26.32) |
| CAPOX+ Zolbetuximab Constipation C18D1 | 41 | -5.69 (Standard Deviation 25.71) |
| CAPOX+ Placebo Constipation C18D1 | 21 | -6.35 (Standard Deviation 29.10) |
| CAPOX+ Zolbetuximab Constipation C19D1 | 40 | -5.83 (Standard Deviation 23.74) |
| CAPOX+ Placebo Constipation C19D1 | 20 | -6.67 (Standard Deviation 17.44) |
| CAPOX+ Zolbetuximab Constipation C20D1 | 39 | 0.00 (Standard Deviation 31.53) |
| CAPOX+ Placebo Constipation C20D1 | 19 | -7.02 (Standard Deviation 26.24) |
| CAPOX+ Zolbetuximab Constipation C21D1 | 36 | 0.00 (Standard Deviation 26.43) |
| CAPOX+ Placebo Constipation C21D1 | 20 | -5.00 (Standard Deviation 31.11) |
| CAPOX+ Zolbetuximab Constipation C22D1 | 31 | -2.15 (Standard Deviation 32.13) |
| CAPOX+ Placebo Constipation C22D1 | 17 | 1.96 (Standard Deviation 24.92) |
| CAPOX+ Zolbetuximab Constipation C23D1 | 31 | -3.23 (Standard Deviation 27.70) |
| CAPOX+ Placebo Constipation C23D1 | 16 | 0.00 (Standard Deviation 34.43) |
| CAPOX+ Zolbetuximab Constipation C24D1 | 29 | -3.45 (Standard Deviation 22.44) |
| CAPOX+ Placebo Constipation C24D1 | 12 | 5.56 (Standard Deviation 31.25) |
| CAPOX+ Zolbetuximab Constipation C25D1 | 28 | -3.57 (Standard Deviation 24.58) |
| CAPOX+ Placebo Constipation C25D1 | 12 | 0.00 (Standard Deviation 24.62) |
| CAPOX+ Zolbetuximab Constipation C26D1 | 26 | -5.13 (Standard Deviation 26.15) |
| CAPOX+ Placebo Constipation C26D1 | 9 | 7.41 (Standard Deviation 14.70) |
| CAPOX+ Zolbetuximab Constipation C27D1 | 25 | -6.67 (Standard Deviation 25.46) |
| CAPOX+ Placebo Constipation C27D1 | 10 | 10.00 (Standard Deviation 22.50) |
| CAPOX+ Zolbetuximab Constipation C28D1 | 21 | -4.76 (Standard Deviation 19.11) |
| CAPOX+ Placebo Constipation C28D1 | 11 | 12.12 (Standard Deviation 22.47) |
| CAPOX+ Zolbetuximab Constipation C29D1 | 22 | 0.00 (Standard Deviation 20.57) |
| CAPOX+ Placebo Constipation C29D1 | 12 | 5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Constipation C30D1 | 20 | -3.33 (Standard Deviation 21.36) |
| CAPOX+ Zolbetuximab Constipation C31D1 | 20 | 0.00 (Standard Deviation 18.73) |
| CAPOX+ Zolbetuximab Constipation C32D1 | 18 | 1.85 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Constipation C33D1 | 15 | -6.67 (Standard Deviation 18.69) |
| CAPOX+ Zolbetuximab Constipation C34D1 | 12 | -8.33 (Standard Deviation 15.08) |
| CAPOX+ Zolbetuximab Constipation C35D1 | 13 | -7.69 (Standard Deviation 14.62) |
| CAPOX+ Zolbetuximab Constipation C36D1 | 12 | -8.33 (Standard Deviation 15.08) |
| CAPOX+ Zolbetuximab Constipation C37D1 | 11 | -12.12 (Standard Deviation 16.82) |
| CAPOX+ Zolbetuximab Constipation C38D1 | 10 | -6.67 (Standard Deviation 14.05) |
| CAPOX+ Zolbetuximab Constipation C39D1 | 9 | -3.70 (Standard Deviation 11.11) |
| CAPOX+ Zolbetuximab Constipation 30 day follow up | 57 | -2.34 (Standard Deviation 30.12) |
| CAPOX+ Placebo Constipation 30 day follow up | 78 | 4.70 (Standard Deviation 28.29) |
| CAPOX+ Zolbetuximab Constipation 90 day follow up | 61 | 1.09 (Standard Deviation 27.19) |
| CAPOX+ Placebo Constipation 90 day follow up | 79 | 5.91 (Standard Deviation 31.01) |
| CAPOX+ Zolbetuximab Diarrhoea Baseline | 243 | 8.09 (Standard Deviation 16.41) |
| CAPOX+ Placebo Diarrhoea Baseline | 242 | 7.71 (Standard Deviation 15.34) |
| CAPOX+ Zolbetuximab Diarrhoea C2D1 | 208 | 2.56 (Standard Deviation 20.56) |
| CAPOX+ Placebo Diarrhoea C2D1 | 217 | 5.68 (Standard Deviation 22.98) |
| CAPOX+ Zolbetuximab Diarrhoea C3D1 | 182 | 2.93 (Standard Deviation 21.40) |
| CAPOX+ Placebo Diarrhoea C3D1 | 197 | 4.06 (Standard Deviation 20.63) |
| CAPOX+ Zolbetuximab Diarrhoea C4D1 | 169 | 1.38 (Standard Deviation 21.00) |
| CAPOX+ Placebo Diarrhoea C4D1 | 169 | 3.94 (Standard Deviation 22.07) |
| CAPOX+ Zolbetuximab Diarrhoea C5D1 | 159 | 1.47 (Standard Deviation 20.66) |
| CAPOX+ Placebo Diarrhoea C5D1 | 165 | 4.44 (Standard Deviation 20.34) |
| CAPOX+ Zolbetuximab Diarrhoea C6D1 | 149 | 2.91 (Standard Deviation 24.79) |
| CAPOX+ Placebo Diarrhoea C6D1 | 146 | 3.65 (Standard Deviation 21.49) |
| CAPOX+ Zolbetuximab Diarrhoea C7D1 | 120 | 1.94 (Standard Deviation 24.17) |
| CAPOX+ Placebo Diarrhoea C7D1 | 126 | 5.29 (Standard Deviation 19.51) |
| CAPOX+ Zolbetuximab Diarrhoea C8D1 | 108 | 1.23 (Standard Deviation 21.82) |
| CAPOX+ Placebo Diarrhoea C8D1 | 110 | 2.12 (Standard Deviation 18.77) |
| CAPOX+ Zolbetuximab Diarrhoea C9D1 | 102 | 1.31 (Standard Deviation 23.42) |
| CAPOX+ Placebo Diarrhoea C9D1 | 103 | 0.65 (Standard Deviation 19.79) |
| CAPOX+ Zolbetuximab Diarrhoea C10D1 | 85 | 1.18 (Standard Deviation 19.55) |
| CAPOX+ Placebo Diarrhoea C10D1 | 79 | -2.53 (Standard Deviation 17.52) |
| CAPOX+ Zolbetuximab Diarrhoea C11D1 | 81 | -3.29 (Standard Deviation 21.48) |
| CAPOX+ Placebo Diarrhoea C11D1 | 71 | -0.94 (Standard Deviation 18.66) |
| CAPOX+ Zolbetuximab Diarrhoea C12D1 | 75 | -1.33 (Standard Deviation 17.71) |
| CAPOX+ Placebo Diarrhoea C12D1 | 57 | -2.92 (Standard Deviation 20.20) |
| CAPOX+ Zolbetuximab Diarrhoea C13D1 | 60 | -3.89 (Standard Deviation 16.34) |
| CAPOX+ Placebo Diarrhoea C13D1 | 48 | -4.17 (Standard Deviation 17.70) |
| CAPOX+ Zolbetuximab Diarrhoea C14D1 | 55 | -3.03 (Standard Deviation 17.30) |
| CAPOX+ Placebo Diarrhoea C14D1 | 44 | -2.27 (Standard Deviation 20.83) |
| CAPOX+ Zolbetuximab Diarrhoea C15D1 | 51 | -1.31 (Standard Deviation 19.96) |
| CAPOX+ Placebo Diarrhoea C15D1 | 36 | -2.78 (Standard Deviation 20.12) |
| CAPOX+ Zolbetuximab Diarrhoea C16D1 | 48 | -1.39 (Standard Deviation 16.78) |
| CAPOX+ Placebo Diarrhoea C16D1 | 31 | -3.23 (Standard Deviation 13.21) |
| CAPOX+ Zolbetuximab Diarrhoea C17D1 | 43 | -0.78 (Standard Deviation 19.91) |
| CAPOX+ Placebo Diarrhoea C17D1 | 25 | -4.00 (Standard Deviation 11.06) |
| CAPOX+ Zolbetuximab Diarrhoea C18D1 | 41 | -1.63 (Standard Deviation 16.59) |
| CAPOX+ Placebo Diarrhoea C18D1 | 21 | -4.76 (Standard Deviation 19.11) |
| CAPOX+ Zolbetuximab Diarrhoea C19D1 | 40 | -2.50 (Standard Deviation 15.81) |
| CAPOX+ Placebo Diarrhoea C19D1 | 20 | -3.33 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Diarrhoea C20D1 | 39 | -1.71 (Standard Deviation 17.01) |
| CAPOX+ Placebo Diarrhoea C20D1 | 19 | -3.51 (Standard Deviation 15.29) |
| CAPOX+ Zolbetuximab Diarrhoea C21D1 | 36 | -0.93 (Standard Deviation 18.66) |
| CAPOX+ Placebo Diarrhoea C21D1 | 20 | -3.33 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Diarrhoea C22D1 | 31 | 0.00 (Standard Deviation 14.91) |
| CAPOX+ Placebo Diarrhoea C22D1 | 17 | -5.88 (Standard Deviation 21.20) |
| CAPOX+ Zolbetuximab Diarrhoea C23D1 | 31 | 1.08 (Standard Deviation 16.06) |
| CAPOX+ Placebo Diarrhoea C23D1 | 16 | -8.33 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Diarrhoea C24D1 | 29 | 2.30 (Standard Deviation 12.38) |
| CAPOX+ Placebo Diarrhoea C24D1 | 12 | -2.78 (Standard Deviation 9.62) |
| CAPOX+ Zolbetuximab Diarrhoea C25D1 | 28 | 0.00 (Standard Deviation 15.71) |
| CAPOX+ Placebo Diarrhoea C25D1 | 12 | -2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Diarrhoea C26D1 | 26 | 0.00 (Standard Deviation 13.33) |
| CAPOX+ Placebo Diarrhoea C26D1 | 9 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Diarrhoea C27D1 | 25 | 1.33 (Standard Deviation 15.15) |
| CAPOX+ Placebo Diarrhoea C27D1 | 10 | -3.33 (Standard Deviation 18.92) |
| CAPOX+ Zolbetuximab Diarrhoea C28D1 | 21 | 0.00 (Standard Deviation 14.91) |
| CAPOX+ Placebo Diarrhoea C28D1 | 11 | -6.06 (Standard Deviation 20.10) |
| CAPOX+ Zolbetuximab Diarrhoea C29D1 | 22 | 3.03 (Standard Deviation 17.55) |
| CAPOX+ Placebo Diarrhoea C29D1 | 12 | -8.33 (Standard Deviation 25.13) |
| CAPOX+ Zolbetuximab Diarrhoea C30D1 | 20 | 1.67 (Standard Deviation 17.01) |
| CAPOX+ Zolbetuximab Diarrhoea C31D1 | 20 | -1.67 (Standard Deviation 13.13) |
| CAPOX+ Zolbetuximab Diarrhoea C32D1 | 18 | 5.56 (Standard Deviation 17.15) |
| CAPOX+ Zolbetuximab Diarrhoea C33D1 | 15 | 0.00 (Standard Deviation 17.82) |
| CAPOX+ Zolbetuximab Diarrhoea C34D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Diarrhoea C35D1 | 13 | 2.56 (Standard Deviation 16.45) |
| CAPOX+ Zolbetuximab Diarrhoea C36D1 | 12 | 0.00 (Standard Deviation 14.21) |
| CAPOX+ Zolbetuximab Diarrhoea C37D1 | 11 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Diarrhoea C38D1 | 10 | 6.67 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Diarrhoea C39D1 | 9 | 3.70 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Diarrhoea 30 day follow up | 57 | -0.58 (Standard Deviation 18.36) |
| CAPOX+ Placebo Diarrhoea 30 day follow up | 78 | 1.71 (Standard Deviation 19.29) |
| CAPOX+ Zolbetuximab Diarrhoea 90 day follow up | 61 | 2.73 (Standard Deviation 20.45) |
| CAPOX+ Placebo Diarrhoea 90 day follow up | 79 | -1.27 (Standard Deviation 23.54) |
| CAPOX+ Zolbetuximab Financial Difficulties Baseline | 243 | 20.71 (Standard Deviation 25.99) |
| CAPOX+ Placebo Financial Difficulties Baseline | 242 | 19.42 (Standard Deviation 25.30) |
| CAPOX+ Zolbetuximab Financial Difficulties C2D1 | 208 | -0.64 (Standard Deviation 25.58) |
| CAPOX+ Placebo Financial Difficulties C2D1 | 217 | -0.92 (Standard Deviation 18.68) |
| CAPOX+ Zolbetuximab Financial Difficulties C3D1 | 182 | -0.92 (Standard Deviation 25.13) |
| CAPOX+ Placebo Financial Difficulties C3D1 | 197 | 1.18 (Standard Deviation 22.43) |
| CAPOX+ Zolbetuximab Financial Difficulties C4D1 | 169 | -2.17 (Standard Deviation 23.33) |
| CAPOX+ Placebo Financial Difficulties C4D1 | 169 | -1.58 (Standard Deviation 22.07) |
| CAPOX+ Zolbetuximab Financial Difficulties C5D1 | 159 | -0.63 (Standard Deviation 28.92) |
| CAPOX+ Placebo Financial Difficulties C5D1 | 165 | 0.81 (Standard Deviation 19.81) |
| CAPOX+ Zolbetuximab Financial Difficulties C6D1 | 149 | -0.89 (Standard Deviation 27.66) |
| CAPOX+ Placebo Financial Difficulties C6D1 | 146 | 0.00 (Standard Deviation 21.80) |
| CAPOX+ Zolbetuximab Financial Difficulties C7D1 | 120 | 0.56 (Standard Deviation 24.05) |
| CAPOX+ Placebo Financial Difficulties C7D1 | 126 | 0.26 (Standard Deviation 24.76) |
| CAPOX+ Zolbetuximab Financial Difficulties C8D1 | 108 | -0.62 (Standard Deviation 26.95) |
| CAPOX+ Placebo Financial Difficulties C8D1 | 110 | 3.33 (Standard Deviation 23.87) |
| CAPOX+ Zolbetuximab Financial Difficulties C9D1 | 102 | 2.29 (Standard Deviation 24.94) |
| CAPOX+ Placebo Financial Difficulties C9D1 | 103 | 1.94 (Standard Deviation 21.30) |
| CAPOX+ Zolbetuximab Financial Difficulties C10D1 | 85 | -2.75 (Standard Deviation 27.80) |
| CAPOX+ Placebo Financial Difficulties C10D1 | 79 | 1.27 (Standard Deviation 24.13) |
| CAPOX+ Zolbetuximab Financial Difficulties C11D1 | 81 | 0.00 (Standard Deviation 27.39) |
| CAPOX+ Placebo Financial Difficulties C11D1 | 71 | 4.69 (Standard Deviation 22.04) |
| CAPOX+ Zolbetuximab Financial Difficulties C12D1 | 75 | -0.89 (Standard Deviation 30.00) |
| CAPOX+ Placebo Financial Difficulties C12D1 | 57 | 3.51 (Standard Deviation 22.44) |
| CAPOX+ Zolbetuximab Financial Difficulties C13D1 | 60 | -3.33 (Standard Deviation 27.92) |
| CAPOX+ Placebo Financial Difficulties C13D1 | 48 | 4.17 (Standard Deviation 25.38) |
| CAPOX+ Zolbetuximab Financial Difficulties C14D1 | 55 | -0.61 (Standard Deviation 29.04) |
| CAPOX+ Placebo Financial Difficulties C14D1 | 44 | 0.00 (Standard Deviation 23.84) |
| CAPOX+ Zolbetuximab Financial Difficulties C15D1 | 51 | 0.00 (Standard Deviation 29.06) |
| CAPOX+ Placebo Financial Difficulties C15D1 | 36 | 4.63 (Standard Deviation 24.11) |
| CAPOX+ Zolbetuximab Financial Difficulties C16D1 | 48 | -2.08 (Standard Deviation 25.18) |
| CAPOX+ Placebo Financial Difficulties C16D1 | 31 | 6.45 (Standard Deviation 26.41) |
| CAPOX+ Zolbetuximab Financial Difficulties C17D1 | 43 | -2.33 (Standard Deviation 23.45) |
| CAPOX+ Placebo Financial Difficulties C17D1 | 25 | 1.33 (Standard Deviation 20.37) |
| CAPOX+ Zolbetuximab Financial Difficulties C18D1 | 41 | 3.25 (Standard Deviation 22.12) |
| CAPOX+ Placebo Financial Difficulties C18D1 | 21 | 4.76 (Standard Deviation 24.23) |
| CAPOX+ Zolbetuximab Financial Difficulties C19D1 | 40 | -2.50 (Standard Deviation 21.86) |
| CAPOX+ Placebo Financial Difficulties C19D1 | 20 | -3.33 (Standard Deviation 18.42) |
| CAPOX+ Zolbetuximab Financial Difficulties C20D1 | 39 | 0.00 (Standard Deviation 24.18) |
| CAPOX+ Placebo Financial Difficulties C20D1 | 19 | -1.75 (Standard Deviation 20.71) |
| CAPOX+ Zolbetuximab Financial Difficulties C21D1 | 36 | 1.85 (Standard Deviation 25.13) |
| CAPOX+ Placebo Financial Difficulties C21D1 | 20 | 3.33 (Standard Deviation 21.36) |
| CAPOX+ Zolbetuximab Financial Difficulties C22D1 | 31 | -3.23 (Standard Deviation 21.70) |
| CAPOX+ Placebo Financial Difficulties C22D1 | 17 | 3.92 (Standard Deviation 26.04) |
| CAPOX+ Zolbetuximab Financial Difficulties C23D1 | 31 | 3.23 (Standard Deviation 23.34) |
| CAPOX+ Placebo Financial Difficulties C23D1 | 16 | 4.17 (Standard Deviation 23.96) |
| CAPOX+ Zolbetuximab Financial Difficulties C24D1 | 29 | 1.15 (Standard Deviation 22.68) |
| CAPOX+ Placebo Financial Difficulties C24D1 | 12 | 2.78 (Standard Deviation 26.43) |
| CAPOX+ Zolbetuximab Financial Difficulties C25D1 | 28 | 0.00 (Standard Deviation 22.22) |
| CAPOX+ Placebo Financial Difficulties C25D1 | 12 | 8.33 (Standard Deviation 20.72) |
| CAPOX+ Zolbetuximab Financial Difficulties C26D1 | 26 | -2.56 (Standard Deviation 20.92) |
| CAPOX+ Placebo Financial Difficulties C26D1 | 9 | -7.41 (Standard Deviation 14.70) |
| CAPOX+ Zolbetuximab Financial Difficulties C27D1 | 25 | 1.33 (Standard Deviation 17.95) |
| CAPOX+ Placebo Financial Difficulties C27D1 | 10 | -6.67 (Standard Deviation 14.05) |
| CAPOX+ Zolbetuximab Financial Difficulties C28D1 | 21 | -4.76 (Standard Deviation 21.82) |
| CAPOX+ Placebo Financial Difficulties C28D1 | 11 | -3.03 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Financial Difficulties C29D1 | 22 | 3.03 (Standard Deviation 17.55) |
| CAPOX+ Placebo Financial Difficulties C29D1 | 12 | 0.00 (Standard Deviation 14.21) |
| CAPOX+ Zolbetuximab Financial Difficulties C30D1 | 20 | 0.00 (Standard Deviation 24.18) |
| CAPOX+ Zolbetuximab Financial Difficulties C31D1 | 20 | 0.00 (Standard Deviation 21.63) |
| CAPOX+ Zolbetuximab Financial Difficulties C32D1 | 18 | -5.56 (Standard Deviation 17.15) |
| CAPOX+ Zolbetuximab Financial Difficulties C33D1 | 15 | -6.67 (Standard Deviation 13.80) |
| CAPOX+ Zolbetuximab Financial Difficulties C34D1 | 12 | -5.56 (Standard Deviation 12.97) |
| CAPOX+ Zolbetuximab Financial Difficulties C35D1 | 13 | -2.56 (Standard Deviation 16.45) |
| CAPOX+ Zolbetuximab Financial Difficulties C36D1 | 12 | -2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Financial Difficulties C37D1 | 11 | -6.06 (Standard Deviation 13.48) |
| CAPOX+ Zolbetuximab Financial Difficulties C38D1 | 10 | -6.67 (Standard Deviation 14.05) |
| CAPOX+ Zolbetuximab Financial Difficulties C39D1 | 9 | -3.70 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Financial Difficulties 30 day follow up | 57 | 4.09 (Standard Deviation 26.03) |
| CAPOX+ Placebo Financial Difficulties 30 day follow up | 78 | 9.40 (Standard Deviation 24.56) |
| CAPOX+ Zolbetuximab Financial Difficulties 90 day follow up | 61 | 3.28 (Standard Deviation 24.87) |
| CAPOX+ Placebo Financial Difficulties 90 day follow up | 79 | 3.80 (Standard Deviation 20.66) |
Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire Plus STO22 Belching Subscale Questionnaire
Secondary outcome · Mean, Unit on a scale · Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab Dysphagia Baseline | 243 | 12.12 (Standard Deviation 18.27) |
| CAPOX+ Placebo Dysphagia Baseline | 242 | 12.59 (Standard Deviation 19.27) |
| CAPOX+ Zolbetuximab Dysphagia C2D1 | 208 | -0.37 (Standard Deviation 17.07) |
| CAPOX+ Placebo Dysphagia C2D1 | 216 | -3.86 (Standard Deviation 15.69) |
| CAPOX+ Zolbetuximab Dysphagia C3D1 | 182 | -0.92 (Standard Deviation 15.22) |
| CAPOX+ Placebo Dysphagia C3D1 | 196 | -4.59 (Standard Deviation 16.22) |
| CAPOX+ Zolbetuximab Dysphagia C4D1 | 166 | -2.68 (Standard Deviation 17.13) |
| CAPOX+ Placebo Dysphagia C4D1 | 169 | -5.00 (Standard Deviation 17.23) |
| CAPOX+ Zolbetuximab Dysphagia C5D1 | 159 | -1.05 (Standard Deviation 20.30) |
| CAPOX+ Placebo Dysphagia C5D1 | 165 | -5.66 (Standard Deviation 17.07) |
| CAPOX+ Zolbetuximab Dysphagia C6D1 | 149 | -1.42 (Standard Deviation 16.81) |
| CAPOX+ Placebo Dysphagia C6D1 | 145 | -3.45 (Standard Deviation 19.00) |
| CAPOX+ Zolbetuximab Dysphagia C7D1 | 119 | -2.61 (Standard Deviation 16.28) |
| CAPOX+ Placebo Dysphagia C7D1 | 125 | -5.16 (Standard Deviation 17.02) |
| CAPOX+ Zolbetuximab Dysphagia C8D1 | 108 | -2.88 (Standard Deviation 18.81) |
| CAPOX+ Placebo Dysphagia C8D1 | 109 | -4.28 (Standard Deviation 17.88) |
| CAPOX+ Zolbetuximab Dysphagia C9D1 | 102 | -2.83 (Standard Deviation 17.67) |
| CAPOX+ Placebo Dysphagia C9D1 | 103 | -5.93 (Standard Deviation 17.17) |
| CAPOX+ Zolbetuximab Dysphagia C10D1 | 85 | -3.27 (Standard Deviation 16.61) |
| CAPOX+ Placebo Dysphagia C10D1 | 79 | -6.75 (Standard Deviation 18.70) |
| CAPOX+ Zolbetuximab Dysphagia C11D1 | 80 | -3.33 (Standard Deviation 16.90) |
| CAPOX+ Placebo Dysphagia C11D1 | 71 | -5.95 (Standard Deviation 19.41) |
| CAPOX+ Zolbetuximab Dysphagia C12D1 | 75 | -3.70 (Standard Deviation 17.07) |
| CAPOX+ Placebo Dysphagia C12D1 | 57 | -5.65 (Standard Deviation 16.15) |
| CAPOX+ Zolbetuximab Dysphagia C13D1 | 60 | -6.30 (Standard Deviation 17.64) |
| CAPOX+ Placebo Dysphagia C13D1 | 48 | -4.40 (Standard Deviation 14.81) |
| CAPOX+ Zolbetuximab Dysphagia C14D1 | 55 | -4.24 (Standard Deviation 15.49) |
| CAPOX+ Placebo Dysphagia C14D1 | 44 | -3.03 (Standard Deviation 14.25) |
| CAPOX+ Zolbetuximab Dysphagia C15D1 | 51 | -3.49 (Standard Deviation 14.82) |
| CAPOX+ Placebo Dysphagia C15D1 | 36 | -1.54 (Standard Deviation 17.24) |
| CAPOX+ Zolbetuximab Dysphagia C16D1 | 48 | -2.31 (Standard Deviation 14.85) |
| CAPOX+ Placebo Dysphagia C16D1 | 31 | 0.00 (Standard Deviation 12.83) |
| CAPOX+ Zolbetuximab Dysphagia C17D1 | 43 | -3.10 (Standard Deviation 13.13) |
| CAPOX+ Placebo Dysphagia C17D1 | 25 | -1.78 (Standard Deviation 11.86) |
| CAPOX+ Zolbetuximab Dysphagia C18D1 | 41 | -3.25 (Standard Deviation 14.96) |
| CAPOX+ Placebo Dysphagia C18D1 | 21 | -4.23 (Standard Deviation 10.82) |
| CAPOX+ Zolbetuximab Dysphagia C19D1 | 40 | -4.17 (Standard Deviation 13.48) |
| CAPOX+ Placebo Dysphagia C19D1 | 20 | -2.78 (Standard Deviation 7.10) |
| CAPOX+ Zolbetuximab Dysphagia C20D1 | 39 | -4.56 (Standard Deviation 11.60) |
| CAPOX+ Placebo Dysphagia C20D1 | 19 | -2.92 (Standard Deviation 11.01) |
| CAPOX+ Zolbetuximab Dysphagia C21D1 | 36 | -3.40 (Standard Deviation 15.22) |
| CAPOX+ Placebo Dysphagia C21D1 | 20 | -3.33 (Standard Deviation 13.05) |
| CAPOX+ Zolbetuximab Dysphagia C22D1 | 31 | -5.38 (Standard Deviation 15.94) |
| CAPOX+ Placebo Dysphagia C22D1 | 17 | -5.23 (Standard Deviation 9.72) |
| CAPOX+ Zolbetuximab Dysphagia C23D1 | 31 | -4.30 (Standard Deviation 14.54) |
| CAPOX+ Placebo Dysphagia C23D1 | 16 | -5.56 (Standard Deviation 10.73) |
| CAPOX+ Zolbetuximab Dysphagia C24D1 | 29 | -4.98 (Standard Deviation 13.80) |
| CAPOX+ Placebo Dysphagia C24D1 | 12 | -2.78 (Standard Deviation 11.73) |
| CAPOX+ Zolbetuximab Dysphagia C25D1 | 28 | -4.37 (Standard Deviation 12.95) |
| CAPOX+ Placebo Dysphagia C25D1 | 12 | -3.70 (Standard Deviation 10.94) |
| CAPOX+ Zolbetuximab Dysphagia C26D1 | 26 | -2.99 (Standard Deviation 18.21) |
| CAPOX+ Placebo Dysphagia C26D1 | 9 | 2.47 (Standard Deviation 9.26) |
| CAPOX+ Zolbetuximab Dysphagia C27D1 | 25 | -5.33 (Standard Deviation 12.88) |
| CAPOX+ Placebo Dysphagia C27D1 | 10 | 0.00 (Standard Deviation 5.24) |
| CAPOX+ Zolbetuximab Dysphagia C28D1 | 21 | -4.76 (Standard Deviation 14.30) |
| CAPOX+ Placebo Dysphagia C28D1 | 11 | 1.01 (Standard Deviation 5.99) |
| CAPOX+ Zolbetuximab Dysphagia C29D1 | 22 | -7.07 (Standard Deviation 13.95) |
| CAPOX+ Placebo Dysphagia C29D1 | 12 | 1.85 (Standard Deviation 13.26) |
| CAPOX+ Zolbetuximab Dysphagia C30D1 | 20 | -5.00 (Standard Deviation 15.07) |
| CAPOX+ Zolbetuximab Dysphagia C31D1 | 20 | -6.11 (Standard Deviation 13.72) |
| CAPOX+ Zolbetuximab Dysphagia C32D1 | 18 | -7.41 (Standard Deviation 14.76) |
| CAPOX+ Zolbetuximab Dysphagia C33D1 | 15 | -3.70 (Standard Deviation 16.08) |
| CAPOX+ Zolbetuximab Dysphagia C34D1 | 12 | -8.33 (Standard Deviation 19.03) |
| CAPOX+ Zolbetuximab Dysphagia C35D1 | 13 | -6.84 (Standard Deviation 19.53) |
| CAPOX+ Zolbetuximab Dysphagia C36D1 | 12 | -9.26 (Standard Deviation 19.44) |
| CAPOX+ Zolbetuximab Dysphagia C37D1 | 11 | -8.08 (Standard Deviation 14.13) |
| CAPOX+ Zolbetuximab Dysphagia C38D1 | 10 | -6.67 (Standard Deviation 16.73) |
| CAPOX+ Zolbetuximab Dysphagia C39D1 | 9 | -4.94 (Standard Deviation 12.56) |
| CAPOX+ Zolbetuximab Dysphagia 30 day follow up | 57 | 4.48 (Standard Deviation 22.60) |
| CAPOX+ Placebo Dysphagia 30 day follow up | 76 | 0.73 (Standard Deviation 24.63) |
| CAPOX+ Zolbetuximab Dysphagia 90 day follow up | 61 | 0.36 (Standard Deviation 12.33) |
| CAPOX+ Placebo Dysphagia 90 day follow up | 79 | -1.83 (Standard Deviation 19.28) |
| CAPOX+ Zolbetuximab Eating Restrictions Baseline | 243 | 22.67 (Standard Deviation 25.20) |
| CAPOX+ Placebo Eating Restrictions Baseline | 242 | 22.51 (Standard Deviation 24.22) |
| CAPOX+ Zolbetuximab Eating Restrictions C2D1 | 208 | -1.24 (Standard Deviation 21.39) |
| CAPOX+ Placebo Eating Restrictions C2D1 | 216 | -4.55 (Standard Deviation 20.82) |
| CAPOX+ Zolbetuximab Eating Restrictions C3D1 | 182 | -4.12 (Standard Deviation 20.26) |
| CAPOX+ Placebo Eating Restrictions C3D1 | 196 | -6.08 (Standard Deviation 20.52) |
| CAPOX+ Zolbetuximab Eating Restrictions C4D1 | 166 | -5.52 (Standard Deviation 21.76) |
| CAPOX+ Placebo Eating Restrictions C4D1 | 169 | -8.19 (Standard Deviation 21.18) |
| CAPOX+ Zolbetuximab Eating Restrictions C5D1 | 159 | -5.14 (Standard Deviation 23.77) |
| CAPOX+ Placebo Eating Restrictions C5D1 | 165 | -7.22 (Standard Deviation 22.12) |
| CAPOX+ Zolbetuximab Eating Restrictions C6D1 | 149 | -3.97 (Standard Deviation 21.24) |
| CAPOX+ Placebo Eating Restrictions C6D1 | 145 | -6.03 (Standard Deviation 23.04) |
| CAPOX+ Zolbetuximab Eating Restrictions C7D1 | 119 | -4.69 (Standard Deviation 21.03) |
| CAPOX+ Placebo Eating Restrictions C7D1 | 125 | -5.07 (Standard Deviation 22.32) |
| CAPOX+ Zolbetuximab Eating Restrictions C8D1 | 108 | -3.70 (Standard Deviation 21.87) |
| CAPOX+ Placebo Eating Restrictions C8D1 | 109 | -6.27 (Standard Deviation 24.35) |
| CAPOX+ Zolbetuximab Eating Restrictions C9D1 | 102 | -3.59 (Standard Deviation 22.75) |
| CAPOX+ Placebo Eating Restrictions C9D1 | 103 | -7.52 (Standard Deviation 22.25) |
| CAPOX+ Zolbetuximab Eating Restrictions C10D1 | 85 | -4.80 (Standard Deviation 24.03) |
| CAPOX+ Placebo Eating Restrictions C10D1 | 79 | -8.54 (Standard Deviation 26.75) |
| CAPOX+ Zolbetuximab Eating Restrictions C11D1 | 80 | -5.83 (Standard Deviation 25.96) |
| CAPOX+ Placebo Eating Restrictions C11D1 | 71 | -9.39 (Standard Deviation 27.17) |
| CAPOX+ Zolbetuximab Eating Restrictions C12D1 | 75 | -6.22 (Standard Deviation 27.47) |
| CAPOX+ Placebo Eating Restrictions C12D1 | 57 | -9.36 (Standard Deviation 22.33) |
| CAPOX+ Zolbetuximab Eating Restrictions C13D1 | 60 | -9.31 (Standard Deviation 28.04) |
| CAPOX+ Placebo Eating Restrictions C13D1 | 48 | -10.59 (Standard Deviation 21.59) |
| CAPOX+ Zolbetuximab Eating Restrictions C14D1 | 55 | -6.97 (Standard Deviation 25.45) |
| CAPOX+ Placebo Eating Restrictions C14D1 | 44 | -7.39 (Standard Deviation 22.17) |
| CAPOX+ Zolbetuximab Eating Restrictions C15D1 | 51 | -7.03 (Standard Deviation 24.46) |
| CAPOX+ Placebo Eating Restrictions C15D1 | 36 | -6.25 (Standard Deviation 21.02) |
| CAPOX+ Zolbetuximab Eating Restrictions C16D1 | 48 | -8.68 (Standard Deviation 22.41) |
| CAPOX+ Placebo Eating Restrictions C16D1 | 31 | -6.72 (Standard Deviation 20.23) |
| CAPOX+ Zolbetuximab Eating Restrictions C17D1 | 43 | -7.75 (Standard Deviation 22.67) |
| CAPOX+ Placebo Eating Restrictions C17D1 | 25 | -3.33 (Standard Deviation 21.52) |
| CAPOX+ Zolbetuximab Eating Restrictions C18D1 | 41 | -7.11 (Standard Deviation 23.68) |
| CAPOX+ Placebo Eating Restrictions C18D1 | 21 | -10.32 (Standard Deviation 21.23) |
| CAPOX+ Zolbetuximab Eating Restrictions C19D1 | 40 | -7.92 (Standard Deviation 20.06) |
| CAPOX+ Placebo Eating Restrictions C19D1 | 20 | -9.17 (Standard Deviation 14.02) |
| CAPOX+ Zolbetuximab Eating Restrictions C20D1 | 39 | -6.41 (Standard Deviation 22.98) |
| CAPOX+ Placebo Eating Restrictions C20D1 | 19 | -9.21 (Standard Deviation 20.95) |
| CAPOX+ Zolbetuximab Eating Restrictions C21D1 | 36 | -5.32 (Standard Deviation 20.52) |
| CAPOX+ Placebo Eating Restrictions C21D1 | 20 | -10.00 (Standard Deviation 19.61) |
| CAPOX+ Zolbetuximab Eating Restrictions C22D1 | 31 | -7.26 (Standard Deviation 23.93) |
| CAPOX+ Placebo Eating Restrictions C22D1 | 17 | -12.25 (Standard Deviation 22.46) |
| CAPOX+ Zolbetuximab Eating Restrictions C23D1 | 31 | -6.18 (Standard Deviation 20.07) |
| CAPOX+ Placebo Eating Restrictions C23D1 | 16 | -12.50 (Standard Deviation 19.95) |
| CAPOX+ Zolbetuximab Eating Restrictions C24D1 | 29 | -6.03 (Standard Deviation 21.12) |
| CAPOX+ Placebo Eating Restrictions C24D1 | 12 | -6.25 (Standard Deviation 20.45) |
| CAPOX+ Zolbetuximab Eating Restrictions C25D1 | 28 | -5.95 (Standard Deviation 23.34) |
| CAPOX+ Placebo Eating Restrictions C25D1 | 12 | -8.33 (Standard Deviation 18.46) |
| CAPOX+ Zolbetuximab Eating Restrictions C26D1 | 26 | -7.37 (Standard Deviation 25.31) |
| CAPOX+ Placebo Eating Restrictions C26D1 | 9 | -2.78 (Standard Deviation 17.68) |
| CAPOX+ Zolbetuximab Eating Restrictions C27D1 | 25 | -7.67 (Standard Deviation 22.30) |
| CAPOX+ Placebo Eating Restrictions C27D1 | 10 | -3.33 (Standard Deviation 13.72) |
| CAPOX+ Zolbetuximab Eating Restrictions C28D1 | 21 | -6.35 (Standard Deviation 24.71) |
| CAPOX+ Placebo Eating Restrictions C28D1 | 11 | 2.27 (Standard Deviation 7.54) |
| CAPOX+ Zolbetuximab Eating Restrictions C29D1 | 22 | -10.23 (Standard Deviation 19.57) |
| CAPOX+ Placebo Eating Restrictions C29D1 | 12 | -3.47 (Standard Deviation 19.29) |
| CAPOX+ Zolbetuximab Eating Restrictions C30D1 | 20 | -5.42 (Standard Deviation 22.01) |
| CAPOX+ Zolbetuximab Eating Restrictions C31D1 | 20 | -10.42 (Standard Deviation 20.75) |
| CAPOX+ Zolbetuximab Eating Restrictions C32D1 | 18 | -9.26 (Standard Deviation 23.90) |
| CAPOX+ Zolbetuximab Eating Restrictions C33D1 | 15 | -7.78 (Standard Deviation 13.90) |
| CAPOX+ Zolbetuximab Eating Restrictions C34D1 | 12 | -17.36 (Standard Deviation 25.74) |
| CAPOX+ Zolbetuximab Eating Restrictions C35D1 | 13 | -11.54 (Standard Deviation 26.25) |
| CAPOX+ Zolbetuximab Eating Restrictions C36D1 | 12 | -15.97 (Standard Deviation 25.24) |
| CAPOX+ Zolbetuximab Eating Restrictions C37D1 | 11 | -12.12 (Standard Deviation 15.08) |
| CAPOX+ Zolbetuximab Eating Restrictions C38D1 | 10 | -17.50 (Standard Deviation 21.68) |
| CAPOX+ Zolbetuximab Eating Restrictions C39D1 | 9 | -7.41 (Standard Deviation 13.47) |
| CAPOX+ Zolbetuximab Eating Restrictions 30 day follow up | 57 | 0.15 (Standard Deviation 27.57) |
| CAPOX+ Placebo Eating Restrictions 30 day follow up | 76 | 0.88 (Standard Deviation 23.47) |
| CAPOX+ Zolbetuximab Eating Restrictions 90 day follow up | 61 | -2.19 (Standard Deviation 22.77) |
| CAPOX+ Placebo Eating Restrictions 90 day follow up | 79 | -0.42 (Standard Deviation 23.19) |
| CAPOX+ Zolbetuximab Reflux Baseline | 243 | 13.17 (Standard Deviation 20.28) |
| CAPOX+ Placebo Reflux Baseline | 242 | 16.11 (Standard Deviation 22.25) |
| CAPOX+ Zolbetuximab Reflux C2D1 | 208 | -1.04 (Standard Deviation 20.79) |
| CAPOX+ Placebo Reflux C2D1 | 216 | -4.01 (Standard Deviation 18.66) |
| CAPOX+ Zolbetuximab Reflux C3D1 | 182 | -0.09 (Standard Deviation 21.71) |
| CAPOX+ Placebo Reflux C3D1 | 196 | -4.17 (Standard Deviation 18.36) |
| CAPOX+ Zolbetuximab Reflux C4D1 | 166 | -0.70 (Standard Deviation 22.80) |
| CAPOX+ Placebo Reflux C4D1 | 169 | -5.82 (Standard Deviation 21.53) |
| CAPOX+ Zolbetuximab Reflux C5D1 | 159 | -0.84 (Standard Deviation 22.17) |
| CAPOX+ Placebo Reflux C5D1 | 165 | -7.88 (Standard Deviation 19.87) |
| CAPOX+ Zolbetuximab Reflux C6D1 | 149 | -0.11 (Standard Deviation 22.39) |
| CAPOX+ Placebo Reflux C6D1 | 145 | -7.01 (Standard Deviation 20.57) |
| CAPOX+ Zolbetuximab Reflux C7D1 | 119 | -1.68 (Standard Deviation 20.40) |
| CAPOX+ Placebo Reflux C7D1 | 125 | -6.67 (Standard Deviation 21.48) |
| CAPOX+ Zolbetuximab Reflux C8D1 | 108 | -1.08 (Standard Deviation 23.04) |
| CAPOX+ Placebo Reflux C8D1 | 109 | -9.17 (Standard Deviation 21.81) |
| CAPOX+ Zolbetuximab Reflux C9D1 | 102 | -0.82 (Standard Deviation 27.49) |
| CAPOX+ Placebo Reflux C9D1 | 103 | -11.00 (Standard Deviation 20.82) |
| CAPOX+ Zolbetuximab Reflux C10D1 | 85 | -1.57 (Standard Deviation 23.80) |
| CAPOX+ Placebo Reflux C10D1 | 79 | -10.34 (Standard Deviation 22.69) |
| CAPOX+ Zolbetuximab Reflux C11D1 | 80 | -3.13 (Standard Deviation 21.23) |
| CAPOX+ Placebo Reflux C11D1 | 71 | -11.03 (Standard Deviation 24.23) |
| CAPOX+ Zolbetuximab Reflux C12D1 | 75 | -4.44 (Standard Deviation 22.48) |
| CAPOX+ Placebo Reflux C12D1 | 57 | -8.48 (Standard Deviation 23.60) |
| CAPOX+ Zolbetuximab Reflux C13D1 | 60 | -3.33 (Standard Deviation 28.26) |
| CAPOX+ Placebo Reflux C13D1 | 48 | -9.03 (Standard Deviation 24.78) |
| CAPOX+ Zolbetuximab Reflux C14D1 | 55 | -1.82 (Standard Deviation 22.38) |
| CAPOX+ Placebo Reflux C14D1 | 44 | -8.71 (Standard Deviation 20.80) |
| CAPOX+ Zolbetuximab Reflux C15D1 | 51 | -3.92 (Standard Deviation 18.13) |
| CAPOX+ Placebo Reflux C15D1 | 36 | -7.41 (Standard Deviation 24.70) |
| CAPOX+ Zolbetuximab Reflux C16D1 | 48 | -3.13 (Standard Deviation 23.23) |
| CAPOX+ Placebo Reflux C16D1 | 31 | -4.84 (Standard Deviation 20.27) |
| CAPOX+ Zolbetuximab Reflux C17D1 | 43 | -5.81 (Standard Deviation 22.09) |
| CAPOX+ Placebo Reflux C17D1 | 25 | -2.67 (Standard Deviation 21.34) |
| CAPOX+ Zolbetuximab Reflux C18D1 | 41 | -3.25 (Standard Deviation 23.04) |
| CAPOX+ Placebo Reflux C18D1 | 21 | -3.17 (Standard Deviation 23.93) |
| CAPOX+ Zolbetuximab Reflux C19D1 | 40 | -2.92 (Standard Deviation 22.61) |
| CAPOX+ Placebo Reflux C19D1 | 20 | -1.67 (Standard Deviation 13.13) |
| CAPOX+ Zolbetuximab Reflux C20D1 | 39 | 0.00 (Standard Deviation 20.94) |
| CAPOX+ Placebo Reflux C20D1 | 19 | -4.39 (Standard Deviation 24.75) |
| CAPOX+ Zolbetuximab Reflux C21D1 | 36 | 0.46 (Standard Deviation 24.07) |
| CAPOX+ Placebo Reflux C21D1 | 20 | -2.50 (Standard Deviation 27.72) |
| CAPOX+ Zolbetuximab Reflux C22D1 | 31 | -5.38 (Standard Deviation 17.94) |
| CAPOX+ Placebo Reflux C22D1 | 17 | -1.96 (Standard Deviation 26.93) |
| CAPOX+ Zolbetuximab Reflux C23D1 | 31 | -4.30 (Standard Deviation 18.74) |
| CAPOX+ Placebo Reflux C23D1 | 16 | -4.17 (Standard Deviation 24.72) |
| CAPOX+ Zolbetuximab Reflux C24D1 | 29 | -2.30 (Standard Deviation 19.78) |
| CAPOX+ Placebo Reflux C24D1 | 12 | -6.94 (Standard Deviation 26.07) |
| CAPOX+ Zolbetuximab Reflux C25D1 | 28 | -1.19 (Standard Deviation 19.74) |
| CAPOX+ Placebo Reflux C25D1 | 12 | -4.17 (Standard Deviation 25.75) |
| CAPOX+ Zolbetuximab Reflux C26D1 | 26 | -1.28 (Standard Deviation 16.95) |
| CAPOX+ Placebo Reflux C26D1 | 9 | 3.70 (Standard Deviation 18.22) |
| CAPOX+ Zolbetuximab Reflux C27D1 | 25 | -1.33 (Standard Deviation 17.29) |
| CAPOX+ Placebo Reflux C27D1 | 10 | 1.67 (Standard Deviation 12.30) |
| CAPOX+ Zolbetuximab Reflux C28D1 | 21 | 0.00 (Standard Deviation 17.48) |
| CAPOX+ Placebo Reflux C28D1 | 11 | 3.03 (Standard Deviation 16.36) |
| CAPOX+ Zolbetuximab Reflux C29D1 | 22 | -3.03 (Standard Deviation 14.21) |
| CAPOX+ Placebo Reflux C29D1 | 12 | -1.39 (Standard Deviation 8.58) |
| CAPOX+ Zolbetuximab Reflux C30D1 | 20 | -0.83 (Standard Deviation 13.76) |
| CAPOX+ Zolbetuximab Reflux C31D1 | 20 | -1.67 (Standard Deviation 16.13) |
| CAPOX+ Zolbetuximab Reflux C32D1 | 18 | 0.00 (Standard Deviation 18.96) |
| CAPOX+ Zolbetuximab Reflux C33D1 | 15 | -3.33 (Standard Deviation 14.36) |
| CAPOX+ Zolbetuximab Reflux C34D1 | 12 | -4.17 (Standard Deviation 18.97) |
| CAPOX+ Zolbetuximab Reflux C35D1 | 13 | 1.28 (Standard Deviation 19.79) |
| CAPOX+ Zolbetuximab Reflux C36D1 | 12 | -4.17 (Standard Deviation 21.47) |
| CAPOX+ Zolbetuximab Reflux C37D1 | 11 | -4.55 (Standard Deviation 18.40) |
| CAPOX+ Zolbetuximab Reflux C38D1 | 10 | 0.00 (Standard Deviation 20.79) |
| CAPOX+ Zolbetuximab Reflux C39D1 | 9 | 7.41 (Standard Deviation 12.11) |
| CAPOX+ Zolbetuximab Reflux 30 day follow up | 57 | 1.46 (Standard Deviation 26.03) |
| CAPOX+ Placebo Reflux 30 day follow up | 76 | 0.44 (Standard Deviation 26.10) |
| CAPOX+ Zolbetuximab Reflux 90 day follow up | 61 | 2.19 (Standard Deviation 19.83) |
| CAPOX+ Placebo Reflux 90 day follow up | 79 | -1.69 (Standard Deviation 21.28) |
| CAPOX+ Zolbetuximab Odynophagia Baseline | 243 | 15.64 (Standard Deviation 22.78) |
| CAPOX+ Placebo Odynophagia Baseline | 242 | 17.29 (Standard Deviation 24.69) |
| CAPOX+ Zolbetuximab Odynophagia C2D1 | 208 | -2.80 (Standard Deviation 21.46) |
| CAPOX+ Placebo Odynophagia C2D1 | 216 | -4.63 (Standard Deviation 22.20) |
| CAPOX+ Zolbetuximab Odynophagia C3D1 | 182 | -3.94 (Standard Deviation 19.38) |
| CAPOX+ Placebo Odynophagia C3D1 | 196 | -6.04 (Standard Deviation 20.37) |
| CAPOX+ Zolbetuximab Odynophagia C4D1 | 166 | -5.22 (Standard Deviation 21.93) |
| CAPOX+ Placebo Odynophagia C4D1 | 169 | -8.19 (Standard Deviation 21.14) |
| CAPOX+ Zolbetuximab Odynophagia C5D1 | 159 | -4.19 (Standard Deviation 22.58) |
| CAPOX+ Placebo Odynophagia C5D1 | 165 | -7.58 (Standard Deviation 23.75) |
| CAPOX+ Zolbetuximab Odynophagia C6D1 | 149 | -2.80 (Standard Deviation 20.54) |
| CAPOX+ Placebo Odynophagia C6D1 | 145 | -5.98 (Standard Deviation 22.96) |
| CAPOX+ Zolbetuximab Odynophagia C7D1 | 119 | -3.92 (Standard Deviation 19.73) |
| CAPOX+ Placebo Odynophagia C7D1 | 125 | -5.33 (Standard Deviation 24.19) |
| CAPOX+ Zolbetuximab Odynophagia C8D1 | 108 | -4.32 (Standard Deviation 21.54) |
| CAPOX+ Placebo Odynophagia C8D1 | 109 | -7.19 (Standard Deviation 23.83) |
| CAPOX+ Zolbetuximab Odynophagia C9D1 | 102 | -2.94 (Standard Deviation 22.30) |
| CAPOX+ Placebo Odynophagia C9D1 | 103 | -7.93 (Standard Deviation 24.35) |
| CAPOX+ Zolbetuximab Odynophagia C10D1 | 85 | -5.10 (Standard Deviation 24.26) |
| CAPOX+ Placebo Odynophagia C10D1 | 79 | -8.02 (Standard Deviation 28.35) |
| CAPOX+ Zolbetuximab Odynophagia C11D1 | 80 | -4.17 (Standard Deviation 25.78) |
| CAPOX+ Placebo Odynophagia C11D1 | 71 | -9.62 (Standard Deviation 27.26) |
| CAPOX+ Zolbetuximab Odynophagia C12D1 | 75 | -6.67 (Standard Deviation 25.70) |
| CAPOX+ Placebo Odynophagia C12D1 | 57 | -7.60 (Standard Deviation 22.29) |
| CAPOX+ Zolbetuximab Odynophagia C13D1 | 60 | -8.06 (Standard Deviation 26.66) |
| CAPOX+ Placebo Odynophagia C13D1 | 48 | -7.99 (Standard Deviation 25.50) |
| CAPOX+ Zolbetuximab Odynophagia C14D1 | 55 | -7.58 (Standard Deviation 24.18) |
| CAPOX+ Placebo Odynophagia C14D1 | 44 | -5.68 (Standard Deviation 24.10) |
| CAPOX+ Zolbetuximab Odynophagia C15D1 | 51 | -7.84 (Standard Deviation 23.18) |
| CAPOX+ Placebo Odynophagia C15D1 | 36 | -3.24 (Standard Deviation 27.55) |
| CAPOX+ Zolbetuximab Odynophagia C16D1 | 48 | -9.37 (Standard Deviation 21.99) |
| CAPOX+ Placebo Odynophagia C16D1 | 31 | 0.00 (Standard Deviation 23.17) |
| CAPOX+ Zolbetuximab Odynophagia C17D1 | 43 | -11.63 (Standard Deviation 21.37) |
| CAPOX+ Placebo Odynophagia C17D1 | 25 | -2.67 (Standard Deviation 24.38) |
| CAPOX+ Zolbetuximab Odynophagia C18D1 | 41 | -9.76 (Standard Deviation 22.66) |
| CAPOX+ Placebo Odynophagia C18D1 | 21 | -5.56 (Standard Deviation 23.77) |
| CAPOX+ Zolbetuximab Odynophagia C19D1 | 40 | -9.58 (Standard Deviation 18.45) |
| CAPOX+ Placebo Odynophagia C19D1 | 20 | -2.50 (Standard Deviation 13.55) |
| CAPOX+ Zolbetuximab Odynophagia C20D1 | 39 | -7.26 (Standard Deviation 21.56) |
| CAPOX+ Placebo Odynophagia C20D1 | 19 | -7.02 (Standard Deviation 25.65) |
| CAPOX+ Zolbetuximab Odynophagia C21D1 | 36 | -5.09 (Standard Deviation 18.61) |
| CAPOX+ Placebo Odynophagia C21D1 | 20 | -7.50 (Standard Deviation 22.60) |
| CAPOX+ Zolbetuximab Odynophagia C22D1 | 31 | -5.91 (Standard Deviation 19.51) |
| CAPOX+ Placebo Odynophagia C22D1 | 17 | -5.88 (Standard Deviation 27.60) |
| CAPOX+ Zolbetuximab Odynophagia C23D1 | 31 | -7.53 (Standard Deviation 21.01) |
| CAPOX+ Placebo Odynophagia C23D1 | 16 | -7.29 (Standard Deviation 29.17) |
| CAPOX+ Zolbetuximab Odynophagia C24D1 | 29 | -6.90 (Standard Deviation 21.14) |
| CAPOX+ Placebo Odynophagia C24D1 | 12 | -11.11 (Standard Deviation 29.59) |
| CAPOX+ Zolbetuximab Odynophagia C25D1 | 28 | -7.14 (Standard Deviation 18.39) |
| CAPOX+ Placebo Odynophagia C25D1 | 12 | -9.72 (Standard Deviation 30.53) |
| CAPOX+ Zolbetuximab Odynophagia C26D1 | 26 | -7.69 (Standard Deviation 23.68) |
| CAPOX+ Placebo Odynophagia C26D1 | 9 | -1.85 (Standard Deviation 13.03) |
| CAPOX+ Zolbetuximab Odynophagia C27D1 | 25 | -7.33 (Standard Deviation 18.05) |
| CAPOX+ Placebo Odynophagia C27D1 | 10 | -1.67 (Standard Deviation 14.59) |
| CAPOX+ Zolbetuximab Odynophagia C28D1 | 21 | -9.52 (Standard Deviation 17.93) |
| CAPOX+ Placebo Odynophagia C28D1 | 11 | -1.52 (Standard Deviation 11.68) |
| CAPOX+ Zolbetuximab Odynophagia C29D1 | 22 | -10.61 (Standard Deviation 18.22) |
| CAPOX+ Placebo Odynophagia C29D1 | 12 | -1.39 (Standard Deviation 8.58) |
| CAPOX+ Zolbetuximab Odynophagia C30D1 | 20 | -9.17 (Standard Deviation 21.95) |
| CAPOX+ Zolbetuximab Odynophagia C31D1 | 20 | -12.50 (Standard Deviation 19.40) |
| CAPOX+ Zolbetuximab Odynophagia C32D1 | 18 | -11.11 (Standard Deviation 19.80) |
| CAPOX+ Zolbetuximab Odynophagia C33D1 | 15 | -10.00 (Standard Deviation 15.17) |
| CAPOX+ Zolbetuximab Odynophagia C34D1 | 12 | -16.67 (Standard Deviation 20.10) |
| CAPOX+ Zolbetuximab Odynophagia C35D1 | 13 | -17.95 (Standard Deviation 20.93) |
| CAPOX+ Zolbetuximab Odynophagia C36D1 | 12 | -18.06 (Standard Deviation 24.06) |
| CAPOX+ Zolbetuximab Odynophagia C37D1 | 11 | -10.61 (Standard Deviation 15.41) |
| CAPOX+ Zolbetuximab Odynophagia C38D1 | 10 | -11.67 (Standard Deviation 15.81) |
| CAPOX+ Zolbetuximab Odynophagia C39D1 | 9 | -16.67 (Standard Deviation 14.43) |
| CAPOX+ Zolbetuximab Odynophagia 30 day follow up | 57 | 1.75 (Standard Deviation 29.66) |
| CAPOX+ Placebo Odynophagia 30 day follow up | 76 | 2.19 (Standard Deviation 27.53) |
| CAPOX+ Zolbetuximab Odynophagia 90 day follow up | 61 | -0.27 (Standard Deviation 18.63) |
| CAPOX+ Placebo Odynophagia 90 day follow up | 79 | -0.21 (Standard Deviation 23.19) |
| CAPOX+ Zolbetuximab Pain and Discomfort Baseline | 243 | 23.53 (Standard Deviation 23.88) |
| CAPOX+ Placebo Pain and Discomfort Baseline | 242 | 25.38 (Standard Deviation 25.42) |
| CAPOX+ Zolbetuximab Pain and Discomfort C2D1 | 208 | -4.25 (Standard Deviation 23.38) |
| CAPOX+ Placebo Pain and Discomfort C2D1 | 216 | -6.94 (Standard Deviation 24.18) |
| CAPOX+ Zolbetuximab Pain and Discomfort C3D1 | 182 | -6.59 (Standard Deviation 22.14) |
| CAPOX+ Placebo Pain and Discomfort C3D1 | 196 | -8.25 (Standard Deviation 21.97) |
| CAPOX+ Zolbetuximab Pain and Discomfort C4D1 | 166 | -7.33 (Standard Deviation 24.99) |
| CAPOX+ Placebo Pain and Discomfort C4D1 | 169 | -11.34 (Standard Deviation 24.08) |
| CAPOX+ Zolbetuximab Pain and Discomfort C5D1 | 159 | -7.44 (Standard Deviation 20.43) |
| CAPOX+ Placebo Pain and Discomfort C5D1 | 165 | -11.41 (Standard Deviation 26.21) |
| CAPOX+ Zolbetuximab Pain and Discomfort C6D1 | 149 | -5.82 (Standard Deviation 25.48) |
| CAPOX+ Placebo Pain and Discomfort C6D1 | 145 | -9.31 (Standard Deviation 27.28) |
| CAPOX+ Zolbetuximab Pain and Discomfort C7D1 | 119 | -8.54 (Standard Deviation 23.95) |
| CAPOX+ Placebo Pain and Discomfort C7D1 | 125 | -9.20 (Standard Deviation 24.54) |
| CAPOX+ Zolbetuximab Pain and Discomfort C8D1 | 108 | -7.10 (Standard Deviation 23.04) |
| CAPOX+ Placebo Pain and Discomfort C8D1 | 109 | -9.94 (Standard Deviation 25.87) |
| CAPOX+ Zolbetuximab Pain and Discomfort C9D1 | 102 | -5.07 (Standard Deviation 24.57) |
| CAPOX+ Placebo Pain and Discomfort C9D1 | 103 | -8.09 (Standard Deviation 26.08) |
| CAPOX+ Zolbetuximab Pain and Discomfort C10D1 | 85 | -8.24 (Standard Deviation 26.80) |
| CAPOX+ Placebo Pain and Discomfort C10D1 | 79 | -8.23 (Standard Deviation 28.48) |
| CAPOX+ Zolbetuximab Pain and Discomfort C11D1 | 80 | -7.71 (Standard Deviation 30.00) |
| CAPOX+ Placebo Pain and Discomfort C11D1 | 71 | -8.22 (Standard Deviation 28.99) |
| CAPOX+ Zolbetuximab Pain and Discomfort C12D1 | 75 | -6.44 (Standard Deviation 27.52) |
| CAPOX+ Placebo Pain and Discomfort C12D1 | 57 | -5.85 (Standard Deviation 25.49) |
| CAPOX+ Zolbetuximab Pain and Discomfort C13D1 | 60 | -11.39 (Standard Deviation 27.19) |
| CAPOX+ Placebo Pain and Discomfort C13D1 | 48 | -8.33 (Standard Deviation 29.97) |
| CAPOX+ Zolbetuximab Pain and Discomfort C14D1 | 55 | -9.39 (Standard Deviation 25.21) |
| CAPOX+ Placebo Pain and Discomfort C14D1 | 44 | -3.79 (Standard Deviation 27.81) |
| CAPOX+ Zolbetuximab Pain and Discomfort C15D1 | 51 | -8.82 (Standard Deviation 24.12) |
| CAPOX+ Placebo Pain and Discomfort C15D1 | 36 | -4.17 (Standard Deviation 29.11) |
| CAPOX+ Zolbetuximab Pain and Discomfort C16D1 | 48 | -12.15 (Standard Deviation 24.73) |
| CAPOX+ Placebo Pain and Discomfort C16D1 | 31 | -5.38 (Standard Deviation 28.35) |
| CAPOX+ Zolbetuximab Pain and Discomfort C17D1 | 43 | -9.69 (Standard Deviation 25.00) |
| CAPOX+ Placebo Pain and Discomfort C17D1 | 25 | -6.00 (Standard Deviation 28.41) |
| CAPOX+ Zolbetuximab Pain and Discomfort C18D1 | 41 | -11.79 (Standard Deviation 22.44) |
| CAPOX+ Placebo Pain and Discomfort C18D1 | 21 | -6.35 (Standard Deviation 28.61) |
| CAPOX+ Zolbetuximab Pain and Discomfort C19D1 | 40 | -5.83 (Standard Deviation 22.82) |
| CAPOX+ Placebo Pain and Discomfort C19D1 | 20 | -5.00 (Standard Deviation 17.18) |
| CAPOX+ Zolbetuximab Pain and Discomfort C20D1 | 39 | -5.56 (Standard Deviation 19.99) |
| CAPOX+ Placebo Pain and Discomfort C20D1 | 19 | -7.02 (Standard Deviation 26.83) |
| CAPOX+ Zolbetuximab Pain and Discomfort C21D1 | 36 | -7.41 (Standard Deviation 20.10) |
| CAPOX+ Placebo Pain and Discomfort C21D1 | 20 | -10.00 (Standard Deviation 23.82) |
| CAPOX+ Zolbetuximab Pain and Discomfort C22D1 | 31 | -8.06 (Standard Deviation 21.89) |
| CAPOX+ Placebo Pain and Discomfort C22D1 | 17 | -5.88 (Standard Deviation 31.70) |
| CAPOX+ Zolbetuximab Pain and Discomfort C23D1 | 31 | -10.22 (Standard Deviation 20.04) |
| CAPOX+ Placebo Pain and Discomfort C23D1 | 16 | -8.33 (Standard Deviation 29.81) |
| CAPOX+ Zolbetuximab Pain and Discomfort C24D1 | 29 | -8.62 (Standard Deviation 21.19) |
| CAPOX+ Placebo Pain and Discomfort C24D1 | 12 | -8.33 (Standard Deviation 29.73) |
| CAPOX+ Zolbetuximab Pain and Discomfort C25D1 | 28 | -11.90 (Standard Deviation 23.07) |
| CAPOX+ Placebo Pain and Discomfort C25D1 | 12 | -9.72 (Standard Deviation 32.14) |
| CAPOX+ Zolbetuximab Pain and Discomfort C26D1 | 26 | -7.69 (Standard Deviation 26.76) |
| CAPOX+ Placebo Pain and Discomfort C26D1 | 9 | -1.85 (Standard Deviation 28.19) |
| CAPOX+ Zolbetuximab Pain and Discomfort C27D1 | 25 | -12.00 (Standard Deviation 21.79) |
| CAPOX+ Placebo Pain and Discomfort C27D1 | 10 | -3.33 (Standard Deviation 15.32) |
| CAPOX+ Zolbetuximab Pain and Discomfort C28D1 | 21 | -11.90 (Standard Deviation 22.45) |
| CAPOX+ Placebo Pain and Discomfort C28D1 | 11 | 3.03 (Standard Deviation 22.13) |
| CAPOX+ Zolbetuximab Pain and Discomfort C29D1 | 22 | -12.88 (Standard Deviation 21.16) |
| CAPOX+ Placebo Pain and Discomfort C29D1 | 12 | -1.39 (Standard Deviation 11.14) |
| CAPOX+ Zolbetuximab Pain and Discomfort C30D1 | 20 | -10.83 (Standard Deviation 24.35) |
| CAPOX+ Zolbetuximab Pain and Discomfort C31D1 | 20 | -15.00 (Standard Deviation 22.23) |
| CAPOX+ Zolbetuximab Pain and Discomfort C32D1 | 18 | -17.59 (Standard Deviation 18.50) |
| CAPOX+ Zolbetuximab Pain and Discomfort C33D1 | 15 | -13.33 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Pain and Discomfort C34D1 | 12 | -20.83 (Standard Deviation 23.70) |
| CAPOX+ Zolbetuximab Pain and Discomfort C35D1 | 13 | -21.79 (Standard Deviation 21.93) |
| CAPOX+ Zolbetuximab Pain and Discomfort C36D1 | 12 | -19.44 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Pain and Discomfort C37D1 | 11 | -13.64 (Standard Deviation 20.84) |
| CAPOX+ Zolbetuximab Pain and Discomfort C38D1 | 10 | -13.33 (Standard Deviation 33.15) |
| CAPOX+ Zolbetuximab Pain and Discomfort C39D1 | 9 | -22.22 (Standard Deviation 18.63) |
| CAPOX+ Zolbetuximab Pain and Discomfort 30 day follow up | 57 | 0.88 (Standard Deviation 29.45) |
| CAPOX+ Placebo Pain and Discomfort 30 day follow up | 76 | 1.32 (Standard Deviation 27.99) |
| CAPOX+ Zolbetuximab Pain and Discomfort 90 day follow up | 61 | -1.37 (Standard Deviation 26.75) |
| CAPOX+ Placebo Pain and Discomfort 90 day follow up | 79 | -2.95 (Standard Deviation 23.08) |
| CAPOX+ Zolbetuximab Anxiety Baseline | 243 | 38.96 (Standard Deviation 28.31) |
| CAPOX+ Placebo Anxiety Baseline | 242 | 42.05 (Standard Deviation 28.30) |
| CAPOX+ Zolbetuximab Anxiety C2D1 | 208 | -3.93 (Standard Deviation 25.15) |
| CAPOX+ Placebo Anxiety C2D1 | 216 | -7.02 (Standard Deviation 25.23) |
| CAPOX+ Zolbetuximab Anxiety C3D1 | 182 | -3.02 (Standard Deviation 24.93) |
| CAPOX+ Placebo Anxiety C3D1 | 196 | -6.04 (Standard Deviation 25.63) |
| CAPOX+ Zolbetuximab Anxiety C4D1 | 166 | -4.12 (Standard Deviation 24.65) |
| CAPOX+ Placebo Anxiety C4D1 | 169 | -7.20 (Standard Deviation 26.96) |
| CAPOX+ Zolbetuximab Anxiety C5D1 | 159 | -2.73 (Standard Deviation 26.24) |
| CAPOX+ Placebo Anxiety C5D1 | 165 | -6.77 (Standard Deviation 27.66) |
| CAPOX+ Zolbetuximab Anxiety C6D1 | 149 | -6.04 (Standard Deviation 23.43) |
| CAPOX+ Placebo Anxiety C6D1 | 145 | -8.51 (Standard Deviation 29.14) |
| CAPOX+ Zolbetuximab Anxiety C7D1 | 119 | -3.64 (Standard Deviation 23.28) |
| CAPOX+ Placebo Anxiety C7D1 | 125 | -8.80 (Standard Deviation 26.23) |
| CAPOX+ Zolbetuximab Anxiety C8D1 | 108 | -4.32 (Standard Deviation 25.21) |
| CAPOX+ Placebo Anxiety C8D1 | 109 | -8.87 (Standard Deviation 29.79) |
| CAPOX+ Zolbetuximab Anxiety C9D1 | 102 | -5.23 (Standard Deviation 25.80) |
| CAPOX+ Placebo Anxiety C9D1 | 103 | -6.96 (Standard Deviation 26.04) |
| CAPOX+ Zolbetuximab Anxiety C10D1 | 85 | -7.45 (Standard Deviation 28.11) |
| CAPOX+ Placebo Anxiety C10D1 | 79 | -11.60 (Standard Deviation 32.40) |
| CAPOX+ Zolbetuximab Anxiety C11D1 | 80 | -7.29 (Standard Deviation 28.54) |
| CAPOX+ Placebo Anxiety C11D1 | 71 | -8.69 (Standard Deviation 31.35) |
| CAPOX+ Zolbetuximab Anxiety C12D1 | 75 | -10.00 (Standard Deviation 29.38) |
| CAPOX+ Placebo Anxiety C12D1 | 57 | -8.19 (Standard Deviation 31.67) |
| CAPOX+ Zolbetuximab Anxiety C13D1 | 60 | -7.78 (Standard Deviation 30.76) |
| CAPOX+ Placebo Anxiety C13D1 | 48 | -6.60 (Standard Deviation 31.08) |
| CAPOX+ Zolbetuximab Anxiety C14D1 | 55 | -7.88 (Standard Deviation 28.30) |
| CAPOX+ Placebo Anxiety C14D1 | 44 | -5.68 (Standard Deviation 31.53) |
| CAPOX+ Zolbetuximab Anxiety C15D1 | 51 | -8.50 (Standard Deviation 28.55) |
| CAPOX+ Placebo Anxiety C15D1 | 36 | -6.02 (Standard Deviation 33.13) |
| CAPOX+ Zolbetuximab Anxiety C16D1 | 48 | -15.62 (Standard Deviation 27.38) |
| CAPOX+ Placebo Anxiety C16D1 | 31 | -3.76 (Standard Deviation 37.44) |
| CAPOX+ Zolbetuximab Anxiety C17D1 | 43 | -6.98 (Standard Deviation 24.19) |
| CAPOX+ Placebo Anxiety C17D1 | 25 | -6.67 (Standard Deviation 34.69) |
| CAPOX+ Zolbetuximab Anxiety C18D1 | 41 | -7.32 (Standard Deviation 28.64) |
| CAPOX+ Placebo Anxiety C18D1 | 21 | -10.32 (Standard Deviation 37.07) |
| CAPOX+ Zolbetuximab Anxiety C19D1 | 40 | -8.33 (Standard Deviation 25.88) |
| CAPOX+ Placebo Anxiety C19D1 | 20 | -2.50 (Standard Deviation 27.72) |
| CAPOX+ Zolbetuximab Anxiety C20D1 | 39 | -9.83 (Standard Deviation 24.99) |
| CAPOX+ Placebo Anxiety C20D1 | 19 | -8.77 (Standard Deviation 35.73) |
| CAPOX+ Zolbetuximab Anxiety C21D1 | 36 | -9.26 (Standard Deviation 29.93) |
| CAPOX+ Placebo Anxiety C21D1 | 20 | -11.67 (Standard Deviation 35.91) |
| CAPOX+ Zolbetuximab Anxiety C22D1 | 31 | -4.84 (Standard Deviation 27.28) |
| CAPOX+ Placebo Anxiety C22D1 | 17 | -7.84 (Standard Deviation 40.45) |
| CAPOX+ Zolbetuximab Anxiety C23D1 | 31 | -10.22 (Standard Deviation 26.76) |
| CAPOX+ Placebo Anxiety C23D1 | 16 | -10.42 (Standard Deviation 35.42) |
| CAPOX+ Zolbetuximab Anxiety C24D1 | 29 | -9.77 (Standard Deviation 28.00) |
| CAPOX+ Placebo Anxiety C24D1 | 12 | -9.72 (Standard Deviation 41.72) |
| CAPOX+ Zolbetuximab Anxiety C25D1 | 28 | -10.71 (Standard Deviation 24.52) |
| CAPOX+ Placebo Anxiety C25D1 | 12 | -11.11 (Standard Deviation 40.41) |
| CAPOX+ Zolbetuximab Anxiety C26D1 | 26 | -7.69 (Standard Deviation 25.49) |
| CAPOX+ Placebo Anxiety C26D1 | 9 | 3.70 (Standard Deviation 34.13) |
| CAPOX+ Zolbetuximab Anxiety C27D1 | 25 | -9.33 (Standard Deviation 30.08) |
| CAPOX+ Placebo Anxiety C27D1 | 10 | 6.67 (Standard Deviation 29.61) |
| CAPOX+ Zolbetuximab Anxiety C28D1 | 21 | -10.32 (Standard Deviation 31.83) |
| CAPOX+ Placebo Anxiety C28D1 | 11 | 1.52 (Standard Deviation 29.30) |
| CAPOX+ Zolbetuximab Anxiety C29D1 | 22 | -6.82 (Standard Deviation 33.20) |
| CAPOX+ Placebo Anxiety C29D1 | 12 | 1.39 (Standard Deviation 37.24) |
| CAPOX+ Zolbetuximab Anxiety C30D1 | 20 | -5.00 (Standard Deviation 26.55) |
| CAPOX+ Zolbetuximab Anxiety C31D1 | 20 | -7.50 (Standard Deviation 28.34) |
| CAPOX+ Zolbetuximab Anxiety C32D1 | 18 | -10.19 (Standard Deviation 32.91) |
| CAPOX+ Zolbetuximab Anxiety C33D1 | 15 | -4.44 (Standard Deviation 30.52) |
| CAPOX+ Zolbetuximab Anxiety C34D1 | 12 | -13.89 (Standard Deviation 27.37) |
| CAPOX+ Zolbetuximab Anxiety C35D1 | 13 | -10.26 (Standard Deviation 25.04) |
| CAPOX+ Zolbetuximab Anxiety C36D1 | 12 | -12.50 (Standard Deviation 26.71) |
| CAPOX+ Zolbetuximab Anxiety C37D1 | 11 | -25.76 (Standard Deviation 20.23) |
| CAPOX+ Zolbetuximab Anxiety C38D1 | 10 | -18.33 (Standard Deviation 22.84) |
| CAPOX+ Zolbetuximab Anxiety C39D1 | 9 | -14.81 (Standard Deviation 34.81) |
| CAPOX+ Zolbetuximab Anxiety 30 day follow up | 57 | 2.34 (Standard Deviation 31.25) |
| CAPOX+ Placebo Anxiety 30 day follow up | 76 | 3.51 (Standard Deviation 26.15) |
| CAPOX+ Zolbetuximab Anxiety 90 day follow up | 61 | 0.27 (Standard Deviation 27.47) |
| CAPOX+ Placebo Anxiety 90 day follow up | 79 | -4.22 (Standard Deviation 31.29) |
| CAPOX+ Zolbetuximab Eating in Front of Others Baseline | 243 | 10.70 (Standard Deviation 21.53) |
| CAPOX+ Placebo Eating in Front of Others Baseline | 242 | 10.51 (Standard Deviation 22.36) |
| CAPOX+ Zolbetuximab Eating in Front of Others C2D1 | 208 | -3.21 (Standard Deviation 18.25) |
| CAPOX+ Placebo Eating in Front of Others C2D1 | 216 | -3.09 (Standard Deviation 19.04) |
| CAPOX+ Zolbetuximab Eating in Front of Others C3D1 | 182 | -2.01 (Standard Deviation 18.26) |
| CAPOX+ Placebo Eating in Front of Others C3D1 | 196 | -3.06 (Standard Deviation 19.15) |
| CAPOX+ Zolbetuximab Eating in Front of Others C4D1 | 166 | -3.01 (Standard Deviation 16.34) |
| CAPOX+ Placebo Eating in Front of Others C4D1 | 169 | -7.10 (Standard Deviation 21.57) |
| CAPOX+ Zolbetuximab Eating in Front of Others C5D1 | 159 | -1.68 (Standard Deviation 15.82) |
| CAPOX+ Placebo Eating in Front of Others C5D1 | 165 | -5.45 (Standard Deviation 23.37) |
| CAPOX+ Zolbetuximab Eating in Front of Others C6D1 | 149 | -0.22 (Standard Deviation 15.25) |
| CAPOX+ Placebo Eating in Front of Others C6D1 | 145 | -4.83 (Standard Deviation 21.51) |
| CAPOX+ Zolbetuximab Eating in Front of Others C7D1 | 119 | -0.84 (Standard Deviation 18.13) |
| CAPOX+ Placebo Eating in Front of Others C7D1 | 125 | -4.53 (Standard Deviation 20.45) |
| CAPOX+ Zolbetuximab Eating in Front of Others C8D1 | 108 | -2.47 (Standard Deviation 18.63) |
| CAPOX+ Placebo Eating in Front of Others C8D1 | 109 | -5.81 (Standard Deviation 21.20) |
| CAPOX+ Zolbetuximab Eating in Front of Others C9D1 | 102 | -1.63 (Standard Deviation 21.69) |
| CAPOX+ Placebo Eating in Front of Others C9D1 | 103 | -5.50 (Standard Deviation 21.44) |
| CAPOX+ Zolbetuximab Eating in Front of Others C10D1 | 85 | -2.35 (Standard Deviation 23.45) |
| CAPOX+ Placebo Eating in Front of Others C10D1 | 79 | -6.33 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Eating in Front of Others C11D1 | 80 | -2.92 (Standard Deviation 19.98) |
| CAPOX+ Placebo Eating in Front of Others C11D1 | 71 | -4.69 (Standard Deviation 19.76) |
| CAPOX+ Zolbetuximab Eating in Front of Others C12D1 | 75 | -3.11 (Standard Deviation 20.63) |
| CAPOX+ Placebo Eating in Front of Others C12D1 | 57 | -4.09 (Standard Deviation 14.18) |
| CAPOX+ Zolbetuximab Eating in Front of Others C13D1 | 60 | -5.56 (Standard Deviation 21.41) |
| CAPOX+ Placebo Eating in Front of Others C13D1 | 48 | 0.00 (Standard Deviation 16.84) |
| CAPOX+ Zolbetuximab Eating in Front of Others C14D1 | 55 | -4.85 (Standard Deviation 20.71) |
| CAPOX+ Placebo Eating in Front of Others C14D1 | 44 | -4.55 (Standard Deviation 13.62) |
| CAPOX+ Zolbetuximab Eating in Front of Others C15D1 | 51 | -8.50 (Standard Deviation 21.95) |
| CAPOX+ Placebo Eating in Front of Others C15D1 | 36 | -0.93 (Standard Deviation 9.71) |
| CAPOX+ Zolbetuximab Eating in Front of Others C16D1 | 48 | -6.94 (Standard Deviation 18.14) |
| CAPOX+ Placebo Eating in Front of Others C16D1 | 31 | -1.08 (Standard Deviation 16.06) |
| CAPOX+ Zolbetuximab Eating in Front of Others C17D1 | 43 | -6.20 (Standard Deviation 19.59) |
| CAPOX+ Placebo Eating in Front of Others C17D1 | 25 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Eating in Front of Others C18D1 | 41 | -8.13 (Standard Deviation 19.41) |
| CAPOX+ Placebo Eating in Front of Others C18D1 | 21 | -3.17 (Standard Deviation 14.55) |
| CAPOX+ Zolbetuximab Eating in Front of Others C19D1 | 40 | -10.83 (Standard Deviation 21.86) |
| CAPOX+ Placebo Eating in Front of Others C19D1 | 20 | -1.67 (Standard Deviation 7.45) |
| CAPOX+ Zolbetuximab Eating in Front of Others C20D1 | 39 | -8.55 (Standard Deviation 19.82) |
| CAPOX+ Placebo Eating in Front of Others C20D1 | 19 | 0.00 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Eating in Front of Others C21D1 | 36 | -8.33 (Standard Deviation 20.12) |
| CAPOX+ Placebo Eating in Front of Others C21D1 | 20 | -3.33 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Eating in Front of Others C22D1 | 31 | -6.45 (Standard Deviation 18.09) |
| CAPOX+ Placebo Eating in Front of Others C22D1 | 17 | -3.92 (Standard Deviation 16.17) |
| CAPOX+ Zolbetuximab Eating in Front of Others C23D1 | 31 | -7.53 (Standard Deviation 18.68) |
| CAPOX+ Placebo Eating in Front of Others C23D1 | 16 | -6.25 (Standard Deviation 18.13) |
| CAPOX+ Zolbetuximab Eating in Front of Others C24D1 | 29 | -3.45 (Standard Deviation 18.57) |
| CAPOX+ Placebo Eating in Front of Others C24D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Eating in Front of Others C25D1 | 28 | -2.38 (Standard Deviation 20.14) |
| CAPOX+ Placebo Eating in Front of Others C25D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Eating in Front of Others C26D1 | 26 | -6.41 (Standard Deviation 18.90) |
| CAPOX+ Placebo Eating in Front of Others C26D1 | 9 | -3.70 (Standard Deviation 11.11) |
| CAPOX+ Zolbetuximab Eating in Front of Others C27D1 | 25 | -2.67 (Standard Deviation 19.05) |
| CAPOX+ Placebo Eating in Front of Others C27D1 | 10 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Eating in Front of Others C28D1 | 21 | -4.76 (Standard Deviation 26.43) |
| CAPOX+ Placebo Eating in Front of Others C28D1 | 11 | -3.03 (Standard Deviation 10.05) |
| CAPOX+ Zolbetuximab Eating in Front of Others C29D1 | 22 | -9.09 (Standard Deviation 21.04) |
| CAPOX+ Placebo Eating in Front of Others C29D1 | 12 | 2.78 (Standard Deviation 9.62) |
| CAPOX+ Zolbetuximab Eating in Front of Others C30D1 | 20 | -6.67 (Standard Deviation 23.20) |
| CAPOX+ Zolbetuximab Eating in Front of Others C31D1 | 20 | -10.00 (Standard Deviation 21.90) |
| CAPOX+ Zolbetuximab Eating in Front of Others C32D1 | 18 | -7.41 (Standard Deviation 24.40) |
| CAPOX+ Zolbetuximab Eating in Front of Others C33D1 | 15 | -8.89 (Standard Deviation 23.46) |
| CAPOX+ Zolbetuximab Eating in Front of Others C34D1 | 12 | -16.67 (Standard Deviation 22.47) |
| CAPOX+ Zolbetuximab Eating in Front of Others C35D1 | 13 | -5.13 (Standard Deviation 22.96) |
| CAPOX+ Zolbetuximab Eating in Front of Others C36D1 | 12 | -11.11 (Standard Deviation 21.71) |
| CAPOX+ Zolbetuximab Eating in Front of Others C37D1 | 11 | -12.12 (Standard Deviation 22.47) |
| CAPOX+ Zolbetuximab Eating in Front of Others C38D1 | 10 | -16.67 (Standard Deviation 23.57) |
| CAPOX+ Zolbetuximab Eating in Front of Others C39D1 | 9 | -7.41 (Standard Deviation 14.70) |
| CAPOX+ Zolbetuximab Eating in Front of Others 30 day follow up | 57 | 2.92 (Standard Deviation 23.81) |
| CAPOX+ Placebo Eating in Front of Others 30 day follow up | 76 | 1.75 (Standard Deviation 24.28) |
| CAPOX+ Zolbetuximab Eating in Front of Others 90 day follow up | 61 | 3.28 (Standard Deviation 18.96) |
| CAPOX+ Placebo Eating in Front of Others 90 day follow up | 79 | 2.53 (Standard Deviation 16.69) |
| CAPOX+ Zolbetuximab Dry Mouth Baseline | 243 | 19.20 (Standard Deviation 24.74) |
| CAPOX+ Placebo Dry Mouth Baseline | 242 | 16.87 (Standard Deviation 23.79) |
| CAPOX+ Zolbetuximab Dry Mouth C2D1 | 208 | -0.32 (Standard Deviation 23.40) |
| CAPOX+ Placebo Dry Mouth C2D1 | 216 | 2.16 (Standard Deviation 23.30) |
| CAPOX+ Zolbetuximab Dry Mouth C3D1 | 182 | -0.55 (Standard Deviation 23.89) |
| CAPOX+ Placebo Dry Mouth C3D1 | 196 | 4.93 (Standard Deviation 26.44) |
| CAPOX+ Zolbetuximab Dry Mouth C4D1 | 166 | -2.01 (Standard Deviation 25.08) |
| CAPOX+ Placebo Dry Mouth C4D1 | 169 | 4.34 (Standard Deviation 28.30) |
| CAPOX+ Zolbetuximab Dry Mouth C5D1 | 159 | -1.05 (Standard Deviation 26.89) |
| CAPOX+ Placebo Dry Mouth C5D1 | 165 | 1.41 (Standard Deviation 27.88) |
| CAPOX+ Zolbetuximab Dry Mouth C6D1 | 149 | 0.89 (Standard Deviation 27.93) |
| CAPOX+ Placebo Dry Mouth C6D1 | 145 | 3.91 (Standard Deviation 27.64) |
| CAPOX+ Zolbetuximab Dry Mouth C7D1 | 119 | -0.28 (Standard Deviation 27.62) |
| CAPOX+ Placebo Dry Mouth C7D1 | 125 | 0.53 (Standard Deviation 28.08) |
| CAPOX+ Zolbetuximab Dry Mouth C8D1 | 108 | -1.85 (Standard Deviation 25.71) |
| CAPOX+ Placebo Dry Mouth C8D1 | 109 | 3.98 (Standard Deviation 29.65) |
| CAPOX+ Zolbetuximab Dry Mouth C9D1 | 102 | 0.00 (Standard Deviation 28.92) |
| CAPOX+ Placebo Dry Mouth C9D1 | 103 | 2.27 (Standard Deviation 28.49) |
| CAPOX+ Zolbetuximab Dry Mouth C10D1 | 85 | -5.88 (Standard Deviation 28.72) |
| CAPOX+ Placebo Dry Mouth C10D1 | 79 | -2.11 (Standard Deviation 27.39) |
| CAPOX+ Zolbetuximab Dry Mouth C11D1 | 80 | -4.58 (Standard Deviation 26.38) |
| CAPOX+ Placebo Dry Mouth C11D1 | 71 | -2.35 (Standard Deviation 26.02) |
| CAPOX+ Zolbetuximab Dry Mouth C12D1 | 75 | -5.78 (Standard Deviation 26.49) |
| CAPOX+ Placebo Dry Mouth C12D1 | 57 | 1.17 (Standard Deviation 25.17) |
| CAPOX+ Zolbetuximab Dry Mouth C13D1 | 60 | -5.00 (Standard Deviation 26.63) |
| CAPOX+ Placebo Dry Mouth C13D1 | 48 | -2.08 (Standard Deviation 27.85) |
| CAPOX+ Zolbetuximab Dry Mouth C14D1 | 55 | -7.27 (Standard Deviation 26.21) |
| CAPOX+ Placebo Dry Mouth C14D1 | 44 | -2.27 (Standard Deviation 26.31) |
| CAPOX+ Zolbetuximab Dry Mouth C15D1 | 51 | -5.88 (Standard Deviation 24.68) |
| CAPOX+ Placebo Dry Mouth C15D1 | 36 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Dry Mouth C16D1 | 48 | -7.64 (Standard Deviation 25.02) |
| CAPOX+ Placebo Dry Mouth C16D1 | 31 | 1.08 (Standard Deviation 16.06) |
| CAPOX+ Zolbetuximab Dry Mouth C17D1 | 43 | -6.20 (Standard Deviation 19.59) |
| CAPOX+ Placebo Dry Mouth C17D1 | 25 | 4.00 (Standard Deviation 17.53) |
| CAPOX+ Zolbetuximab Dry Mouth C18D1 | 41 | -5.69 (Standard Deviation 19.58) |
| CAPOX+ Placebo Dry Mouth C18D1 | 21 | 4.76 (Standard Deviation 15.94) |
| CAPOX+ Zolbetuximab Dry Mouth C19D1 | 40 | -9.17 (Standard Deviation 25.02) |
| CAPOX+ Placebo Dry Mouth C19D1 | 20 | 3.33 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Dry Mouth C20D1 | 39 | -8.55 (Standard Deviation 21.24) |
| CAPOX+ Placebo Dry Mouth C20D1 | 19 | 3.51 (Standard Deviation 24.58) |
| CAPOX+ Zolbetuximab Dry Mouth C21D1 | 36 | -5.56 (Standard Deviation 24.56) |
| CAPOX+ Placebo Dry Mouth C21D1 | 20 | 3.33 (Standard Deviation 18.42) |
| CAPOX+ Zolbetuximab Dry Mouth C22D1 | 31 | -9.68 (Standard Deviation 23.08) |
| CAPOX+ Placebo Dry Mouth C22D1 | 17 | 7.84 (Standard Deviation 18.74) |
| CAPOX+ Zolbetuximab Dry Mouth C23D1 | 31 | -7.53 (Standard Deviation 23.90) |
| CAPOX+ Placebo Dry Mouth C23D1 | 16 | 2.08 (Standard Deviation 14.75) |
| CAPOX+ Zolbetuximab Dry Mouth C24D1 | 29 | -6.90 (Standard Deviation 24.20) |
| CAPOX+ Placebo Dry Mouth C24D1 | 12 | 5.56 (Standard Deviation 27.83) |
| CAPOX+ Zolbetuximab Dry Mouth C25D1 | 28 | -10.71 (Standard Deviation 22.32) |
| CAPOX+ Placebo Dry Mouth C25D1 | 12 | 2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Dry Mouth C26D1 | 26 | -8.97 (Standard Deviation 27.58) |
| CAPOX+ Placebo Dry Mouth C26D1 | 9 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Dry Mouth C27D1 | 25 | -6.67 (Standard Deviation 21.52) |
| CAPOX+ Placebo Dry Mouth C27D1 | 10 | 3.33 (Standard Deviation 18.92) |
| CAPOX+ Zolbetuximab Dry Mouth C28D1 | 21 | -4.76 (Standard Deviation 26.43) |
| CAPOX+ Placebo Dry Mouth C28D1 | 11 | 0.00 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Dry Mouth C29D1 | 22 | -6.06 (Standard Deviation 28.43) |
| CAPOX+ Placebo Dry Mouth C29D1 | 12 | -2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Dry Mouth C30D1 | 20 | -5.00 (Standard Deviation 24.84) |
| CAPOX+ Zolbetuximab Dry Mouth C31D1 | 20 | -8.33 (Standard Deviation 28.36) |
| CAPOX+ Zolbetuximab Dry Mouth C32D1 | 18 | -11.11 (Standard Deviation 30.25) |
| CAPOX+ Zolbetuximab Dry Mouth C33D1 | 15 | -15.56 (Standard Deviation 21.33) |
| CAPOX+ Zolbetuximab Dry Mouth C34D1 | 12 | -22.22 (Standard Deviation 21.71) |
| CAPOX+ Zolbetuximab Dry Mouth C35D1 | 13 | -17.95 (Standard Deviation 25.88) |
| CAPOX+ Zolbetuximab Dry Mouth C36D1 | 12 | -16.67 (Standard Deviation 17.41) |
| CAPOX+ Zolbetuximab Dry Mouth C37D1 | 11 | -18.18 (Standard Deviation 31.14) |
| CAPOX+ Zolbetuximab Dry Mouth C38D1 | 10 | -20.00 (Standard Deviation 32.20) |
| CAPOX+ Zolbetuximab Dry Mouth C39D1 | 9 | -22.22 (Standard Deviation 33.33) |
| CAPOX+ Zolbetuximab Dry Mouth 30 day follow up | 57 | -4.68 (Standard Deviation 26.31) |
| CAPOX+ Placebo Dry Mouth 30 day follow up | 76 | 5.70 (Standard Deviation 26.88) |
| CAPOX+ Zolbetuximab Dry Mouth 90 day follow up | 61 | 3.83 (Standard Deviation 25.16) |
| CAPOX+ Placebo Dry Mouth 90 day follow up | 79 | 6.75 (Standard Deviation 28.43) |
| CAPOX+ Zolbetuximab Trouble with Taste Baseline | 243 | 9.47 (Standard Deviation 21.58) |
| CAPOX+ Placebo Trouble with Taste Baseline | 242 | 7.47 (Standard Deviation 18.50) |
| CAPOX+ Zolbetuximab Trouble with Taste C2D1 | 208 | 3.85 (Standard Deviation 22.85) |
| CAPOX+ Placebo Trouble with Taste C2D1 | 216 | 2.47 (Standard Deviation 20.69) |
| CAPOX+ Zolbetuximab Trouble with Taste C3D1 | 182 | 7.33 (Standard Deviation 25.41) |
| CAPOX+ Placebo Trouble with Taste C3D1 | 196 | 5.27 (Standard Deviation 20.55) |
| CAPOX+ Zolbetuximab Trouble with Taste C4D1 | 166 | 5.62 (Standard Deviation 24.24) |
| CAPOX+ Placebo Trouble with Taste C4D1 | 169 | 5.52 (Standard Deviation 24.31) |
| CAPOX+ Zolbetuximab Trouble with Taste C5D1 | 159 | 8.18 (Standard Deviation 26.71) |
| CAPOX+ Placebo Trouble with Taste C5D1 | 165 | 8.08 (Standard Deviation 25.01) |
| CAPOX+ Zolbetuximab Trouble with Taste C6D1 | 149 | 12.30 (Standard Deviation 27.77) |
| CAPOX+ Placebo Trouble with Taste C6D1 | 145 | 11.72 (Standard Deviation 27.65) |
| CAPOX+ Zolbetuximab Trouble with Taste C7D1 | 119 | 10.92 (Standard Deviation 28.82) |
| CAPOX+ Placebo Trouble with Taste C7D1 | 125 | 9.33 (Standard Deviation 25.96) |
| CAPOX+ Zolbetuximab Trouble with Taste C8D1 | 108 | 10.49 (Standard Deviation 25.23) |
| CAPOX+ Placebo Trouble with Taste C8D1 | 109 | 10.40 (Standard Deviation 28.58) |
| CAPOX+ Zolbetuximab Trouble with Taste C9D1 | 102 | 8.17 (Standard Deviation 29.83) |
| CAPOX+ Placebo Trouble with Taste C9D1 | 103 | 6.47 (Standard Deviation 25.16) |
| CAPOX+ Zolbetuximab Trouble with Taste C10D1 | 85 | 7.06 (Standard Deviation 29.59) |
| CAPOX+ Placebo Trouble with Taste C10D1 | 79 | 2.95 (Standard Deviation 26.25) |
| CAPOX+ Zolbetuximab Trouble with Taste C11D1 | 80 | 2.92 (Standard Deviation 27.14) |
| CAPOX+ Placebo Trouble with Taste C11D1 | 71 | 4.23 (Standard Deviation 26.39) |
| CAPOX+ Zolbetuximab Trouble with Taste C12D1 | 75 | 2.22 (Standard Deviation 26.47) |
| CAPOX+ Placebo Trouble with Taste C12D1 | 57 | 0.00 (Standard Deviation 21.82) |
| CAPOX+ Zolbetuximab Trouble with Taste C13D1 | 60 | 0.56 (Standard Deviation 32.18) |
| CAPOX+ Placebo Trouble with Taste C13D1 | 48 | 3.47 (Standard Deviation 19.74) |
| CAPOX+ Zolbetuximab Trouble with Taste C14D1 | 55 | 1.82 (Standard Deviation 25.99) |
| CAPOX+ Placebo Trouble with Taste C14D1 | 44 | 1.52 (Standard Deviation 22.68) |
| CAPOX+ Zolbetuximab Trouble with Taste C15D1 | 51 | 0.00 (Standard Deviation 27.49) |
| CAPOX+ Placebo Trouble with Taste C15D1 | 36 | 1.85 (Standard Deviation 23.83) |
| CAPOX+ Zolbetuximab Trouble with Taste C16D1 | 48 | 1.39 (Standard Deviation 25.69) |
| CAPOX+ Placebo Trouble with Taste C16D1 | 31 | 3.23 (Standard Deviation 15.76) |
| CAPOX+ Zolbetuximab Trouble with Taste C17D1 | 43 | 1.55 (Standard Deviation 24.07) |
| CAPOX+ Placebo Trouble with Taste C17D1 | 25 | 8.00 (Standard Deviation 14.53) |
| CAPOX+ Zolbetuximab Trouble with Taste C18D1 | 41 | 0.81 (Standard Deviation 24.14) |
| CAPOX+ Placebo Trouble with Taste C18D1 | 21 | 4.76 (Standard Deviation 11.95) |
| CAPOX+ Zolbetuximab Trouble with Taste C19D1 | 40 | 0.83 (Standard Deviation 21.99) |
| CAPOX+ Placebo Trouble with Taste C19D1 | 20 | 1.67 (Standard Deviation 7.45) |
| CAPOX+ Zolbetuximab Trouble with Taste C20D1 | 39 | 2.56 (Standard Deviation 22.14) |
| CAPOX+ Placebo Trouble with Taste C20D1 | 19 | 7.02 (Standard Deviation 13.96) |
| CAPOX+ Zolbetuximab Trouble with Taste C21D1 | 36 | -0.93 (Standard Deviation 24.54) |
| CAPOX+ Placebo Trouble with Taste C21D1 | 20 | 10.00 (Standard Deviation 15.67) |
| CAPOX+ Zolbetuximab Trouble with Taste C22D1 | 31 | -1.08 (Standard Deviation 26.50) |
| CAPOX+ Placebo Trouble with Taste C22D1 | 17 | 5.88 (Standard Deviation 13.10) |
| CAPOX+ Zolbetuximab Trouble with Taste C23D1 | 31 | 2.15 (Standard Deviation 24.24) |
| CAPOX+ Placebo Trouble with Taste C23D1 | 16 | 8.33 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Trouble with Taste C24D1 | 29 | 0.00 (Standard Deviation 19.92) |
| CAPOX+ Placebo Trouble with Taste C24D1 | 12 | 2.78 (Standard Deviation 9.62) |
| CAPOX+ Zolbetuximab Trouble with Taste C25D1 | 28 | 2.38 (Standard Deviation 20.14) |
| CAPOX+ Placebo Trouble with Taste C25D1 | 12 | 5.56 (Standard Deviation 12.97) |
| CAPOX+ Zolbetuximab Trouble with Taste C26D1 | 26 | -1.28 (Standard Deviation 19.96) |
| CAPOX+ Placebo Trouble with Taste C26D1 | 9 | 11.11 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Trouble with Taste C27D1 | 25 | 0.00 (Standard Deviation 19.25) |
| CAPOX+ Placebo Trouble with Taste C27D1 | 10 | 3.33 (Standard Deviation 10.54) |
| CAPOX+ Zolbetuximab Trouble with Taste C28D1 | 21 | 3.17 (Standard Deviation 23.34) |
| CAPOX+ Placebo Trouble with Taste C28D1 | 11 | 3.03 (Standard Deviation 10.05) |
| CAPOX+ Zolbetuximab Trouble with Taste C29D1 | 22 | 4.55 (Standard Deviation 21.32) |
| CAPOX+ Placebo Trouble with Taste C29D1 | 12 | 8.33 (Standard Deviation 15.08) |
| CAPOX+ Zolbetuximab Trouble with Taste C30D1 | 20 | 1.67 (Standard Deviation 20.16) |
| CAPOX+ Zolbetuximab Trouble with Taste C31D1 | 20 | 1.67 (Standard Deviation 22.88) |
| CAPOX+ Zolbetuximab Trouble with Taste C32D1 | 18 | 0.00 (Standard Deviation 22.87) |
| CAPOX+ Zolbetuximab Trouble with Taste C33D1 | 15 | -2.22 (Standard Deviation 23.46) |
| CAPOX+ Zolbetuximab Trouble with Taste C34D1 | 12 | -8.33 (Standard Deviation 20.72) |
| CAPOX+ Zolbetuximab Trouble with Taste C35D1 | 13 | -2.56 (Standard Deviation 21.35) |
| CAPOX+ Zolbetuximab Trouble with Taste C36D1 | 12 | -2.78 (Standard Deviation 22.29) |
| CAPOX+ Zolbetuximab Trouble with Taste C37D1 | 11 | -3.03 (Standard Deviation 27.71) |
| CAPOX+ Zolbetuximab Trouble with Taste C38D1 | 10 | -3.33 (Standard Deviation 29.19) |
| CAPOX+ Zolbetuximab Trouble with Taste C39D1 | 9 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Trouble with Taste 30 day follow up | 57 | 4.09 (Standard Deviation 23.63) |
| CAPOX+ Placebo Trouble with Taste 30 day follow up | 76 | 9.21 (Standard Deviation 29.11) |
| CAPOX+ Zolbetuximab Trouble with Taste 90 day follow up | 61 | 7.65 (Standard Deviation 25.38) |
| CAPOX+ Placebo Trouble with Taste 90 day follow up | 79 | 7.59 (Standard Deviation 22.61) |
| CAPOX+ Zolbetuximab Body Image Baseline | 243 | 17.97 (Standard Deviation 25.75) |
| CAPOX+ Placebo Body Image Baseline | 242 | 19.64 (Standard Deviation 23.99) |
| CAPOX+ Zolbetuximab Body Image C2D1 | 208 | -0.80 (Standard Deviation 22.80) |
| CAPOX+ Placebo Body Image C2D1 | 216 | -2.31 (Standard Deviation 22.04) |
| CAPOX+ Zolbetuximab Body Image C3D1 | 182 | 1.47 (Standard Deviation 24.48) |
| CAPOX+ Placebo Body Image C3D1 | 196 | -1.53 (Standard Deviation 23.94) |
| CAPOX+ Zolbetuximab Body Image C4D1 | 166 | 1.00 (Standard Deviation 26.32) |
| CAPOX+ Placebo Body Image C4D1 | 169 | -0.99 (Standard Deviation 22.25) |
| CAPOX+ Zolbetuximab Body Image C5D1 | 159 | 2.52 (Standard Deviation 28.45) |
| CAPOX+ Placebo Body Image C5D1 | 165 | 0.61 (Standard Deviation 22.83) |
| CAPOX+ Zolbetuximab Body Image C6D1 | 149 | 3.58 (Standard Deviation 24.55) |
| CAPOX+ Placebo Body Image C6D1 | 145 | -1.38 (Standard Deviation 26.61) |
| CAPOX+ Zolbetuximab Body Image C7D1 | 119 | 0.28 (Standard Deviation 25.85) |
| CAPOX+ Placebo Body Image C7D1 | 125 | -0.80 (Standard Deviation 25.56) |
| CAPOX+ Zolbetuximab Body Image C8D1 | 108 | 2.78 (Standard Deviation 26.62) |
| CAPOX+ Placebo Body Image C8D1 | 109 | 0.00 (Standard Deviation 24.43) |
| CAPOX+ Zolbetuximab Body Image C9D1 | 102 | 1.31 (Standard Deviation 24.34) |
| CAPOX+ Placebo Body Image C9D1 | 103 | -0.97 (Standard Deviation 24.01) |
| CAPOX+ Zolbetuximab Body Image C10D1 | 85 | -1.57 (Standard Deviation 29.95) |
| CAPOX+ Placebo Body Image C10D1 | 79 | -0.42 (Standard Deviation 26.95) |
| CAPOX+ Zolbetuximab Body Image C11D1 | 80 | -5.00 (Standard Deviation 26.57) |
| CAPOX+ Placebo Body Image C11D1 | 71 | 0.94 (Standard Deviation 26.41) |
| CAPOX+ Zolbetuximab Body Image C12D1 | 75 | -3.56 (Standard Deviation 29.29) |
| CAPOX+ Placebo Body Image C12D1 | 57 | -2.34 (Standard Deviation 22.59) |
| CAPOX+ Zolbetuximab Body Image C13D1 | 60 | -7.22 (Standard Deviation 30.12) |
| CAPOX+ Placebo Body Image C13D1 | 48 | 0.00 (Standard Deviation 26.63) |
| CAPOX+ Zolbetuximab Body Image C14D1 | 55 | -6.06 (Standard Deviation 27.29) |
| CAPOX+ Placebo Body Image C14D1 | 44 | -2.27 (Standard Deviation 25.31) |
| CAPOX+ Zolbetuximab Body Image C15D1 | 51 | -5.88 (Standard Deviation 28.83) |
| CAPOX+ Placebo Body Image C15D1 | 36 | -0.93 (Standard Deviation 28.16) |
| CAPOX+ Zolbetuximab Body Image C16D1 | 48 | -7.64 (Standard Deviation 27.71) |
| CAPOX+ Placebo Body Image C16D1 | 31 | 1.08 (Standard Deviation 26.50) |
| CAPOX+ Zolbetuximab Body Image C17D1 | 43 | -6.20 (Standard Deviation 27.46) |
| CAPOX+ Placebo Body Image C17D1 | 25 | -2.67 (Standard Deviation 23.41) |
| CAPOX+ Zolbetuximab Body Image C18D1 | 41 | -8.13 (Standard Deviation 25.58) |
| CAPOX+ Placebo Body Image C18D1 | 21 | -4.76 (Standard Deviation 26.43) |
| CAPOX+ Zolbetuximab Body Image C19D1 | 40 | -6.67 (Standard Deviation 24.11) |
| CAPOX+ Placebo Body Image C19D1 | 20 | -1.67 (Standard Deviation 13.13) |
| CAPOX+ Zolbetuximab Body Image C20D1 | 39 | -3.42 (Standard Deviation 23.93) |
| CAPOX+ Placebo Body Image C20D1 | 19 | -3.51 (Standard Deviation 29.18) |
| CAPOX+ Zolbetuximab Body Image C21D1 | 36 | -9.26 (Standard Deviation 20.49) |
| CAPOX+ Placebo Body Image C21D1 | 20 | -8.33 (Standard Deviation 23.88) |
| CAPOX+ Zolbetuximab Body Image C22D1 | 31 | -5.38 (Standard Deviation 24.49) |
| CAPOX+ Placebo Body Image C22D1 | 17 | -3.92 (Standard Deviation 30.92) |
| CAPOX+ Zolbetuximab Body Image C23D1 | 31 | -8.60 (Standard Deviation 19.18) |
| CAPOX+ Placebo Body Image C23D1 | 16 | -8.33 (Standard Deviation 28.54) |
| CAPOX+ Zolbetuximab Body Image C24D1 | 29 | -8.05 (Standard Deviation 17.03) |
| CAPOX+ Placebo Body Image C24D1 | 12 | -5.56 (Standard Deviation 34.33) |
| CAPOX+ Zolbetuximab Body Image C25D1 | 28 | -8.33 (Standard Deviation 23.35) |
| CAPOX+ Placebo Body Image C25D1 | 12 | -2.78 (Standard Deviation 33.21) |
| CAPOX+ Zolbetuximab Body Image C26D1 | 26 | -6.41 (Standard Deviation 23.13) |
| CAPOX+ Placebo Body Image C26D1 | 9 | 3.70 (Standard Deviation 11.11) |
| CAPOX+ Zolbetuximab Body Image C27D1 | 25 | -6.67 (Standard Deviation 19.25) |
| CAPOX+ Placebo Body Image C27D1 | 10 | 3.33 (Standard Deviation 10.54) |
| CAPOX+ Zolbetuximab Body Image C28D1 | 21 | -9.52 (Standard Deviation 21.46) |
| CAPOX+ Placebo Body Image C28D1 | 11 | 6.06 (Standard Deviation 13.48) |
| CAPOX+ Zolbetuximab Body Image C29D1 | 22 | -9.09 (Standard Deviation 25.58) |
| CAPOX+ Placebo Body Image C29D1 | 12 | 5.56 (Standard Deviation 12.97) |
| CAPOX+ Zolbetuximab Body Image C30D1 | 20 | -3.33 (Standard Deviation 21.36) |
| CAPOX+ Zolbetuximab Body Image C31D1 | 20 | -10.00 (Standard Deviation 21.90) |
| CAPOX+ Zolbetuximab Body Image C32D1 | 18 | -11.11 (Standard Deviation 22.87) |
| CAPOX+ Zolbetuximab Body Image C33D1 | 15 | -15.56 (Standard Deviation 24.77) |
| CAPOX+ Zolbetuximab Body Image C34D1 | 12 | -13.89 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Body Image C35D1 | 13 | -10.26 (Standard Deviation 16.01) |
| CAPOX+ Zolbetuximab Body Image C36D1 | 12 | -11.11 (Standard Deviation 16.41) |
| CAPOX+ Zolbetuximab Body Image C37D1 | 11 | -15.15 (Standard Deviation 17.41) |
| CAPOX+ Zolbetuximab Body Image C38D1 | 10 | -16.67 (Standard Deviation 17.57) |
| CAPOX+ Zolbetuximab Body Image C39D1 | 9 | -11.11 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Body Image 30 day follow up | 57 | 3.51 (Standard Deviation 30.00) |
| CAPOX+ Placebo Body Image 30 day follow up | 76 | 5.26 (Standard Deviation 26.70) |
| CAPOX+ Zolbetuximab Body Image 90 day follow up | 61 | 7.10 (Standard Deviation 20.29) |
| CAPOX+ Placebo Body Image 90 day follow up | 79 | 6.75 (Standard Deviation 29.42) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva Baseline | 243 | 3.84 (Standard Deviation 12.64) |
| CAPOX+ Placebo Trouble Swallowing Saliva Baseline | 242 | 5.26 (Standard Deviation 15.52) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C2D1 | 208 | 0.48 (Standard Deviation 13.70) |
| CAPOX+ Placebo Trouble Swallowing Saliva C2D1 | 216 | -1.85 (Standard Deviation 14.62) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C3D1 | 182 | 0.00 (Standard Deviation 13.57) |
| CAPOX+ Placebo Trouble Swallowing Saliva C3D1 | 196 | -1.19 (Standard Deviation 15.97) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C4D1 | 166 | 0.20 (Standard Deviation 16.20) |
| CAPOX+ Placebo Trouble Swallowing Saliva C4D1 | 169 | -0.59 (Standard Deviation 16.05) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C5D1 | 159 | 0.21 (Standard Deviation 15.23) |
| CAPOX+ Placebo Trouble Swallowing Saliva C5D1 | 165 | -2.63 (Standard Deviation 16.04) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C6D1 | 149 | 2.91 (Standard Deviation 18.96) |
| CAPOX+ Placebo Trouble Swallowing Saliva C6D1 | 145 | 0.00 (Standard Deviation 18.84) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C7D1 | 119 | 1.40 (Standard Deviation 18.61) |
| CAPOX+ Placebo Trouble Swallowing Saliva C7D1 | 125 | -1.33 (Standard Deviation 18.16) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C8D1 | 108 | -0.62 (Standard Deviation 15.77) |
| CAPOX+ Placebo Trouble Swallowing Saliva C8D1 | 109 | -3.06 (Standard Deviation 16.06) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C9D1 | 102 | 0.65 (Standard Deviation 15.54) |
| CAPOX+ Placebo Trouble Swallowing Saliva C9D1 | 103 | -3.56 (Standard Deviation 19.75) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C10D1 | 85 | 0.78 (Standard Deviation 17.04) |
| CAPOX+ Placebo Trouble Swallowing Saliva C10D1 | 79 | -4.22 (Standard Deviation 20.23) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C11D1 | 80 | -0.42 (Standard Deviation 13.52) |
| CAPOX+ Placebo Trouble Swallowing Saliva C11D1 | 71 | -4.69 (Standard Deviation 18.94) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C12D1 | 75 | 0.00 (Standard Deviation 10.96) |
| CAPOX+ Placebo Trouble Swallowing Saliva C12D1 | 57 | -4.68 (Standard Deviation 19.35) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C13D1 | 60 | 0.00 (Standard Deviation 12.27) |
| CAPOX+ Placebo Trouble Swallowing Saliva C13D1 | 48 | -2.78 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C14D1 | 55 | -1.21 (Standard Deviation 11.04) |
| CAPOX+ Placebo Trouble Swallowing Saliva C14D1 | 44 | -3.79 (Standard Deviation 25.13) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C15D1 | 51 | -1.96 (Standard Deviation 14.00) |
| CAPOX+ Placebo Trouble Swallowing Saliva C15D1 | 36 | -6.48 (Standard Deviation 23.66) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C16D1 | 48 | 0.00 (Standard Deviation 16.84) |
| CAPOX+ Placebo Trouble Swallowing Saliva C16D1 | 31 | -4.30 (Standard Deviation 20.62) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C17D1 | 43 | -2.33 (Standard Deviation 13.40) |
| CAPOX+ Placebo Trouble Swallowing Saliva C17D1 | 25 | -6.67 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C18D1 | 41 | -2.44 (Standard Deviation 13.72) |
| CAPOX+ Placebo Trouble Swallowing Saliva C18D1 | 21 | -6.35 (Standard Deviation 22.65) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C19D1 | 40 | -0.83 (Standard Deviation 15.99) |
| CAPOX+ Placebo Trouble Swallowing Saliva C19D1 | 20 | -5.00 (Standard Deviation 16.31) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C20D1 | 39 | -3.42 (Standard Deviation 16.75) |
| CAPOX+ Placebo Trouble Swallowing Saliva C20D1 | 19 | -7.02 (Standard Deviation 23.78) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C21D1 | 36 | 0.00 (Standard Deviation 17.82) |
| CAPOX+ Placebo Trouble Swallowing Saliva C21D1 | 20 | -5.00 (Standard Deviation 27.09) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C22D1 | 31 | 0.00 (Standard Deviation 12.17) |
| CAPOX+ Placebo Trouble Swallowing Saliva C22D1 | 17 | -5.88 (Standard Deviation 24.25) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C23D1 | 31 | 0.00 (Standard Deviation 12.17) |
| CAPOX+ Placebo Trouble Swallowing Saliva C23D1 | 16 | -10.42 (Standard Deviation 23.47) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C24D1 | 29 | 0.00 (Standard Deviation 12.60) |
| CAPOX+ Placebo Trouble Swallowing Saliva C24D1 | 12 | -8.33 (Standard Deviation 20.72) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C25D1 | 28 | 1.19 (Standard Deviation 14.29) |
| CAPOX+ Placebo Trouble Swallowing Saliva C25D1 | 12 | -13.89 (Standard Deviation 26.43) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C26D1 | 26 | -1.28 (Standard Deviation 11.47) |
| CAPOX+ Placebo Trouble Swallowing Saliva C26D1 | 9 | -11.11 (Standard Deviation 23.57) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C27D1 | 25 | 0.00 (Standard Deviation 13.61) |
| CAPOX+ Placebo Trouble Swallowing Saliva C27D1 | 10 | -10.00 (Standard Deviation 22.50) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C28D1 | 21 | 0.00 (Standard Deviation 10.54) |
| CAPOX+ Placebo Trouble Swallowing Saliva C28D1 | 11 | -9.09 (Standard Deviation 21.56) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C29D1 | 22 | 1.52 (Standard Deviation 12.50) |
| CAPOX+ Placebo Trouble Swallowing Saliva C29D1 | 12 | -8.33 (Standard Deviation 20.72) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C30D1 | 20 | 0.00 (Standard Deviation 10.81) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C31D1 | 20 | 0.00 (Standard Deviation 10.81) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C32D1 | 18 | -1.85 (Standard Deviation 7.86) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C33D1 | 15 | -2.22 (Standard Deviation 8.61) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C34D1 | 12 | 0.00 (Standard Deviation 14.21) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C35D1 | 13 | 0.00 (Standard Deviation 13.61) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C36D1 | 12 | -2.78 (Standard Deviation 9.62) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C37D1 | 11 | 0.00 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C38D1 | 10 | 0.00 (Standard Deviation 15.71) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva C39D1 | 9 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva 30 day follow up | 57 | 1.75 (Standard Deviation 20.34) |
| CAPOX+ Placebo Trouble Swallowing Saliva 30 day follow up | 76 | -1.75 (Standard Deviation 17.12) |
| CAPOX+ Zolbetuximab Trouble Swallowing Saliva 90 day follow up | 61 | 1.64 (Standard Deviation 16.58) |
| CAPOX+ Placebo Trouble Swallowing Saliva 90 day follow up | 79 | -2.95 (Standard Deviation 21.48) |
| CAPOX+ Zolbetuximab Choked When Swallowing Baseline | 243 | 5.35 (Standard Deviation 14.01) |
| CAPOX+ Placebo Choked When Swallowing Baseline | 242 | 6.64 (Standard Deviation 17.00) |
| CAPOX+ Zolbetuximab Choked When Swallowing C2D1 | 208 | -1.60 (Standard Deviation 13.81) |
| CAPOX+ Placebo Choked When Swallowing C2D1 | 216 | -1.54 (Standard Deviation 15.00) |
| CAPOX+ Zolbetuximab Choked When Swallowing C3D1 | 182 | -1.10 (Standard Deviation 12.09) |
| CAPOX+ Placebo Choked When Swallowing C3D1 | 196 | -1.87 (Standard Deviation 17.92) |
| CAPOX+ Zolbetuximab Choked When Swallowing C4D1 | 166 | -2.01 (Standard Deviation 14.07) |
| CAPOX+ Placebo Choked When Swallowing C4D1 | 169 | -1.38 (Standard Deviation 16.41) |
| CAPOX+ Zolbetuximab Choked When Swallowing C5D1 | 159 | -1.68 (Standard Deviation 15.82) |
| CAPOX+ Placebo Choked When Swallowing C5D1 | 165 | -2.42 (Standard Deviation 17.09) |
| CAPOX+ Zolbetuximab Choked When Swallowing C6D1 | 149 | -1.12 (Standard Deviation 15.70) |
| CAPOX+ Placebo Choked When Swallowing C6D1 | 145 | -1.84 (Standard Deviation 18.33) |
| CAPOX+ Zolbetuximab Choked When Swallowing C7D1 | 119 | 0.56 (Standard Deviation 19.40) |
| CAPOX+ Placebo Choked When Swallowing C7D1 | 125 | -2.93 (Standard Deviation 19.41) |
| CAPOX+ Zolbetuximab Choked When Swallowing C8D1 | 108 | -0.31 (Standard Deviation 14.76) |
| CAPOX+ Placebo Choked When Swallowing C8D1 | 109 | -3.67 (Standard Deviation 18.89) |
| CAPOX+ Zolbetuximab Choked When Swallowing C9D1 | 102 | -0.65 (Standard Deviation 14.82) |
| CAPOX+ Placebo Choked When Swallowing C9D1 | 103 | -2.27 (Standard Deviation 19.95) |
| CAPOX+ Zolbetuximab Choked When Swallowing C10D1 | 85 | -1.96 (Standard Deviation 14.87) |
| CAPOX+ Placebo Choked When Swallowing C10D1 | 79 | -2.95 (Standard Deviation 19.39) |
| CAPOX+ Zolbetuximab Choked When Swallowing C11D1 | 80 | -0.83 (Standard Deviation 14.98) |
| CAPOX+ Placebo Choked When Swallowing C11D1 | 71 | -2.82 (Standard Deviation 18.47) |
| CAPOX+ Zolbetuximab Choked When Swallowing C12D1 | 75 | -2.22 (Standard Deviation 14.84) |
| CAPOX+ Placebo Choked When Swallowing C12D1 | 57 | -1.75 (Standard Deviation 15.96) |
| CAPOX+ Zolbetuximab Choked When Swallowing C13D1 | 60 | -3.33 (Standard Deviation 14.65) |
| CAPOX+ Placebo Choked When Swallowing C13D1 | 48 | -4.17 (Standard Deviation 18.99) |
| CAPOX+ Zolbetuximab Choked When Swallowing C14D1 | 55 | -3.03 (Standard Deviation 11.61) |
| CAPOX+ Placebo Choked When Swallowing C14D1 | 44 | -1.52 (Standard Deviation 21.51) |
| CAPOX+ Zolbetuximab Choked When Swallowing C15D1 | 51 | -3.92 (Standard Deviation 12.73) |
| CAPOX+ Placebo Choked When Swallowing C15D1 | 36 | 0.93 (Standard Deviation 24.54) |
| CAPOX+ Zolbetuximab Choked When Swallowing C16D1 | 48 | -2.08 (Standard Deviation 12.69) |
| CAPOX+ Placebo Choked When Swallowing C16D1 | 31 | 1.08 (Standard Deviation 21.92) |
| CAPOX+ Zolbetuximab Choked When Swallowing C17D1 | 43 | -1.55 (Standard Deviation 7.10) |
| CAPOX+ Placebo Choked When Swallowing C17D1 | 25 | -4.00 (Standard Deviation 22.19) |
| CAPOX+ Zolbetuximab Choked When Swallowing C18D1 | 41 | -0.81 (Standard Deviation 11.76) |
| CAPOX+ Placebo Choked When Swallowing C18D1 | 21 | -3.17 (Standard Deviation 17.97) |
| CAPOX+ Zolbetuximab Choked When Swallowing C19D1 | 40 | -1.67 (Standard Deviation 10.54) |
| CAPOX+ Placebo Choked When Swallowing C19D1 | 20 | -1.67 (Standard Deviation 7.45) |
| CAPOX+ Zolbetuximab Choked When Swallowing C20D1 | 39 | -2.56 (Standard Deviation 11.81) |
| CAPOX+ Placebo Choked When Swallowing C20D1 | 19 | -3.51 (Standard Deviation 18.90) |
| CAPOX+ Zolbetuximab Choked When Swallowing C21D1 | 36 | -1.85 (Standard Deviation 15.83) |
| CAPOX+ Placebo Choked When Swallowing C21D1 | 20 | -5.00 (Standard Deviation 16.31) |
| CAPOX+ Zolbetuximab Choked When Swallowing C22D1 | 31 | -2.15 (Standard Deviation 11.97) |
| CAPOX+ Placebo Choked When Swallowing C22D1 | 17 | -3.92 (Standard Deviation 20.01) |
| CAPOX+ Zolbetuximab Choked When Swallowing C23D1 | 31 | -2.15 (Standard Deviation 14.75) |
| CAPOX+ Placebo Choked When Swallowing C23D1 | 16 | -4.17 (Standard Deviation 20.64) |
| CAPOX+ Zolbetuximab Choked When Swallowing C24D1 | 29 | -1.15 (Standard Deviation 14.04) |
| CAPOX+ Placebo Choked When Swallowing C24D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Choked When Swallowing C25D1 | 28 | -3.57 (Standard Deviation 13.88) |
| CAPOX+ Placebo Choked When Swallowing C25D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Choked When Swallowing C26D1 | 26 | -2.56 (Standard Deviation 13.07) |
| CAPOX+ Placebo Choked When Swallowing C26D1 | 9 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Choked When Swallowing C27D1 | 25 | -1.33 (Standard Deviation 17.95) |
| CAPOX+ Placebo Choked When Swallowing C27D1 | 10 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Choked When Swallowing C28D1 | 21 | 0.00 (Standard Deviation 18.26) |
| CAPOX+ Placebo Choked When Swallowing C28D1 | 11 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Choked When Swallowing C29D1 | 22 | 1.52 (Standard Deviation 16.19) |
| CAPOX+ Placebo Choked When Swallowing C29D1 | 12 | -2.78 (Standard Deviation 9.62) |
| CAPOX+ Zolbetuximab Choked When Swallowing C30D1 | 20 | 3.33 (Standard Deviation 18.42) |
| CAPOX+ Zolbetuximab Choked When Swallowing C31D1 | 20 | 1.67 (Standard Deviation 17.01) |
| CAPOX+ Zolbetuximab Choked When Swallowing C32D1 | 18 | 0.00 (Standard Deviation 19.80) |
| CAPOX+ Zolbetuximab Choked When Swallowing C33D1 | 15 | -2.22 (Standard Deviation 15.26) |
| CAPOX+ Zolbetuximab Choked When Swallowing C34D1 | 12 | 0.00 (Standard Deviation 20.10) |
| CAPOX+ Zolbetuximab Choked When Swallowing C35D1 | 13 | 2.56 (Standard Deviation 21.35) |
| CAPOX+ Zolbetuximab Choked When Swallowing C36D1 | 12 | 2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Choked When Swallowing C37D1 | 11 | -3.03 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Choked When Swallowing C38D1 | 10 | -3.33 (Standard Deviation 18.92) |
| CAPOX+ Zolbetuximab Choked When Swallowing C39D1 | 9 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Choked When Swallowing 30 day follow up | 57 | 4.09 (Standard Deviation 21.89) |
| CAPOX+ Placebo Choked When Swallowing 30 day follow up | 76 | -3.07 (Standard Deviation 19.00) |
| CAPOX+ Zolbetuximab Choked When Swallowing 90 day follow up | 61 | 0.00 (Standard Deviation 14.91) |
| CAPOX+ Placebo Choked When Swallowing 90 day follow up | 79 | -1.69 (Standard Deviation 21.94) |
| CAPOX+ Zolbetuximab Trouble with Coughing Baseline | 243 | 10.56 (Standard Deviation 17.49) |
| CAPOX+ Placebo Trouble with Coughing Baseline | 242 | 9.82 (Standard Deviation 19.49) |
| CAPOX+ Zolbetuximab Trouble with Coughing C2D1 | 208 | -0.48 (Standard Deviation 16.86) |
| CAPOX+ Placebo Trouble with Coughing C2D1 | 216 | -0.77 (Standard Deviation 18.59) |
| CAPOX+ Zolbetuximab Trouble with Coughing C3D1 | 182 | -2.01 (Standard Deviation 17.92) |
| CAPOX+ Placebo Trouble with Coughing C3D1 | 196 | -0.68 (Standard Deviation 19.08) |
| CAPOX+ Zolbetuximab Trouble with Coughing C4D1 | 166 | -1.61 (Standard Deviation 19.00) |
| CAPOX+ Placebo Trouble with Coughing C4D1 | 169 | -0.99 (Standard Deviation 20.39) |
| CAPOX+ Zolbetuximab Trouble with Coughing C5D1 | 159 | 0.21 (Standard Deviation 19.30) |
| CAPOX+ Placebo Trouble with Coughing C5D1 | 165 | -2.63 (Standard Deviation 18.03) |
| CAPOX+ Zolbetuximab Trouble with Coughing C6D1 | 149 | 0.22 (Standard Deviation 23.41) |
| CAPOX+ Placebo Trouble with Coughing C6D1 | 145 | -1.38 (Standard Deviation 16.61) |
| CAPOX+ Zolbetuximab Trouble with Coughing C7D1 | 119 | -2.24 (Standard Deviation 19.76) |
| CAPOX+ Placebo Trouble with Coughing C7D1 | 125 | -1.87 (Standard Deviation 19.54) |
| CAPOX+ Zolbetuximab Trouble with Coughing C8D1 | 108 | -0.31 (Standard Deviation 17.94) |
| CAPOX+ Placebo Trouble with Coughing C8D1 | 109 | -1.22 (Standard Deviation 20.75) |
| CAPOX+ Zolbetuximab Trouble with Coughing C9D1 | 102 | -3.92 (Standard Deviation 20.06) |
| CAPOX+ Placebo Trouble with Coughing C9D1 | 103 | -2.91 (Standard Deviation 21.44) |
| CAPOX+ Zolbetuximab Trouble with Coughing C10D1 | 85 | -3.53 (Standard Deviation 22.43) |
| CAPOX+ Placebo Trouble with Coughing C10D1 | 79 | -2.11 (Standard Deviation 25.79) |
| CAPOX+ Zolbetuximab Trouble with Coughing C11D1 | 80 | -4.17 (Standard Deviation 22.73) |
| CAPOX+ Placebo Trouble with Coughing C11D1 | 71 | -4.23 (Standard Deviation 25.15) |
| CAPOX+ Zolbetuximab Trouble with Coughing C12D1 | 75 | -2.67 (Standard Deviation 23.09) |
| CAPOX+ Placebo Trouble with Coughing C12D1 | 57 | -8.19 (Standard Deviation 22.96) |
| CAPOX+ Zolbetuximab Trouble with Coughing C13D1 | 60 | -5.00 (Standard Deviation 25.91) |
| CAPOX+ Placebo Trouble with Coughing C13D1 | 48 | -6.94 (Standard Deviation 22.76) |
| CAPOX+ Zolbetuximab Trouble with Coughing C14D1 | 55 | -6.06 (Standard Deviation 15.83) |
| CAPOX+ Placebo Trouble with Coughing C14D1 | 44 | -6.82 (Standard Deviation 23.38) |
| CAPOX+ Zolbetuximab Trouble with Coughing C15D1 | 51 | -7.19 (Standard Deviation 20.35) |
| CAPOX+ Placebo Trouble with Coughing C15D1 | 36 | -7.41 (Standard Deviation 21.25) |
| CAPOX+ Zolbetuximab Trouble with Coughing C16D1 | 48 | -4.17 (Standard Deviation 23.44) |
| CAPOX+ Placebo Trouble with Coughing C16D1 | 31 | -8.60 (Standard Deviation 19.18) |
| CAPOX+ Zolbetuximab Trouble with Coughing C17D1 | 43 | -7.75 (Standard Deviation 22.81) |
| CAPOX+ Placebo Trouble with Coughing C17D1 | 25 | 1.33 (Standard Deviation 17.95) |
| CAPOX+ Zolbetuximab Trouble with Coughing C18D1 | 41 | -6.50 (Standard Deviation 21.37) |
| CAPOX+ Placebo Trouble with Coughing C18D1 | 21 | -4.76 (Standard Deviation 19.11) |
| CAPOX+ Zolbetuximab Trouble with Coughing C19D1 | 40 | -5.00 (Standard Deviation 17.78) |
| CAPOX+ Placebo Trouble with Coughing C19D1 | 20 | -1.67 (Standard Deviation 7.45) |
| CAPOX+ Zolbetuximab Trouble with Coughing C20D1 | 39 | -3.42 (Standard Deviation 19.93) |
| CAPOX+ Placebo Trouble with Coughing C20D1 | 19 | -5.26 (Standard Deviation 22.94) |
| CAPOX+ Zolbetuximab Trouble with Coughing C21D1 | 36 | -4.63 (Standard Deviation 19.76) |
| CAPOX+ Placebo Trouble with Coughing C21D1 | 20 | -1.67 (Standard Deviation 20.16) |
| CAPOX+ Zolbetuximab Trouble with Coughing C22D1 | 31 | -5.38 (Standard Deviation 17.42) |
| CAPOX+ Placebo Trouble with Coughing C22D1 | 17 | -5.88 (Standard Deviation 21.20) |
| CAPOX+ Zolbetuximab Trouble with Coughing C23D1 | 31 | -4.30 (Standard Deviation 18.74) |
| CAPOX+ Placebo Trouble with Coughing C23D1 | 16 | -6.25 (Standard Deviation 21.84) |
| CAPOX+ Zolbetuximab Trouble with Coughing C24D1 | 29 | -3.45 (Standard Deviation 18.57) |
| CAPOX+ Placebo Trouble with Coughing C24D1 | 12 | -5.56 (Standard Deviation 23.92) |
| CAPOX+ Zolbetuximab Trouble with Coughing C25D1 | 28 | -2.38 (Standard Deviation 17.98) |
| CAPOX+ Placebo Trouble with Coughing C25D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Trouble with Coughing C26D1 | 26 | -1.28 (Standard Deviation 17.59) |
| CAPOX+ Placebo Trouble with Coughing C26D1 | 9 | -3.70 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Trouble with Coughing C27D1 | 25 | -4.00 (Standard Deviation 17.53) |
| CAPOX+ Placebo Trouble with Coughing C27D1 | 10 | -3.33 (Standard Deviation 18.92) |
| CAPOX+ Zolbetuximab Trouble with Coughing C28D1 | 21 | -1.59 (Standard Deviation 12.81) |
| CAPOX+ Placebo Trouble with Coughing C28D1 | 11 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Trouble with Coughing C29D1 | 22 | 3.03 (Standard Deviation 22.79) |
| CAPOX+ Placebo Trouble with Coughing C29D1 | 12 | -2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Trouble with Coughing C30D1 | 20 | 1.67 (Standard Deviation 17.01) |
| CAPOX+ Zolbetuximab Trouble with Coughing C31D1 | 20 | 3.33 (Standard Deviation 21.36) |
| CAPOX+ Zolbetuximab Trouble with Coughing C32D1 | 18 | 3.70 (Standard Deviation 19.43) |
| CAPOX+ Zolbetuximab Trouble with Coughing C33D1 | 15 | -4.44 (Standard Deviation 11.73) |
| CAPOX+ Zolbetuximab Trouble with Coughing C34D1 | 12 | 0.00 (Standard Deviation 14.21) |
| CAPOX+ Zolbetuximab Trouble with Coughing C35D1 | 13 | -2.56 (Standard Deviation 16.45) |
| CAPOX+ Zolbetuximab Trouble with Coughing C36D1 | 12 | -5.56 (Standard Deviation 12.97) |
| CAPOX+ Zolbetuximab Trouble with Coughing C37D1 | 11 | -6.06 (Standard Deviation 13.48) |
| CAPOX+ Zolbetuximab Trouble with Coughing C38D1 | 10 | 0.00 (Standard Deviation 15.71) |
| CAPOX+ Zolbetuximab Trouble with Coughing C39D1 | 9 | 3.70 (Standard Deviation 11.11) |
| CAPOX+ Zolbetuximab Trouble with Coughing 30 day follow up | 57 | 1.17 (Standard Deviation 21.79) |
| CAPOX+ Placebo Trouble with Coughing 30 day follow up | 76 | 1.32 (Standard Deviation 28.51) |
| CAPOX+ Zolbetuximab Trouble with Coughing 90 day follow up | 61 | 2.19 (Standard Deviation 15.95) |
| CAPOX+ Placebo Trouble with Coughing 90 day follow up | 79 | 1.27 (Standard Deviation 25.29) |
| CAPOX+ Zolbetuximab Trouble Talking Baseline | 243 | 3.84 (Standard Deviation 14.34) |
| CAPOX+ Placebo Trouble Talking Baseline | 242 | 3.60 (Standard Deviation 12.40) |
| CAPOX+ Zolbetuximab Trouble Talking C2D1 | 208 | 0.96 (Standard Deviation 13.07) |
| CAPOX+ Placebo Trouble Talking C2D1 | 216 | -0.31 (Standard Deviation 9.64) |
| CAPOX+ Zolbetuximab Trouble Talking C3D1 | 182 | -0.18 (Standard Deviation 11.35) |
| CAPOX+ Placebo Trouble Talking C3D1 | 196 | -1.02 (Standard Deviation 11.65) |
| CAPOX+ Zolbetuximab Trouble Talking C4D1 | 166 | -0.40 (Standard Deviation 12.71) |
| CAPOX+ Placebo Trouble Talking C4D1 | 169 | 0.99 (Standard Deviation 14.28) |
| CAPOX+ Zolbetuximab Trouble Talking C5D1 | 159 | 1.68 (Standard Deviation 11.74) |
| CAPOX+ Placebo Trouble Talking C5D1 | 165 | -0.81 (Standard Deviation 11.01) |
| CAPOX+ Zolbetuximab Trouble Talking C6D1 | 149 | 0.67 (Standard Deviation 13.68) |
| CAPOX+ Placebo Trouble Talking C6D1 | 145 | 0.46 (Standard Deviation 11.78) |
| CAPOX+ Zolbetuximab Trouble Talking C7D1 | 119 | 0.84 (Standard Deviation 15.32) |
| CAPOX+ Placebo Trouble Talking C7D1 | 125 | -0.53 (Standard Deviation 11.19) |
| CAPOX+ Zolbetuximab Trouble Talking C8D1 | 108 | 0.93 (Standard Deviation 12.45) |
| CAPOX+ Placebo Trouble Talking C8D1 | 109 | -1.22 (Standard Deviation 13.55) |
| CAPOX+ Zolbetuximab Trouble Talking C9D1 | 102 | 0.65 (Standard Deviation 15.54) |
| CAPOX+ Placebo Trouble Talking C9D1 | 103 | 0.32 (Standard Deviation 13.60) |
| CAPOX+ Zolbetuximab Trouble Talking C10D1 | 85 | 0.39 (Standard Deviation 14.08) |
| CAPOX+ Placebo Trouble Talking C10D1 | 79 | -1.27 (Standard Deviation 15.51) |
| CAPOX+ Zolbetuximab Trouble Talking C11D1 | 80 | 0.42 (Standard Deviation 12.43) |
| CAPOX+ Placebo Trouble Talking C11D1 | 71 | -1.41 (Standard Deviation 13.14) |
| CAPOX+ Zolbetuximab Trouble Talking C12D1 | 75 | -1.33 (Standard Deviation 11.55) |
| CAPOX+ Placebo Trouble Talking C12D1 | 57 | 0.58 (Standard Deviation 7.69) |
| CAPOX+ Zolbetuximab Trouble Talking C13D1 | 60 | -2.78 (Standard Deviation 12.71) |
| CAPOX+ Placebo Trouble Talking C13D1 | 48 | -1.39 (Standard Deviation 15.31) |
| CAPOX+ Zolbetuximab Trouble Talking C14D1 | 55 | -3.03 (Standard Deviation 11.61) |
| CAPOX+ Placebo Trouble Talking C14D1 | 44 | 0.00 (Standard Deviation 16.07) |
| CAPOX+ Zolbetuximab Trouble Talking C15D1 | 51 | -3.27 (Standard Deviation 13.75) |
| CAPOX+ Placebo Trouble Talking C15D1 | 36 | -1.85 (Standard Deviation 13.67) |
| CAPOX+ Zolbetuximab Trouble Talking C16D1 | 48 | 0.00 (Standard Deviation 16.84) |
| CAPOX+ Placebo Trouble Talking C16D1 | 31 | -1.08 (Standard Deviation 16.06) |
| CAPOX+ Zolbetuximab Trouble Talking C17D1 | 43 | -4.65 (Standard Deviation 13.77) |
| CAPOX+ Placebo Trouble Talking C17D1 | 25 | 2.67 (Standard Deviation 13.33) |
| CAPOX+ Zolbetuximab Trouble Talking C18D1 | 41 | -3.25 (Standard Deviation 12.48) |
| CAPOX+ Placebo Trouble Talking C18D1 | 21 | 3.17 (Standard Deviation 14.55) |
| CAPOX+ Zolbetuximab Trouble Talking C19D1 | 40 | 0.00 (Standard Deviation 15.10) |
| CAPOX+ Placebo Trouble Talking C19D1 | 20 | 1.67 (Standard Deviation 7.45) |
| CAPOX+ Zolbetuximab Trouble Talking C20D1 | 39 | -2.56 (Standard Deviation 14.07) |
| CAPOX+ Placebo Trouble Talking C20D1 | 19 | 1.75 (Standard Deviation 13.49) |
| CAPOX+ Zolbetuximab Trouble Talking C21D1 | 36 | -0.93 (Standard Deviation 18.66) |
| CAPOX+ Placebo Trouble Talking C21D1 | 20 | 3.33 (Standard Deviation 18.42) |
| CAPOX+ Zolbetuximab Trouble Talking C22D1 | 31 | -3.23 (Standard Deviation 13.21) |
| CAPOX+ Placebo Trouble Talking C22D1 | 17 | 0.00 (Standard Deviation 20.41) |
| CAPOX+ Zolbetuximab Trouble Talking C23D1 | 31 | -1.08 (Standard Deviation 13.56) |
| CAPOX+ Placebo Trouble Talking C23D1 | 16 | -2.08 (Standard Deviation 19.12) |
| CAPOX+ Zolbetuximab Trouble Talking C24D1 | 29 | -2.30 (Standard Deviation 12.38) |
| CAPOX+ Placebo Trouble Talking C24D1 | 12 | 0.00 (Standard Deviation 24.62) |
| CAPOX+ Zolbetuximab Trouble Talking C25D1 | 28 | -1.19 (Standard Deviation 14.29) |
| CAPOX+ Placebo Trouble Talking C25D1 | 12 | 2.78 (Standard Deviation 17.16) |
| CAPOX+ Zolbetuximab Trouble Talking C26D1 | 26 | -1.28 (Standard Deviation 14.85) |
| CAPOX+ Placebo Trouble Talking C26D1 | 9 | 3.70 (Standard Deviation 11.11) |
| CAPOX+ Zolbetuximab Trouble Talking C27D1 | 25 | -2.67 (Standard Deviation 13.33) |
| CAPOX+ Placebo Trouble Talking C27D1 | 10 | 3.33 (Standard Deviation 10.54) |
| CAPOX+ Zolbetuximab Trouble Talking C28D1 | 21 | -3.17 (Standard Deviation 14.55) |
| CAPOX+ Placebo Trouble Talking C28D1 | 11 | 3.03 (Standard Deviation 10.05) |
| CAPOX+ Zolbetuximab Trouble Talking C29D1 | 22 | -1.52 (Standard Deviation 16.19) |
| CAPOX+ Placebo Trouble Talking C29D1 | 12 | 2.78 (Standard Deviation 9.62) |
| CAPOX+ Zolbetuximab Trouble Talking C30D1 | 20 | -1.67 (Standard Deviation 17.01) |
| CAPOX+ Zolbetuximab Trouble Talking C31D1 | 20 | 0.00 (Standard Deviation 18.73) |
| CAPOX+ Zolbetuximab Trouble Talking C32D1 | 18 | -1.85 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Trouble Talking C33D1 | 15 | -4.44 (Standard Deviation 17.21) |
| CAPOX+ Zolbetuximab Trouble Talking C34D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Trouble Talking C35D1 | 13 | -5.13 (Standard Deviation 18.49) |
| CAPOX+ Zolbetuximab Trouble Talking C36D1 | 12 | -5.56 (Standard Deviation 19.25) |
| CAPOX+ Zolbetuximab Trouble Talking C37D1 | 11 | -6.06 (Standard Deviation 20.10) |
| CAPOX+ Zolbetuximab Trouble Talking C38D1 | 10 | -6.67 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Trouble Talking C39D1 | 9 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Trouble Talking 30 day follow up | 57 | 4.68 (Standard Deviation 18.30) |
| CAPOX+ Placebo Trouble Talking 30 day follow up | 76 | 2.19 (Standard Deviation 15.72) |
| CAPOX+ Zolbetuximab Trouble Talking 90 day follow up | 61 | 3.83 (Standard Deviation 10.71) |
| CAPOX+ Placebo Trouble Talking 90 day follow up | 79 | 3.38 (Standard Deviation 20.39) |
| CAPOX+ Zolbetuximab Weight Loss Baseline | 243 | 23.05 (Standard Deviation 27.43) |
| CAPOX+ Placebo Weight Loss Baseline | 242 | 24.07 (Standard Deviation 28.25) |
| CAPOX+ Zolbetuximab Weight Loss C2D1 | 208 | 0.16 (Standard Deviation 23.28) |
| CAPOX+ Placebo Weight Loss C2D1 | 216 | 0.46 (Standard Deviation 26.99) |
| CAPOX+ Zolbetuximab Weight Loss C3D1 | 182 | 0.92 (Standard Deviation 26.78) |
| CAPOX+ Placebo Weight Loss C3D1 | 196 | 1.02 (Standard Deviation 27.20) |
| CAPOX+ Zolbetuximab Weight Loss C4D1 | 166 | 0.00 (Standard Deviation 28.19) |
| CAPOX+ Placebo Weight Loss C4D1 | 169 | -1.18 (Standard Deviation 25.69) |
| CAPOX+ Zolbetuximab Weight Loss C5D1 | 159 | 2.52 (Standard Deviation 32.38) |
| CAPOX+ Placebo Weight Loss C5D1 | 165 | -2.42 (Standard Deviation 26.43) |
| CAPOX+ Zolbetuximab Weight Loss C6D1 | 149 | -0.45 (Standard Deviation 25.99) |
| CAPOX+ Placebo Weight Loss C6D1 | 145 | -5.29 (Standard Deviation 29.05) |
| CAPOX+ Zolbetuximab Weight Loss C7D1 | 119 | -2.52 (Standard Deviation 27.84) |
| CAPOX+ Placebo Weight Loss C7D1 | 125 | -3.47 (Standard Deviation 28.02) |
| CAPOX+ Zolbetuximab Weight Loss C8D1 | 108 | -2.47 (Standard Deviation 26.46) |
| CAPOX+ Placebo Weight Loss C8D1 | 109 | -3.67 (Standard Deviation 29.17) |
| CAPOX+ Zolbetuximab Weight Loss C9D1 | 102 | -5.88 (Standard Deviation 29.45) |
| CAPOX+ Placebo Weight Loss C9D1 | 103 | -7.12 (Standard Deviation 29.76) |
| CAPOX+ Zolbetuximab Weight Loss C10D1 | 85 | -7.06 (Standard Deviation 32.57) |
| CAPOX+ Placebo Weight Loss C10D1 | 79 | -5.91 (Standard Deviation 28.12) |
| CAPOX+ Zolbetuximab Weight Loss C11D1 | 80 | -9.58 (Standard Deviation 30.56) |
| CAPOX+ Placebo Weight Loss C11D1 | 71 | -8.45 (Standard Deviation 25.65) |
| CAPOX+ Zolbetuximab Weight Loss C12D1 | 75 | -10.22 (Standard Deviation 30.50) |
| CAPOX+ Placebo Weight Loss C12D1 | 57 | -10.53 (Standard Deviation 24.53) |
| CAPOX+ Zolbetuximab Weight Loss C13D1 | 60 | -11.67 (Standard Deviation 28.67) |
| CAPOX+ Placebo Weight Loss C13D1 | 48 | -10.42 (Standard Deviation 25.87) |
| CAPOX+ Zolbetuximab Weight Loss C14D1 | 55 | -13.94 (Standard Deviation 26.21) |
| CAPOX+ Placebo Weight Loss C14D1 | 44 | -6.82 (Standard Deviation 23.38) |
| CAPOX+ Zolbetuximab Weight Loss C15D1 | 51 | -12.42 (Standard Deviation 26.63) |
| CAPOX+ Placebo Weight Loss C15D1 | 36 | -8.33 (Standard Deviation 30.21) |
| CAPOX+ Zolbetuximab Weight Loss C16D1 | 48 | -15.97 (Standard Deviation 22.79) |
| CAPOX+ Placebo Weight Loss C16D1 | 31 | -8.60 (Standard Deviation 22.72) |
| CAPOX+ Zolbetuximab Weight Loss C17D1 | 43 | -14.73 (Standard Deviation 19.66) |
| CAPOX+ Placebo Weight Loss C17D1 | 25 | -13.33 (Standard Deviation 21.52) |
| CAPOX+ Zolbetuximab Weight Loss C18D1 | 41 | -11.38 (Standard Deviation 25.40) |
| CAPOX+ Placebo Weight Loss C18D1 | 21 | -14.29 (Standard Deviation 27.02) |
| CAPOX+ Zolbetuximab Weight Loss C19D1 | 40 | -16.67 (Standard Deviation 22.65) |
| CAPOX+ Placebo Weight Loss C19D1 | 20 | -11.67 (Standard Deviation 16.31) |
| CAPOX+ Zolbetuximab Weight Loss C20D1 | 39 | -10.26 (Standard Deviation 21.84) |
| CAPOX+ Placebo Weight Loss C20D1 | 19 | -12.28 (Standard Deviation 25.36) |
| CAPOX+ Zolbetuximab Weight Loss C21D1 | 36 | -12.96 (Standard Deviation 22.93) |
| CAPOX+ Placebo Weight Loss C21D1 | 20 | -16.67 (Standard Deviation 25.36) |
| CAPOX+ Zolbetuximab Weight Loss C22D1 | 31 | -12.90 (Standard Deviation 23.85) |
| CAPOX+ Placebo Weight Loss C22D1 | 17 | -17.65 (Standard Deviation 26.66) |
| CAPOX+ Zolbetuximab Weight Loss C23D1 | 31 | -10.75 (Standard Deviation 19.98) |
| CAPOX+ Placebo Weight Loss C23D1 | 16 | -22.92 (Standard Deviation 29.11) |
| CAPOX+ Zolbetuximab Weight Loss C24D1 | 29 | -10.34 (Standard Deviation 26.88) |
| CAPOX+ Placebo Weight Loss C24D1 | 12 | -13.89 (Standard Deviation 30.01) |
| CAPOX+ Zolbetuximab Weight Loss C25D1 | 28 | -10.71 (Standard Deviation 20.39) |
| CAPOX+ Placebo Weight Loss C25D1 | 12 | -11.11 (Standard Deviation 25.95) |
| CAPOX+ Zolbetuximab Weight Loss C26D1 | 26 | -16.67 (Standard Deviation 25.39) |
| CAPOX+ Placebo Weight Loss C26D1 | 9 | -11.11 (Standard Deviation 16.67) |
| CAPOX+ Zolbetuximab Weight Loss C27D1 | 25 | -12.00 (Standard Deviation 21.26) |
| CAPOX+ Placebo Weight Loss C27D1 | 10 | -13.33 (Standard Deviation 23.31) |
| CAPOX+ Zolbetuximab Weight Loss C28D1 | 21 | -14.29 (Standard Deviation 22.54) |
| CAPOX+ Placebo Weight Loss C28D1 | 11 | -6.06 (Standard Deviation 13.48) |
| CAPOX+ Zolbetuximab Weight Loss C29D1 | 22 | -13.64 (Standard Deviation 19.68) |
| CAPOX+ Placebo Weight Loss C29D1 | 12 | -8.33 (Standard Deviation 15.08) |
| CAPOX+ Zolbetuximab Weight Loss C30D1 | 20 | -15.00 (Standard Deviation 20.16) |
| CAPOX+ Zolbetuximab Weight Loss C31D1 | 20 | -11.67 (Standard Deviation 19.57) |
| CAPOX+ Zolbetuximab Weight Loss C32D1 | 18 | -20.37 (Standard Deviation 20.26) |
| CAPOX+ Zolbetuximab Weight Loss C33D1 | 15 | -15.56 (Standard Deviation 24.77) |
| CAPOX+ Zolbetuximab Weight Loss C34D1 | 12 | -16.67 (Standard Deviation 26.59) |
| CAPOX+ Zolbetuximab Weight Loss C35D1 | 13 | -15.38 (Standard Deviation 22.01) |
| CAPOX+ Zolbetuximab Weight Loss C36D1 | 12 | -13.89 (Standard Deviation 22.29) |
| CAPOX+ Zolbetuximab Weight Loss C37D1 | 11 | -18.18 (Standard Deviation 27.34) |
| CAPOX+ Zolbetuximab Weight Loss C38D1 | 10 | -20.00 (Standard Deviation 23.31) |
| CAPOX+ Zolbetuximab Weight Loss C39D1 | 9 | -14.81 (Standard Deviation 24.22) |
| CAPOX+ Zolbetuximab Weight Loss 30 day follow up | 57 | -1.75 (Standard Deviation 30.49) |
| CAPOX+ Placebo Weight Loss 30 day follow up | 76 | 3.95 (Standard Deviation 27.74) |
| CAPOX+ Zolbetuximab Weight Loss 90 day follow up | 61 | -1.64 (Standard Deviation 24.67) |
| CAPOX+ Placebo Weight Loss 90 day follow up | 79 | 2.95 (Standard Deviation 30.75) |
| CAPOX+ Zolbetuximab Hair Loss Baseline | 243 | 12.09 (Standard Deviation 20.80) |
| CAPOX+ Placebo Hair Loss Baseline | 242 | 12.55 (Standard Deviation 23.56) |
| CAPOX+ Zolbetuximab Hair Loss C2D1 | 59 | -2.26 (Standard Deviation 18.43) |
| CAPOX+ Placebo Hair Loss C2D1 | 60 | -1.67 (Standard Deviation 15.56) |
| CAPOX+ Zolbetuximab Hair Loss C3D1 | 54 | -3.09 (Standard Deviation 19.71) |
| CAPOX+ Placebo Hair Loss C3D1 | 49 | -4.76 (Standard Deviation 23.57) |
| CAPOX+ Zolbetuximab Hair Loss C4D1 | 53 | -0.63 (Standard Deviation 24.01) |
| CAPOX+ Placebo Hair Loss C4D1 | 46 | 0.00 (Standard Deviation 15.71) |
| CAPOX+ Zolbetuximab Hair Loss C5D1 | 44 | -3.03 (Standard Deviation 20.10) |
| CAPOX+ Placebo Hair Loss C5D1 | 41 | -0.81 (Standard Deviation 18.99) |
| CAPOX+ Zolbetuximab Hair Loss C6D1 | 45 | 2.96 (Standard Deviation 23.38) |
| CAPOX+ Placebo Hair Loss C6D1 | 36 | -4.63 (Standard Deviation 21.31) |
| CAPOX+ Zolbetuximab Hair Loss C7D1 | 30 | -3.33 (Standard Deviation 22.06) |
| CAPOX+ Placebo Hair Loss C7D1 | 29 | -4.60 (Standard Deviation 17.19) |
| CAPOX+ Zolbetuximab Hair Loss C8D1 | 35 | -5.71 (Standard Deviation 27.40) |
| CAPOX+ Placebo Hair Loss C8D1 | 26 | -8.97 (Standard Deviation 20.13) |
| CAPOX+ Zolbetuximab Hair Loss C9D1 | 30 | -2.22 (Standard Deviation 26.16) |
| CAPOX+ Placebo Hair Loss C9D1 | 21 | -9.52 (Standard Deviation 26.13) |
| CAPOX+ Zolbetuximab Hair Loss C10D1 | 20 | -1.67 (Standard Deviation 25.31) |
| CAPOX+ Placebo Hair Loss C10D1 | 16 | -8.33 (Standard Deviation 28.54) |
| CAPOX+ Zolbetuximab Hair Loss C11D1 | 20 | -1.67 (Standard Deviation 27.52) |
| CAPOX+ Placebo Hair Loss C11D1 | 11 | 3.03 (Standard Deviation 17.98) |
| CAPOX+ Zolbetuximab Hair Loss C12D1 | 22 | -4.55 (Standard Deviation 25.81) |
| CAPOX+ Placebo Hair Loss C12D1 | 12 | 0.00 (Standard Deviation 20.10) |
| CAPOX+ Zolbetuximab Hair Loss C13D1 | 19 | -5.26 (Standard Deviation 29.94) |
| CAPOX+ Placebo Hair Loss C13D1 | 10 | -6.67 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Hair Loss C14D1 | 12 | -11.11 (Standard Deviation 29.59) |
| CAPOX+ Placebo Hair Loss C14D1 | 7 | 4.76 (Standard Deviation 12.60) |
| CAPOX+ Zolbetuximab Hair Loss C15D1 | 11 | 6.06 (Standard Deviation 25.03) |
| CAPOX+ Placebo Hair Loss C15D1 | 7 | -4.76 (Standard Deviation 12.60) |
| CAPOX+ Zolbetuximab Hair Loss C16D1 | 13 | -2.56 (Standard Deviation 16.45) |
| CAPOX+ Placebo Hair Loss C16D1 | 5 | -6.67 (Standard Deviation 14.91) |
| CAPOX+ Zolbetuximab Hair Loss C17D1 | 11 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Placebo Hair Loss C17D1 | 4 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Hair Loss C18D1 | 10 | 0.00 (Standard Deviation 22.22) |
| CAPOX+ Zolbetuximab Hair Loss C19D1 | 8 | 0.00 (Standard Deviation 17.82) |
| CAPOX+ Placebo Hair Loss C19D1 | 5 | -13.33 (Standard Deviation 18.26) |
| CAPOX+ Zolbetuximab Hair Loss C20D1 | 10 | -3.33 (Standard Deviation 18.92) |
| CAPOX+ Placebo Hair Loss C20D1 | 4 | 0.00 (Standard Deviation 0.00) |
| CAPOX+ Zolbetuximab Hair Loss C21D1 | 10 | -3.33 (Standard Deviation 18.92) |
| CAPOX+ Zolbetuximab Hair Loss C22D1 | 8 | 0.00 (Standard Deviation 17.82) |
| CAPOX+ Zolbetuximab Hair Loss C23D1 | 6 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Hair Loss C24D1 | 7 | -4.76 (Standard Deviation 23.00) |
| CAPOX+ Zolbetuximab Hair Loss C25D1 | 6 | 0.00 (Standard Deviation 21.08) |
| CAPOX+ Zolbetuximab Hair Loss 30 day follow up | 8 | 8.33 (Standard Deviation 23.57) |
| CAPOX+ Placebo Hair Loss 30 day follow up | 14 | 2.38 (Standard Deviation 30.56) |
| CAPOX+ Zolbetuximab Hair Loss 90 day follow up | 17 | 23.53 (Standard Deviation 40.42) |
| CAPOX+ Placebo Hair Loss 90 day follow up | 22 | 15.15 (Standard Deviation 26.68) |
| CAPOX+ Zolbetuximab Belching Baseline | 243 | 12.14 (Standard Deviation 18.62) |
| CAPOX+ Placebo Belching Baseline | 242 | 14.11 (Standard Deviation 21.01) |
| CAPOX+ Zolbetuximab Belching C2D1 | 208 | -1.52 (Standard Deviation 15.68) |
| CAPOX+ Placebo Belching C2D1 | 216 | -3.09 (Standard Deviation 14.93) |
| CAPOX+ Zolbetuximab Belching C3D1 | 182 | 0.92 (Standard Deviation 17.84) |
| CAPOX+ Placebo Belching C3D1 | 196 | -1.87 (Standard Deviation 16.94) |
| CAPOX+ Zolbetuximab Belching C4D1 | 166 | 0.20 (Standard Deviation 16.51) |
| CAPOX+ Placebo Belching C4D1 | 169 | -3.16 (Standard Deviation 18.81) |
| CAPOX+ Zolbetuximab Belching C5D1 | 159 | 1.68 (Standard Deviation 17.81) |
| CAPOX+ Placebo Belching C5D1 | 165 | -5.35 (Standard Deviation 18.59) |
| CAPOX+ Zolbetuximab Belching C6D1 | 149 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Placebo Belching C6D1 | 145 | -4.02 (Standard Deviation 20.53) |
| CAPOX+ Zolbetuximab Belching C7D1 | 119 | 0.28 (Standard Deviation 17.36) |
| CAPOX+ Placebo Belching C7D1 | 125 | -5.07 (Standard Deviation 20.66) |
| CAPOX+ Zolbetuximab Belching C8D1 | 108 | 1.54 (Standard Deviation 20.95) |
| CAPOX+ Placebo Belching C8D1 | 109 | -5.05 (Standard Deviation 21.46) |
| CAPOX+ Zolbetuximab Belching C9D1 | 102 | 1.31 (Standard Deviation 18.27) |
| CAPOX+ Placebo Belching C9D1 | 103 | -9.39 (Standard Deviation 20.44) |
| CAPOX+ Zolbetuximab Belching C10D1 | 85 | 0.39 (Standard Deviation 18.54) |
| CAPOX+ Placebo Belching C10D1 | 79 | -7.38 (Standard Deviation 19.93) |
| CAPOX+ Zolbetuximab Belching C11D1 | 80 | -2.08 (Standard Deviation 17.26) |
| CAPOX+ Placebo Belching C11D1 | 71 | -9.62 (Standard Deviation 21.21) |
| CAPOX+ Zolbetuximab Belching C12D1 | 75 | -1.78 (Standard Deviation 16.11) |
| CAPOX+ Placebo Belching C12D1 | 57 | -7.60 (Standard Deviation 18.65) |
| CAPOX+ Zolbetuximab Belching C13D1 | 60 | -0.28 (Standard Deviation 20.00) |
| CAPOX+ Placebo Belching C13D1 | 48 | -7.64 (Standard Deviation 22.27) |
| CAPOX+ Zolbetuximab Belching C14D1 | 55 | 0.00 (Standard Deviation 17.27) |
| CAPOX+ Placebo Belching C14D1 | 44 | -6.06 (Standard Deviation 20.99) |
| CAPOX+ Zolbetuximab Belching C15D1 | 51 | -1.31 (Standard Deviation 16.61) |
| CAPOX+ Placebo Belching C15D1 | 36 | -5.56 (Standard Deviation 19.92) |
| CAPOX+ Zolbetuximab Belching C16D1 | 48 | -2.78 (Standard Deviation 18.30) |
| CAPOX+ Placebo Belching C16D1 | 31 | -5.91 (Standard Deviation 22.17) |
| CAPOX+ Zolbetuximab Belching C17D1 | 43 | -2.71 (Standard Deviation 18.87) |
| CAPOX+ Placebo Belching C17D1 | 25 | -5.33 (Standard Deviation 22.42) |
| CAPOX+ Zolbetuximab Belching C18D1 | 41 | -2.03 (Standard Deviation 17.16) |
| CAPOX+ Placebo Belching C18D1 | 21 | -3.17 (Standard Deviation 27.19) |
| CAPOX+ Zolbetuximab Belching C19D1 | 40 | 0.42 (Standard Deviation 15.33) |
| CAPOX+ Placebo Belching C19D1 | 20 | -2.50 (Standard Deviation 11.18) |
| CAPOX+ Zolbetuximab Belching C20D1 | 39 | 1.28 (Standard Deviation 18.09) |
| CAPOX+ Placebo Belching C20D1 | 19 | -7.02 (Standard Deviation 21.74) |
| CAPOX+ Zolbetuximab Belching C21D1 | 36 | -0.93 (Standard Deviation 14.33) |
| CAPOX+ Placebo Belching C21D1 | 20 | -5.00 (Standard Deviation 23.63) |
| CAPOX+ Zolbetuximab Belching C22D1 | 31 | -0.54 (Standard Deviation 17.99) |
| CAPOX+ Placebo Belching C22D1 | 17 | -4.90 (Standard Deviation 28.73) |
| CAPOX+ Zolbetuximab Belching C23D1 | 31 | -3.23 (Standard Deviation 16.34) |
| CAPOX+ Placebo Belching C23D1 | 16 | -9.38 (Standard Deviation 23.55) |
| CAPOX+ Zolbetuximab Belching C24D1 | 29 | 0.00 (Standard Deviation 16.67) |
| CAPOX+ Placebo Belching C24D1 | 12 | -5.56 (Standard Deviation 32.05) |
| CAPOX+ Zolbetuximab Belching C25D1 | 28 | 0.60 (Standard Deviation 17.26) |
| CAPOX+ Placebo Belching C25D1 | 12 | -8.33 (Standard Deviation 31.38) |
| CAPOX+ Zolbetuximab Belching C26D1 | 26 | 1.92 (Standard Deviation 17.21) |
| CAPOX+ Placebo Belching C26D1 | 9 | 3.70 (Standard Deviation 20.03) |
| CAPOX+ Zolbetuximab Belching C27D1 | 25 | 0.00 (Standard Deviation 15.21) |
| CAPOX+ Placebo Belching C27D1 | 10 | 0.00 (Standard Deviation 13.61) |
| CAPOX+ Zolbetuximab Belching C28D1 | 21 | 3.97 (Standard Deviation 13.85) |
| CAPOX+ Placebo Belching C28D1 | 11 | 1.52 (Standard Deviation 13.85) |
| CAPOX+ Zolbetuximab Belching C29D1 | 22 | 0.00 (Standard Deviation 15.43) |
| CAPOX+ Placebo Belching C29D1 | 12 | -1.39 (Standard Deviation 11.14) |
| CAPOX+ Zolbetuximab Belching C30D1 | 20 | 0.83 (Standard Deviation 14.78) |
| CAPOX+ Zolbetuximab Belching C31D1 | 20 | 2.50 (Standard Deviation 16.47) |
| CAPOX+ Zolbetuximab Belching C32D1 | 18 | 4.63 (Standard Deviation 17.90) |
| CAPOX+ Zolbetuximab Belching C33D1 | 15 | -1.11 (Standard Deviation 14.73) |
| CAPOX+ Zolbetuximab Belching C34D1 | 12 | 0.00 (Standard Deviation 12.31) |
| CAPOX+ Zolbetuximab Belching C35D1 | 13 | 3.85 (Standard Deviation 20.59) |
| CAPOX+ Zolbetuximab Belching C36D1 | 12 | 1.39 (Standard Deviation 19.41) |
| CAPOX+ Zolbetuximab Belching C37D1 | 11 | 6.06 (Standard Deviation 11.24) |
| CAPOX+ Zolbetuximab Belching C38D1 | 10 | 1.67 (Standard Deviation 16.57) |
| CAPOX+ Zolbetuximab Belching C39D1 | 9 | 3.70 (Standard Deviation 7.35) |
| CAPOX+ Zolbetuximab Belching 30 day follow up | 57 | 3.22 (Standard Deviation 21.23) |
| CAPOX+ Placebo Belching 30 day follow up | 76 | 0.66 (Standard Deviation 19.52) |
| CAPOX+ Zolbetuximab Belching 90 day follow up | 61 | -0.55 (Standard Deviation 15.20) |
| CAPOX+ Placebo Belching 90 day follow up | 79 | -1.90 (Standard Deviation 17.50) |
Change From Baseline in HRQoL Measured by Global Pain (GP)
Secondary outcome · Mean, Unit on a scale · Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab Baseline | 243 | 2.45 (Standard Deviation 2.49) |
| CAPOX+ Placebo Baseline | 236 | 2.64 (Standard Deviation 2.55) |
| CAPOX+ Zolbetuximab C2D1 | 208 | -0.60 (Standard Deviation 2.61) |
| CAPOX+ Placebo C2D1 | 211 | -0.63 (Standard Deviation 2.59) |
| CAPOX+ Zolbetuximab C3D1 | 180 | -0.74 (Standard Deviation 2.30) |
| CAPOX+ Placebo C3D1 | 190 | -0.82 (Standard Deviation 2.33) |
| CAPOX+ Zolbetuximab C4D1 | 166 | -0.63 (Standard Deviation 2.58) |
| CAPOX+ Placebo C4D1 | 167 | -0.91 (Standard Deviation 2.68) |
| CAPOX+ Zolbetuximab C5D1 | 159 | -0.37 (Standard Deviation 2.89) |
| CAPOX+ Placebo C5D1 | 164 | -0.79 (Standard Deviation 2.84) |
| CAPOX+ Zolbetuximab C6D1 | 149 | -0.51 (Standard Deviation 2.61) |
| CAPOX+ Placebo C6D1 | 143 | -0.57 (Standard Deviation 3.00) |
| CAPOX+ Zolbetuximab C7D1 | 117 | -0.61 (Standard Deviation 2.65) |
| CAPOX+ Placebo C7D1 | 122 | -0.38 (Standard Deviation 2.74) |
| CAPOX+ Zolbetuximab C8D1 | 106 | -0.59 (Standard Deviation 2.45) |
| CAPOX+ Placebo C8D1 | 109 | -0.36 (Standard Deviation 2.48) |
| CAPOX+ Zolbetuximab C9D1 | 102 | -0.65 (Standard Deviation 2.62) |
| CAPOX+ Placebo C9D1 | 103 | -0.36 (Standard Deviation 2.63) |
| CAPOX+ Zolbetuximab C10D1 | 85 | -0.71 (Standard Deviation 2.67) |
| CAPOX+ Placebo C10D1 | 78 | -0.71 (Standard Deviation 2.65) |
| CAPOX+ Zolbetuximab C11D1 | 80 | -0.40 (Standard Deviation 2.96) |
| CAPOX+ Placebo C11D1 | 70 | -0.61 (Standard Deviation 2.55) |
| CAPOX+ Zolbetuximab C12D1 | 75 | 0.08 (Standard Deviation 2.91) |
| CAPOX+ Placebo C12D1 | 57 | -0.53 (Standard Deviation 2.41) |
| CAPOX+ Zolbetuximab C13D1 | 60 | 0.05 (Standard Deviation 3.40) |
| CAPOX+ Placebo C13D1 | 48 | -0.63 (Standard Deviation 2.44) |
| CAPOX+ Zolbetuximab C14D1 | 55 | -0.95 (Standard Deviation 2.63) |
| CAPOX+ Placebo C14D1 | 44 | -0.34 (Standard Deviation 2.12) |
| CAPOX+ Zolbetuximab C15D1 | 51 | -0.80 (Standard Deviation 2.62) |
| CAPOX+ Placebo C15D1 | 36 | -0.44 (Standard Deviation 1.81) |
| CAPOX+ Zolbetuximab C16D1 | 48 | -0.19 (Standard Deviation 3.07) |
| CAPOX+ Placebo C16D1 | 31 | 0.10 (Standard Deviation 2.23) |
| CAPOX+ Zolbetuximab C17D1 | 43 | -0.74 (Standard Deviation 2.46) |
| CAPOX+ Placebo C17D1 | 25 | -0.20 (Standard Deviation 1.32) |
| CAPOX+ Zolbetuximab C18D1 | 41 | 0.17 (Standard Deviation 3.26) |
| CAPOX+ Placebo C18D1 | 21 | -0.48 (Standard Deviation 1.29) |
| CAPOX+ Zolbetuximab C19D1 | 40 | -0.20 (Standard Deviation 2.53) |
| CAPOX+ Placebo C19D1 | 20 | -0.25 (Standard Deviation 0.97) |
| CAPOX+ Zolbetuximab C20D1 | 39 | 0.05 (Standard Deviation 2.72) |
| CAPOX+ Placebo C20D1 | 19 | 0.21 (Standard Deviation 2.90) |
| CAPOX+ Zolbetuximab C21D1 | 36 | -0.06 (Standard Deviation 2.86) |
| CAPOX+ Placebo C21D1 | 20 | 0.50 (Standard Deviation 2.96) |
| CAPOX+ Zolbetuximab C22D1 | 31 | 0.00 (Standard Deviation 2.89) |
| CAPOX+ Placebo C22D1 | 17 | 0.00 (Standard Deviation 2.92) |
| CAPOX+ Zolbetuximab C23D1 | 31 | -0.19 (Standard Deviation 2.17) |
| CAPOX+ Placebo C23D1 | 16 | 0.69 (Standard Deviation 3.22) |
| CAPOX+ Zolbetuximab C24D1 | 29 | -0.45 (Standard Deviation 3.41) |
| CAPOX+ Placebo C24D1 | 12 | -0.33 (Standard Deviation 1.72) |
| CAPOX+ Zolbetuximab C25D1 | 28 | -0.86 (Standard Deviation 2.17) |
| CAPOX+ Placebo C25D1 | 12 | 0.17 (Standard Deviation 3.21) |
| CAPOX+ Zolbetuximab C26D1 | 26 | -0.58 (Standard Deviation 2.53) |
| CAPOX+ Placebo C26D1 | 9 | 0.22 (Standard Deviation 1.86) |
| CAPOX+ Zolbetuximab C27D1 | 25 | -1.08 (Standard Deviation 2.25) |
| CAPOX+ Placebo C27D1 | 10 | 0.80 (Standard Deviation 3.29) |
| CAPOX+ Zolbetuximab C28D1 | 21 | 0.05 (Standard Deviation 2.89) |
| CAPOX+ Placebo C28D1 | 11 | 0.18 (Standard Deviation 1.33) |
| CAPOX+ Zolbetuximab C29D1 | 22 | -0.14 (Standard Deviation 2.25) |
| CAPOX+ Placebo C29D1 | 12 | -0.17 (Standard Deviation 0.72) |
| CAPOX+ Zolbetuximab C30D1 | 20 | -0.45 (Standard Deviation 2.11) |
| CAPOX+ Zolbetuximab C31D1 | 20 | -0.45 (Standard Deviation 2.24) |
| CAPOX+ Zolbetuximab C32D1 | 18 | -0.50 (Standard Deviation 2.71) |
| CAPOX+ Zolbetuximab C33D1 | 15 | 0.07 (Standard Deviation 3.24) |
| CAPOX+ Zolbetuximab C34D1 | 12 | -0.67 (Standard Deviation 3.20) |
| CAPOX+ Zolbetuximab C35D1 | 13 | -0.69 (Standard Deviation 2.84) |
| CAPOX+ Zolbetuximab C36D1 | 12 | -1.42 (Standard Deviation 1.56) |
| CAPOX+ Zolbetuximab C37D1 | 11 | 0.18 (Standard Deviation 3.06) |
| CAPOX+ Zolbetuximab C38D1 | 10 | 0.00 (Standard Deviation 3.53) |
| CAPOX+ Zolbetuximab C39D1 | 9 | -0.89 (Standard Deviation 1.27) |
| CAPOX+ Zolbetuximab 30 day follow up | 57 | 0.74 (Standard Deviation 3.34) |
| CAPOX+ Placebo 30 day follow up | 73 | 0.56 (Standard Deviation 2.63) |
| CAPOX+ Zolbetuximab 90 day follow up | 61 | 0.08 (Standard Deviation 3.34) |
| CAPOX+ Placebo 90 day follow up | 77 | 0.62 (Standard Deviation 2.81) |
Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire
Secondary outcome · Mean, Unit on a scale · Baseline, on D1 from C2 through C39, 30-day follow up, 90-day follow up
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab Mobility Baseline | 243 | 1.33 (Standard Deviation 0.67) |
| CAPOX+ Placebo Mobility Baseline | 243 | 1.33 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Mobility C2D1 | 208 | 0.02 (Standard Deviation 0.60) |
| CAPOX+ Placebo Mobility C2D1 | 218 | 0.06 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Mobility C3D1 | 183 | -0.01 (Standard Deviation 0.61) |
| CAPOX+ Placebo Mobility C3D1 | 198 | 0.05 (Standard Deviation 0.65) |
| CAPOX+ Zolbetuximab Mobility C4D1 | 169 | -0.01 (Standard Deviation 0.62) |
| CAPOX+ Placebo Mobility C4D1 | 171 | 0.02 (Standard Deviation 0.76) |
| CAPOX+ Zolbetuximab Mobility C5D1 | 159 | 0.05 (Standard Deviation 0.65) |
| CAPOX+ Placebo Mobility C5D1 | 167 | 0.00 (Standard Deviation 0.78) |
| CAPOX+ Zolbetuximab Mobility C6D1 | 149 | 0.04 (Standard Deviation 0.77) |
| CAPOX+ Placebo Mobility C6D1 | 147 | 0.03 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Mobility C7D1 | 121 | 0.02 (Standard Deviation 0.72) |
| CAPOX+ Placebo Mobility C7D1 | 127 | 0.02 (Standard Deviation 0.70) |
| CAPOX+ Zolbetuximab Mobility C8D1 | 109 | 0.20 (Standard Deviation 0.81) |
| CAPOX+ Placebo Mobility C8D1 | 111 | 0.05 (Standard Deviation 0.78) |
| CAPOX+ Zolbetuximab Mobility C9D1 | 102 | 0.18 (Standard Deviation 0.78) |
| CAPOX+ Placebo Mobility C9D1 | 104 | 0.06 (Standard Deviation 0.75) |
| CAPOX+ Zolbetuximab Mobility C10D1 | 85 | 0.08 (Standard Deviation 0.74) |
| CAPOX+ Placebo Mobility C10D1 | 80 | 0.13 (Standard Deviation 0.74) |
| CAPOX+ Zolbetuximab Mobility C11D1 | 81 | 0.12 (Standard Deviation 0.68) |
| CAPOX+ Placebo Mobility C11D1 | 72 | 0.15 (Standard Deviation 0.87) |
| CAPOX+ Zolbetuximab Mobility C12D1 | 75 | 0.08 (Standard Deviation 0.65) |
| CAPOX+ Placebo Mobility C12D1 | 58 | 0.02 (Standard Deviation 0.66) |
| CAPOX+ Zolbetuximab Mobility C13D1 | 60 | 0.08 (Standard Deviation 0.74) |
| CAPOX+ Placebo Mobility C13D1 | 49 | 0.10 (Standard Deviation 0.85) |
| CAPOX+ Zolbetuximab Mobility C14D1 | 56 | -0.05 (Standard Deviation 0.64) |
| CAPOX+ Placebo Mobility C14D1 | 45 | 0.11 (Standard Deviation 0.53) |
| CAPOX+ Zolbetuximab Mobility C15D1 | 51 | -0.04 (Standard Deviation 0.69) |
| CAPOX+ Placebo Mobility C15D1 | 37 | 0.03 (Standard Deviation 0.55) |
| CAPOX+ Zolbetuximab Mobility C16D1 | 48 | 0.02 (Standard Deviation 0.64) |
| CAPOX+ Placebo Mobility C16D1 | 32 | 0.06 (Standard Deviation 0.56) |
| CAPOX+ Zolbetuximab Mobility C17D1 | 43 | 0.00 (Standard Deviation 0.72) |
| CAPOX+ Placebo Mobility C17D1 | 26 | 0.08 (Standard Deviation 0.48) |
| CAPOX+ Zolbetuximab Mobility C18D1 | 41 | 0.07 (Standard Deviation 0.52) |
| CAPOX+ Placebo Mobility C18D1 | 22 | 0.09 (Standard Deviation 0.43) |
| CAPOX+ Zolbetuximab Mobility C19D1 | 40 | 0.03 (Standard Deviation 0.53) |
| CAPOX+ Placebo Mobility C19D1 | 21 | 0.00 (Standard Deviation 0.32) |
| CAPOX+ Zolbetuximab Mobility C20D1 | 39 | 0.10 (Standard Deviation 0.55) |
| CAPOX+ Placebo Mobility C20D1 | 20 | 0.10 (Standard Deviation 0.55) |
| CAPOX+ Zolbetuximab Mobility C21D1 | 36 | 0.03 (Standard Deviation 0.51) |
| CAPOX+ Placebo Mobility C21D1 | 21 | -0.14 (Standard Deviation 0.48) |
| CAPOX+ Zolbetuximab Mobility C22D1 | 31 | 0.03 (Standard Deviation 0.55) |
| CAPOX+ Placebo Mobility C22D1 | 18 | -0.11 (Standard Deviation 0.58) |
| CAPOX+ Zolbetuximab Mobility C23D1 | 31 | 0.00 (Standard Deviation 0.58) |
| CAPOX+ Placebo Mobility C23D1 | 17 | -0.12 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Mobility C24D1 | 29 | 0.07 (Standard Deviation 0.53) |
| CAPOX+ Placebo Mobility C24D1 | 13 | -0.15 (Standard Deviation 0.69) |
| CAPOX+ Zolbetuximab Mobility C25D1 | 28 | 0.21 (Standard Deviation 0.63) |
| CAPOX+ Placebo Mobility C25D1 | 13 | -0.08 (Standard Deviation 0.76) |
| CAPOX+ Zolbetuximab Mobility C26D1 | 26 | 0.15 (Standard Deviation 0.54) |
| CAPOX+ Placebo Mobility C26D1 | 10 | 0.10 (Standard Deviation 0.32) |
| CAPOX+ Zolbetuximab Mobility C27D1 | 25 | 0.08 (Standard Deviation 0.76) |
| CAPOX+ Placebo Mobility C27D1 | 11 | -0.09 (Standard Deviation 0.30) |
| CAPOX+ Zolbetuximab Mobility C28D1 | 21 | 0.24 (Standard Deviation 0.89) |
| CAPOX+ Placebo Mobility C28D1 | 11 | 0.09 (Standard Deviation 0.30) |
| CAPOX+ Zolbetuximab Mobility C29D1 | 22 | 0.05 (Standard Deviation 0.65) |
| CAPOX+ Placebo Mobility C29D1 | 12 | -0.08 (Standard Deviation 0.51) |
| CAPOX+ Zolbetuximab Mobility C30D1 | 20 | 0.10 (Standard Deviation 0.64) |
| CAPOX+ Zolbetuximab Mobility C31D1 | 20 | 0.00 (Standard Deviation 0.56) |
| CAPOX+ Zolbetuximab Mobility C32D1 | 18 | 0.06 (Standard Deviation 0.54) |
| CAPOX+ Zolbetuximab Mobility C33D1 | 15 | 0.00 (Standard Deviation 0.76) |
| CAPOX+ Zolbetuximab Mobility C34D1 | 12 | -0.08 (Standard Deviation 0.79) |
| CAPOX+ Zolbetuximab Mobility C35D1 | 13 | -0.08 (Standard Deviation 0.76) |
| CAPOX+ Zolbetuximab Mobility C36D1 | 12 | -0.08 (Standard Deviation 0.51) |
| CAPOX+ Zolbetuximab Mobility C37D1 | 11 | 0.00 (Standard Deviation 0.63) |
| CAPOX+ Zolbetuximab Mobility C38D1 | 10 | 0.00 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Mobility C39D1 | 9 | 0.22 (Standard Deviation 0.83) |
| CAPOX+ Zolbetuximab Mobility 30 day follow up | 58 | 0.47 (Standard Deviation 0.96) |
| CAPOX+ Placebo Mobility 30 day follow up | 78 | 0.36 (Standard Deviation 0.98) |
| CAPOX+ Zolbetuximab Mobility 90 day follow up | 63 | 0.32 (Standard Deviation 0.76) |
| CAPOX+ Placebo Mobility 90 day follow up | 80 | 0.43 (Standard Deviation 0.90) |
| CAPOX+ Zolbetuximab Self-Care Baseline | 243 | 1.12 (Standard Deviation 0.39) |
| CAPOX+ Placebo Self-Care Baseline | 243 | 1.18 (Standard Deviation 0.56) |
| CAPOX+ Zolbetuximab Self-Care C2D1 | 208 | 0.05 (Standard Deviation 0.48) |
| CAPOX+ Placebo Self-Care C2D1 | 218 | 0.07 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Self-Care C3D1 | 183 | 0.02 (Standard Deviation 0.44) |
| CAPOX+ Placebo Self-Care C3D1 | 198 | 0.03 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Self-Care C4D1 | 169 | 0.05 (Standard Deviation 0.46) |
| CAPOX+ Placebo Self-Care C4D1 | 171 | 0.02 (Standard Deviation 0.64) |
| CAPOX+ Zolbetuximab Self-Care C5D1 | 159 | 0.05 (Standard Deviation 0.55) |
| CAPOX+ Placebo Self-Care C5D1 | 167 | 0.07 (Standard Deviation 0.72) |
| CAPOX+ Zolbetuximab Self-Care C6D1 | 149 | 0.05 (Standard Deviation 0.51) |
| CAPOX+ Placebo Self-Care C6D1 | 147 | 0.09 (Standard Deviation 0.63) |
| CAPOX+ Zolbetuximab Self-Care C7D1 | 121 | 0.07 (Standard Deviation 0.60) |
| CAPOX+ Placebo Self-Care C7D1 | 127 | 0.02 (Standard Deviation 0.70) |
| CAPOX+ Zolbetuximab Self-Care C8D1 | 109 | 0.10 (Standard Deviation 0.64) |
| CAPOX+ Placebo Self-Care C8D1 | 111 | 0.05 (Standard Deviation 0.62) |
| CAPOX+ Zolbetuximab Self-Care C9D1 | 102 | 0.15 (Standard Deviation 0.79) |
| CAPOX+ Placebo Self-Care C9D1 | 104 | 0.10 (Standard Deviation 0.58) |
| CAPOX+ Zolbetuximab Self-Care C10D1 | 85 | 0.11 (Standard Deviation 0.66) |
| CAPOX+ Placebo Self-Care C10D1 | 80 | 0.10 (Standard Deviation 0.65) |
| CAPOX+ Zolbetuximab Self-Care C11D1 | 81 | 0.09 (Standard Deviation 0.64) |
| CAPOX+ Placebo Self-Care C11D1 | 72 | 0.06 (Standard Deviation 0.69) |
| CAPOX+ Zolbetuximab Self-Care C12D1 | 75 | 0.09 (Standard Deviation 0.64) |
| CAPOX+ Placebo Self-Care C12D1 | 58 | 0.10 (Standard Deviation 0.55) |
| CAPOX+ Zolbetuximab Self-Care C13D1 | 60 | 0.05 (Standard Deviation 0.62) |
| CAPOX+ Placebo Self-Care C13D1 | 49 | 0.12 (Standard Deviation 0.56) |
| CAPOX+ Zolbetuximab Self-Care C14D1 | 56 | 0.04 (Standard Deviation 0.50) |
| CAPOX+ Placebo Self-Care C14D1 | 45 | 0.11 (Standard Deviation 0.61) |
| CAPOX+ Zolbetuximab Self-Care C15D1 | 51 | 0.00 (Standard Deviation 0.49) |
| CAPOX+ Placebo Self-Care C15D1 | 37 | 0.05 (Standard Deviation 0.52) |
| CAPOX+ Zolbetuximab Self-Care C16D1 | 48 | 0.00 (Standard Deviation 0.62) |
| CAPOX+ Placebo Self-Care C16D1 | 32 | 0.09 (Standard Deviation 0.59) |
| CAPOX+ Zolbetuximab Self-Care C17D1 | 43 | 0.02 (Standard Deviation 0.64) |
| CAPOX+ Placebo Self-Care C17D1 | 26 | 0.04 (Standard Deviation 0.53) |
| CAPOX+ Zolbetuximab Self-Care C18D1 | 41 | 0.10 (Standard Deviation 0.49) |
| CAPOX+ Placebo Self-Care C18D1 | 22 | -0.05 (Standard Deviation 0.49) |
| CAPOX+ Zolbetuximab Self-Care C19D1 | 40 | 0.00 (Standard Deviation 0.32) |
| CAPOX+ Placebo Self-Care C19D1 | 21 | -0.10 (Standard Deviation 0.44) |
| CAPOX+ Zolbetuximab Self-Care C20D1 | 39 | 0.00 (Standard Deviation 0.32) |
| CAPOX+ Placebo Self-Care C20D1 | 20 | 0.05 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Self-Care C21D1 | 36 | 0.03 (Standard Deviation 0.38) |
| CAPOX+ Placebo Self-Care C21D1 | 21 | -0.10 (Standard Deviation 0.44) |
| CAPOX+ Zolbetuximab Self-Care C22D1 | 31 | 0.00 (Standard Deviation 0.37) |
| CAPOX+ Placebo Self-Care C22D1 | 18 | 0.00 (Standard Deviation 0.59) |
| CAPOX+ Zolbetuximab Self-Care C23D1 | 31 | 0.06 (Standard Deviation 0.36) |
| CAPOX+ Placebo Self-Care C23D1 | 17 | -0.12 (Standard Deviation 0.49) |
| CAPOX+ Zolbetuximab Self-Care C24D1 | 29 | 0.07 (Standard Deviation 0.26) |
| CAPOX+ Placebo Self-Care C24D1 | 13 | -0.08 (Standard Deviation 0.64) |
| CAPOX+ Zolbetuximab Self-Care C25D1 | 28 | 0.11 (Standard Deviation 0.31) |
| CAPOX+ Placebo Self-Care C25D1 | 13 | -0.08 (Standard Deviation 0.64) |
| CAPOX+ Zolbetuximab Self-Care C26D1 | 26 | 0.12 (Standard Deviation 0.33) |
| CAPOX+ Placebo Self-Care C26D1 | 10 | -0.20 (Standard Deviation 0.63) |
| CAPOX+ Zolbetuximab Self-Care C27D1 | 25 | 0.08 (Standard Deviation 0.28) |
| CAPOX+ Placebo Self-Care C27D1 | 11 | -0.18 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Self-Care C28D1 | 21 | 0.10 (Standard Deviation 0.44) |
| CAPOX+ Placebo Self-Care C28D1 | 11 | -0.18 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Self-Care C29D1 | 22 | 0.14 (Standard Deviation 0.47) |
| CAPOX+ Placebo Self-Care C29D1 | 12 | -0.17 (Standard Deviation 0.58) |
| CAPOX+ Zolbetuximab Self-Care C30D1 | 20 | 0.10 (Standard Deviation 0.45) |
| CAPOX+ Zolbetuximab Self-Care C31D1 | 20 | 0.10 (Standard Deviation 0.45) |
| CAPOX+ Zolbetuximab Self-Care C32D1 | 18 | 0.06 (Standard Deviation 0.54) |
| CAPOX+ Zolbetuximab Self-Care C33D1 | 15 | 0.13 (Standard Deviation 0.35) |
| CAPOX+ Zolbetuximab Self-Care C34D1 | 12 | 0.08 (Standard Deviation 0.29) |
| CAPOX+ Zolbetuximab Self-Care C35D1 | 13 | 0.08 (Standard Deviation 0.28) |
| CAPOX+ Zolbetuximab Self-Care C36D1 | 12 | 0.08 (Standard Deviation 0.29) |
| CAPOX+ Zolbetuximab Self-Care C37D1 | 11 | 0.27 (Standard Deviation 0.47) |
| CAPOX+ Zolbetuximab Self-Care C38D1 | 10 | 0.20 (Standard Deviation 0.42) |
| CAPOX+ Zolbetuximab Self-Care C39D1 | 9 | 0.22 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Self-Care 30 day follow up | 58 | 0.34 (Standard Deviation 0.89) |
| CAPOX+ Placebo Self-Care 30 day follow up | 78 | 0.38 (Standard Deviation 0.81) |
| CAPOX+ Zolbetuximab Self-Care 90 day follow up | 63 | 0.30 (Standard Deviation 0.82) |
| CAPOX+ Placebo Self-Care 90 day follow up | 80 | 0.25 (Standard Deviation 0.82) |
| CAPOX+ Zolbetuximab Usual Activities Baseline | 243 | 1.40 (Standard Deviation 0.72) |
| CAPOX+ Placebo Usual Activities Baseline | 243 | 1.49 (Standard Deviation 0.81) |
| CAPOX+ Zolbetuximab Usual Activities C2D1 | 208 | 0.08 (Standard Deviation 0.81) |
| CAPOX+ Placebo Usual Activities C2D1 | 218 | 0.06 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Usual Activities C3D1 | 183 | 0.02 (Standard Deviation 0.66) |
| CAPOX+ Placebo Usual Activities C3D1 | 198 | 0.04 (Standard Deviation 0.77) |
| CAPOX+ Zolbetuximab Usual Activities C4D1 | 169 | 0.01 (Standard Deviation 0.76) |
| CAPOX+ Placebo Usual Activities C4D1 | 171 | -0.01 (Standard Deviation 0.78) |
| CAPOX+ Zolbetuximab Usual Activities C5D1 | 159 | 0.10 (Standard Deviation 0.86) |
| CAPOX+ Placebo Usual Activities C5D1 | 167 | 0.01 (Standard Deviation 0.89) |
| CAPOX+ Zolbetuximab Usual Activities C6D1 | 149 | 0.05 (Standard Deviation 0.71) |
| CAPOX+ Placebo Usual Activities C6D1 | 147 | -0.03 (Standard Deviation 0.81) |
| CAPOX+ Zolbetuximab Usual Activities C7D1 | 121 | 0.05 (Standard Deviation 0.81) |
| CAPOX+ Placebo Usual Activities C7D1 | 127 | -0.01 (Standard Deviation 0.83) |
| CAPOX+ Zolbetuximab Usual Activities C8D1 | 109 | 0.19 (Standard Deviation 0.76) |
| CAPOX+ Placebo Usual Activities C8D1 | 111 | 0.07 (Standard Deviation 0.82) |
| CAPOX+ Zolbetuximab Usual Activities C9D1 | 102 | 0.19 (Standard Deviation 0.78) |
| CAPOX+ Placebo Usual Activities C9D1 | 104 | -0.03 (Standard Deviation 0.82) |
| CAPOX+ Zolbetuximab Usual Activities C10D1 | 85 | 0.06 (Standard Deviation 0.75) |
| CAPOX+ Placebo Usual Activities C10D1 | 80 | 0.03 (Standard Deviation 0.89) |
| CAPOX+ Zolbetuximab Usual Activities C11D1 | 81 | 0.11 (Standard Deviation 0.72) |
| CAPOX+ Placebo Usual Activities C11D1 | 72 | -0.04 (Standard Deviation 0.74) |
| CAPOX+ Zolbetuximab Usual Activities C12D1 | 75 | 0.04 (Standard Deviation 0.71) |
| CAPOX+ Placebo Usual Activities C12D1 | 58 | -0.03 (Standard Deviation 0.94) |
| CAPOX+ Zolbetuximab Usual Activities C13D1 | 60 | 0.02 (Standard Deviation 0.79) |
| CAPOX+ Placebo Usual Activities C13D1 | 49 | 0.02 (Standard Deviation 0.80) |
| CAPOX+ Zolbetuximab Usual Activities C14D1 | 56 | 0.02 (Standard Deviation 0.73) |
| CAPOX+ Placebo Usual Activities C14D1 | 45 | 0.00 (Standard Deviation 0.64) |
| CAPOX+ Zolbetuximab Usual Activities C15D1 | 51 | 0.10 (Standard Deviation 0.67) |
| CAPOX+ Placebo Usual Activities C15D1 | 37 | -0.14 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Usual Activities C16D1 | 48 | 0.04 (Standard Deviation 0.65) |
| CAPOX+ Placebo Usual Activities C16D1 | 32 | -0.06 (Standard Deviation 0.56) |
| CAPOX+ Zolbetuximab Usual Activities C17D1 | 43 | 0.00 (Standard Deviation 0.65) |
| CAPOX+ Placebo Usual Activities C17D1 | 26 | -0.08 (Standard Deviation 0.63) |
| CAPOX+ Zolbetuximab Usual Activities C18D1 | 41 | 0.15 (Standard Deviation 0.57) |
| CAPOX+ Placebo Usual Activities C18D1 | 22 | -0.14 (Standard Deviation 0.77) |
| CAPOX+ Zolbetuximab Usual Activities C19D1 | 40 | 0.13 (Standard Deviation 0.61) |
| CAPOX+ Placebo Usual Activities C19D1 | 21 | -0.38 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Usual Activities C20D1 | 39 | 0.13 (Standard Deviation 0.57) |
| CAPOX+ Placebo Usual Activities C20D1 | 20 | -0.25 (Standard Deviation 0.79) |
| CAPOX+ Zolbetuximab Usual Activities C21D1 | 36 | 0.17 (Standard Deviation 0.51) |
| CAPOX+ Placebo Usual Activities C21D1 | 21 | -0.24 (Standard Deviation 0.70) |
| CAPOX+ Zolbetuximab Usual Activities C22D1 | 31 | 0.06 (Standard Deviation 0.44) |
| CAPOX+ Placebo Usual Activities C22D1 | 18 | -0.22 (Standard Deviation 0.65) |
| CAPOX+ Zolbetuximab Usual Activities C23D1 | 31 | 0.06 (Standard Deviation 0.51) |
| CAPOX+ Placebo Usual Activities C23D1 | 17 | -0.24 (Standard Deviation 0.66) |
| CAPOX+ Zolbetuximab Usual Activities C24D1 | 29 | 0.17 (Standard Deviation 0.47) |
| CAPOX+ Placebo Usual Activities C24D1 | 13 | -0.38 (Standard Deviation 0.87) |
| CAPOX+ Zolbetuximab Usual Activities C25D1 | 28 | 0.25 (Standard Deviation 0.52) |
| CAPOX+ Placebo Usual Activities C25D1 | 13 | -0.15 (Standard Deviation 0.99) |
| CAPOX+ Zolbetuximab Usual Activities C26D1 | 26 | 0.12 (Standard Deviation 0.43) |
| CAPOX+ Placebo Usual Activities C26D1 | 10 | -0.30 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Usual Activities C27D1 | 25 | 0.12 (Standard Deviation 0.44) |
| CAPOX+ Placebo Usual Activities C27D1 | 11 | -0.36 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Usual Activities C28D1 | 21 | 0.29 (Standard Deviation 0.56) |
| CAPOX+ Placebo Usual Activities C28D1 | 11 | -0.18 (Standard Deviation 0.75) |
| CAPOX+ Zolbetuximab Usual Activities C29D1 | 22 | 0.14 (Standard Deviation 0.56) |
| CAPOX+ Placebo Usual Activities C29D1 | 12 | -0.33 (Standard Deviation 0.65) |
| CAPOX+ Zolbetuximab Usual Activities C30D1 | 20 | 0.15 (Standard Deviation 0.59) |
| CAPOX+ Zolbetuximab Usual Activities C31D1 | 20 | 0.05 (Standard Deviation 0.51) |
| CAPOX+ Zolbetuximab Usual Activities C32D1 | 18 | 0.11 (Standard Deviation 0.76) |
| CAPOX+ Zolbetuximab Usual Activities C33D1 | 15 | -0.07 (Standard Deviation 0.59) |
| CAPOX+ Zolbetuximab Usual Activities C34D1 | 12 | -0.08 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Usual Activities C35D1 | 13 | 0.08 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Usual Activities C36D1 | 12 | -0.08 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Usual Activities C37D1 | 11 | 0.00 (Standard Deviation 0.77) |
| CAPOX+ Zolbetuximab Usual Activities C38D1 | 10 | 0.10 (Standard Deviation 0.57) |
| CAPOX+ Zolbetuximab Usual Activities C39D1 | 9 | 0.22 (Standard Deviation 0.44) |
| CAPOX+ Zolbetuximab Usual Activities 30 day follow up | 58 | 0.57 (Standard Deviation 1.16) |
| CAPOX+ Placebo Usual Activities 30 day follow up | 78 | 0.40 (Standard Deviation 0.93) |
| CAPOX+ Zolbetuximab Usual Activities 90 day follow up | 63 | 0.41 (Standard Deviation 0.87) |
| CAPOX+ Placebo Usual Activities 90 day follow up | 80 | 0.29 (Standard Deviation 0.94) |
| CAPOX+ Zolbetuximab Pain/Discomfort Baseline | 243 | 1.86 (Standard Deviation 0.86) |
| CAPOX+ Placebo Pain/Discomfort Baseline | 243 | 1.84 (Standard Deviation 0.84) |
| CAPOX+ Zolbetuximab Pain/Discomfort C2D1 | 208 | -0.17 (Standard Deviation 0.86) |
| CAPOX+ Placebo Pain/Discomfort C2D1 | 218 | -0.13 (Standard Deviation 0.88) |
| CAPOX+ Zolbetuximab Pain/Discomfort C3D1 | 183 | -0.21 (Standard Deviation 0.76) |
| CAPOX+ Placebo Pain/Discomfort C3D1 | 198 | -0.16 (Standard Deviation 0.75) |
| CAPOX+ Zolbetuximab Pain/Discomfort C4D1 | 169 | -0.26 (Standard Deviation 0.87) |
| CAPOX+ Placebo Pain/Discomfort C4D1 | 171 | -0.29 (Standard Deviation 0.91) |
| CAPOX+ Zolbetuximab Pain/Discomfort C5D1 | 159 | -0.23 (Standard Deviation 0.87) |
| CAPOX+ Placebo Pain/Discomfort C5D1 | 167 | -0.26 (Standard Deviation 0.90) |
| CAPOX+ Zolbetuximab Pain/Discomfort C6D1 | 149 | -0.18 (Standard Deviation 0.82) |
| CAPOX+ Placebo Pain/Discomfort C6D1 | 147 | -0.22 (Standard Deviation 0.99) |
| CAPOX+ Zolbetuximab Pain/Discomfort C7D1 | 121 | -0.26 (Standard Deviation 0.87) |
| CAPOX+ Placebo Pain/Discomfort C7D1 | 127 | -0.20 (Standard Deviation 0.83) |
| CAPOX+ Zolbetuximab Pain/Discomfort C8D1 | 109 | -0.23 (Standard Deviation 0.86) |
| CAPOX+ Placebo Pain/Discomfort C8D1 | 111 | -0.19 (Standard Deviation 0.89) |
| CAPOX+ Zolbetuximab Pain/Discomfort C9D1 | 102 | -0.14 (Standard Deviation 0.75) |
| CAPOX+ Placebo Pain/Discomfort C9D1 | 104 | -0.18 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Pain/Discomfort C10D1 | 85 | -0.19 (Standard Deviation 0.87) |
| CAPOX+ Placebo Pain/Discomfort C10D1 | 80 | -0.18 (Standard Deviation 0.91) |
| CAPOX+ Zolbetuximab Pain/Discomfort C11D1 | 81 | -0.28 (Standard Deviation 0.93) |
| CAPOX+ Placebo Pain/Discomfort C11D1 | 72 | -0.11 (Standard Deviation 0.96) |
| CAPOX+ Zolbetuximab Pain/Discomfort C12D1 | 75 | -0.19 (Standard Deviation 0.83) |
| CAPOX+ Placebo Pain/Discomfort C12D1 | 58 | -0.09 (Standard Deviation 0.90) |
| CAPOX+ Zolbetuximab Pain/Discomfort C13D1 | 60 | -0.25 (Standard Deviation 0.84) |
| CAPOX+ Placebo Pain/Discomfort C13D1 | 49 | 0.04 (Standard Deviation 0.89) |
| CAPOX+ Zolbetuximab Pain/Discomfort C14D1 | 56 | -0.36 (Standard Deviation 0.82) |
| CAPOX+ Placebo Pain/Discomfort C14D1 | 45 | -0.02 (Standard Deviation 0.78) |
| CAPOX+ Zolbetuximab Pain/Discomfort C15D1 | 51 | -0.27 (Standard Deviation 0.80) |
| CAPOX+ Placebo Pain/Discomfort C15D1 | 37 | 0.00 (Standard Deviation 0.88) |
| CAPOX+ Zolbetuximab Pain/Discomfort C16D1 | 48 | -0.35 (Standard Deviation 0.86) |
| CAPOX+ Placebo Pain/Discomfort C16D1 | 32 | -0.03 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Pain/Discomfort C17D1 | 43 | -0.26 (Standard Deviation 0.73) |
| CAPOX+ Placebo Pain/Discomfort C17D1 | 26 | 0.08 (Standard Deviation 0.98) |
| CAPOX+ Zolbetuximab Pain/Discomfort C18D1 | 41 | -0.15 (Standard Deviation 0.69) |
| CAPOX+ Placebo Pain/Discomfort C18D1 | 22 | 0.00 (Standard Deviation 0.93) |
| CAPOX+ Zolbetuximab Pain/Discomfort C19D1 | 40 | -0.15 (Standard Deviation 0.80) |
| CAPOX+ Placebo Pain/Discomfort C19D1 | 21 | -0.05 (Standard Deviation 0.50) |
| CAPOX+ Zolbetuximab Pain/Discomfort C20D1 | 39 | -0.05 (Standard Deviation 0.72) |
| CAPOX+ Placebo Pain/Discomfort C20D1 | 20 | -0.15 (Standard Deviation 0.99) |
| CAPOX+ Zolbetuximab Pain/Discomfort C21D1 | 36 | -0.22 (Standard Deviation 0.72) |
| CAPOX+ Placebo Pain/Discomfort C21D1 | 21 | -0.05 (Standard Deviation 0.80) |
| CAPOX+ Zolbetuximab Pain/Discomfort C22D1 | 31 | -0.16 (Standard Deviation 0.78) |
| CAPOX+ Placebo Pain/Discomfort C22D1 | 18 | -0.28 (Standard Deviation 0.89) |
| CAPOX+ Zolbetuximab Pain/Discomfort C23D1 | 31 | -0.16 (Standard Deviation 0.73) |
| CAPOX+ Placebo Pain/Discomfort C23D1 | 17 | -0.18 (Standard Deviation 1.01) |
| CAPOX+ Zolbetuximab Pain/Discomfort C24D1 | 29 | -0.14 (Standard Deviation 0.79) |
| CAPOX+ Placebo Pain/Discomfort C24D1 | 13 | 0.00 (Standard Deviation 1.08) |
| CAPOX+ Zolbetuximab Pain/Discomfort C25D1 | 28 | -0.14 (Standard Deviation 0.85) |
| CAPOX+ Placebo Pain/Discomfort C25D1 | 13 | 0.00 (Standard Deviation 1.08) |
| CAPOX+ Zolbetuximab Pain/Discomfort C26D1 | 26 | -0.19 (Standard Deviation 0.75) |
| CAPOX+ Placebo Pain/Discomfort C26D1 | 10 | 0.20 (Standard Deviation 0.63) |
| CAPOX+ Zolbetuximab Pain/Discomfort C27D1 | 25 | -0.16 (Standard Deviation 0.80) |
| CAPOX+ Placebo Pain/Discomfort C27D1 | 11 | 0.00 (Standard Deviation 0.45) |
| CAPOX+ Zolbetuximab Pain/Discomfort C28D1 | 21 | -0.29 (Standard Deviation 0.85) |
| CAPOX+ Placebo Pain/Discomfort C28D1 | 11 | 0.18 (Standard Deviation 0.75) |
| CAPOX+ Zolbetuximab Pain/Discomfort C29D1 | 22 | -0.14 (Standard Deviation 0.77) |
| CAPOX+ Placebo Pain/Discomfort C29D1 | 12 | -0.08 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Pain/Discomfort C30D1 | 20 | -0.30 (Standard Deviation 0.73) |
| CAPOX+ Zolbetuximab Pain/Discomfort C31D1 | 20 | -0.40 (Standard Deviation 0.68) |
| CAPOX+ Zolbetuximab Pain/Discomfort C32D1 | 18 | -0.33 (Standard Deviation 0.84) |
| CAPOX+ Zolbetuximab Pain/Discomfort C33D1 | 15 | -0.40 (Standard Deviation 0.74) |
| CAPOX+ Zolbetuximab Pain/Discomfort C34D1 | 12 | -0.33 (Standard Deviation 0.78) |
| CAPOX+ Zolbetuximab Pain/Discomfort C35D1 | 13 | -0.23 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Pain/Discomfort C36D1 | 12 | -0.42 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Pain/Discomfort C37D1 | 11 | -0.27 (Standard Deviation 0.65) |
| CAPOX+ Zolbetuximab Pain/Discomfort C38D1 | 10 | -0.30 (Standard Deviation 0.95) |
| CAPOX+ Zolbetuximab Pain/Discomfort C39D1 | 9 | -0.44 (Standard Deviation 0.53) |
| CAPOX+ Zolbetuximab Pain/Discomfort 30 day follow up | 58 | 0.29 (Standard Deviation 1.14) |
| CAPOX+ Placebo Pain/Discomfort 30 day follow up | 78 | 0.32 (Standard Deviation 0.95) |
| CAPOX+ Zolbetuximab Pain/Discomfort 90 day follow up | 63 | -0.03 (Standard Deviation 0.92) |
| CAPOX+ Placebo Pain/Discomfort 90 day follow up | 80 | 0.10 (Standard Deviation 0.94) |
| CAPOX+ Zolbetuximab Anxiety/Depression Baseline | 243 | 1.65 (Standard Deviation 0.82) |
| CAPOX+ Placebo Anxiety/Depression Baseline | 243 | 1.64 (Standard Deviation 0.77) |
| CAPOX+ Zolbetuximab Anxiety/Depression C2D1 | 208 | -0.01 (Standard Deviation 0.83) |
| CAPOX+ Placebo Anxiety/Depression C2D1 | 218 | -0.11 (Standard Deviation 0.79) |
| CAPOX+ Zolbetuximab Anxiety/Depression C3D1 | 183 | -0.05 (Standard Deviation 0.68) |
| CAPOX+ Placebo Anxiety/Depression C3D1 | 198 | -0.01 (Standard Deviation 0.88) |
| CAPOX+ Zolbetuximab Anxiety/Depression C4D1 | 169 | -0.04 (Standard Deviation 0.74) |
| CAPOX+ Placebo Anxiety/Depression C4D1 | 171 | -0.08 (Standard Deviation 0.89) |
| CAPOX+ Zolbetuximab Anxiety/Depression C5D1 | 159 | -0.08 (Standard Deviation 0.77) |
| CAPOX+ Placebo Anxiety/Depression C5D1 | 167 | -0.07 (Standard Deviation 0.98) |
| CAPOX+ Zolbetuximab Anxiety/Depression C6D1 | 149 | -0.07 (Standard Deviation 0.75) |
| CAPOX+ Placebo Anxiety/Depression C6D1 | 147 | 0.00 (Standard Deviation 0.88) |
| CAPOX+ Zolbetuximab Anxiety/Depression C7D1 | 121 | -0.04 (Standard Deviation 0.80) |
| CAPOX+ Placebo Anxiety/Depression C7D1 | 127 | -0.04 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Anxiety/Depression C8D1 | 109 | -0.02 (Standard Deviation 0.77) |
| CAPOX+ Placebo Anxiety/Depression C8D1 | 111 | 0.06 (Standard Deviation 0.83) |
| CAPOX+ Zolbetuximab Anxiety/Depression C9D1 | 102 | -0.05 (Standard Deviation 0.81) |
| CAPOX+ Placebo Anxiety/Depression C9D1 | 104 | 0.03 (Standard Deviation 0.83) |
| CAPOX+ Zolbetuximab Anxiety/Depression C10D1 | 85 | -0.13 (Standard Deviation 0.84) |
| CAPOX+ Placebo Anxiety/Depression C10D1 | 80 | 0.13 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Anxiety/Depression C11D1 | 81 | -0.11 (Standard Deviation 0.81) |
| CAPOX+ Placebo Anxiety/Depression C11D1 | 72 | 0.21 (Standard Deviation 0.98) |
| CAPOX+ Zolbetuximab Anxiety/Depression C12D1 | 75 | -0.11 (Standard Deviation 0.83) |
| CAPOX+ Placebo Anxiety/Depression C12D1 | 58 | 0.17 (Standard Deviation 0.99) |
| CAPOX+ Zolbetuximab Anxiety/Depression C13D1 | 60 | -0.12 (Standard Deviation 0.74) |
| CAPOX+ Placebo Anxiety/Depression C13D1 | 49 | 0.20 (Standard Deviation 0.87) |
| CAPOX+ Zolbetuximab Anxiety/Depression C14D1 | 56 | -0.07 (Standard Deviation 0.78) |
| CAPOX+ Placebo Anxiety/Depression C14D1 | 45 | 0.22 (Standard Deviation 0.85) |
| CAPOX+ Zolbetuximab Anxiety/Depression C15D1 | 51 | -0.02 (Standard Deviation 0.62) |
| CAPOX+ Placebo Anxiety/Depression C15D1 | 37 | 0.19 (Standard Deviation 0.84) |
| CAPOX+ Zolbetuximab Anxiety/Depression C16D1 | 48 | 0.00 (Standard Deviation 0.71) |
| CAPOX+ Placebo Anxiety/Depression C16D1 | 32 | 0.06 (Standard Deviation 0.62) |
| CAPOX+ Zolbetuximab Anxiety/Depression C17D1 | 43 | 0.05 (Standard Deviation 0.72) |
| CAPOX+ Placebo Anxiety/Depression C17D1 | 26 | 0.15 (Standard Deviation 0.67) |
| CAPOX+ Zolbetuximab Anxiety/Depression C18D1 | 41 | 0.12 (Standard Deviation 0.78) |
| CAPOX+ Placebo Anxiety/Depression C18D1 | 22 | 0.00 (Standard Deviation 0.69) |
| CAPOX+ Zolbetuximab Anxiety/Depression C19D1 | 40 | -0.10 (Standard Deviation 0.78) |
| CAPOX+ Placebo Anxiety/Depression C19D1 | 21 | -0.05 (Standard Deviation 0.38) |
| CAPOX+ Zolbetuximab Anxiety/Depression C20D1 | 39 | -0.03 (Standard Deviation 0.71) |
| CAPOX+ Placebo Anxiety/Depression C20D1 | 20 | 0.05 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Anxiety/Depression C21D1 | 36 | -0.03 (Standard Deviation 0.84) |
| CAPOX+ Placebo Anxiety/Depression C21D1 | 21 | -0.05 (Standard Deviation 0.59) |
| CAPOX+ Zolbetuximab Anxiety/Depression C22D1 | 31 | -0.10 (Standard Deviation 0.54) |
| CAPOX+ Placebo Anxiety/Depression C22D1 | 18 | 0.17 (Standard Deviation 0.71) |
| CAPOX+ Zolbetuximab Anxiety/Depression C23D1 | 31 | -0.03 (Standard Deviation 0.71) |
| CAPOX+ Placebo Anxiety/Depression C23D1 | 17 | 0.18 (Standard Deviation 0.95) |
| CAPOX+ Zolbetuximab Anxiety/Depression C24D1 | 29 | -0.10 (Standard Deviation 0.62) |
| CAPOX+ Placebo Anxiety/Depression C24D1 | 13 | 0.00 (Standard Deviation 0.58) |
| CAPOX+ Zolbetuximab Anxiety/Depression C25D1 | 28 | 0.11 (Standard Deviation 1.03) |
| CAPOX+ Placebo Anxiety/Depression C25D1 | 13 | 0.15 (Standard Deviation 0.55) |
| CAPOX+ Zolbetuximab Anxiety/Depression C26D1 | 26 | 0.00 (Standard Deviation 0.80) |
| CAPOX+ Placebo Anxiety/Depression C26D1 | 10 | 0.20 (Standard Deviation 0.42) |
| CAPOX+ Zolbetuximab Anxiety/Depression C27D1 | 25 | 0.00 (Standard Deviation 1.04) |
| CAPOX+ Placebo Anxiety/Depression C27D1 | 11 | 0.09 (Standard Deviation 0.30) |
| CAPOX+ Zolbetuximab Anxiety/Depression C28D1 | 21 | 0.14 (Standard Deviation 1.06) |
| CAPOX+ Placebo Anxiety/Depression C28D1 | 11 | 0.09 (Standard Deviation 0.30) |
| CAPOX+ Zolbetuximab Anxiety/Depression C29D1 | 22 | -0.09 (Standard Deviation 0.97) |
| CAPOX+ Placebo Anxiety/Depression C29D1 | 12 | 0.25 (Standard Deviation 0.45) |
| CAPOX+ Zolbetuximab Anxiety/Depression C30D1 | 20 | -0.10 (Standard Deviation 0.85) |
| CAPOX+ Zolbetuximab Anxiety/Depression C31D1 | 20 | 0.00 (Standard Deviation 1.08) |
| CAPOX+ Zolbetuximab Anxiety/Depression C32D1 | 18 | -0.17 (Standard Deviation 0.86) |
| CAPOX+ Zolbetuximab Anxiety/Depression C33D1 | 15 | -0.07 (Standard Deviation 0.88) |
| CAPOX+ Zolbetuximab Anxiety/Depression C34D1 | 12 | -0.42 (Standard Deviation 0.51) |
| CAPOX+ Zolbetuximab Anxiety/Depression C35D1 | 13 | -0.23 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Anxiety/Depression C36D1 | 12 | -0.25 (Standard Deviation 0.45) |
| CAPOX+ Zolbetuximab Anxiety/Depression C37D1 | 11 | -0.45 (Standard Deviation 0.52) |
| CAPOX+ Zolbetuximab Anxiety/Depression C38D1 | 10 | -0.60 (Standard Deviation 0.84) |
| CAPOX+ Zolbetuximab Anxiety/Depression C39D1 | 9 | -0.11 (Standard Deviation 0.60) |
| CAPOX+ Zolbetuximab Anxiety/Depression 30 day follow up | 58 | 0.41 (Standard Deviation 1.27) |
| CAPOX+ Placebo Anxiety/Depression 30 day follow up | 78 | 0.45 (Standard Deviation 1.00) |
| CAPOX+ Zolbetuximab Anxiety/Depression 90 day follow up | 63 | 0.10 (Standard Deviation 0.76) |
| CAPOX+ Placebo Anxiety/Depression 90 day follow up | 80 | 0.24 (Standard Deviation 1.00) |
| CAPOX+ Zolbetuximab Visual Analog Scale Baseline | 243 | 71.50 (Standard Deviation 19.60) |
| CAPOX+ Placebo Visual Analog Scale Baseline | 243 | 72.65 (Standard Deviation 18.73) |
| CAPOX+ Zolbetuximab Visual Analog Scale C2D1 | 208 | 3.01 (Standard Deviation 15.83) |
| CAPOX+ Placebo Visual Analog Scale C2D1 | 218 | 1.67 (Standard Deviation 13.60) |
| CAPOX+ Zolbetuximab Visual Analog Scale C3D1 | 183 | 2.17 (Standard Deviation 15.19) |
| CAPOX+ Placebo Visual Analog Scale C3D1 | 198 | 2.07 (Standard Deviation 14.70) |
| CAPOX+ Zolbetuximab Visual Analog Scale C4D1 | 169 | 3.89 (Standard Deviation 16.60) |
| CAPOX+ Placebo Visual Analog Scale C4D1 | 171 | 3.27 (Standard Deviation 18.37) |
| CAPOX+ Zolbetuximab Visual Analog Scale C5D1 | 159 | 1.50 (Standard Deviation 17.20) |
| CAPOX+ Placebo Visual Analog Scale C5D1 | 167 | 3.74 (Standard Deviation 17.32) |
| CAPOX+ Zolbetuximab Visual Analog Scale C6D1 | 149 | 1.18 (Standard Deviation 17.61) |
| CAPOX+ Placebo Visual Analog Scale C6D1 | 147 | 1.95 (Standard Deviation 15.93) |
| CAPOX+ Zolbetuximab Visual Analog Scale C7D1 | 121 | 3.21 (Standard Deviation 15.60) |
| CAPOX+ Placebo Visual Analog Scale C7D1 | 127 | 2.73 (Standard Deviation 19.74) |
| CAPOX+ Zolbetuximab Visual Analog Scale C8D1 | 109 | 3.22 (Standard Deviation 19.72) |
| CAPOX+ Placebo Visual Analog Scale C8D1 | 111 | 1.73 (Standard Deviation 17.82) |
| CAPOX+ Zolbetuximab Visual Analog Scale C9D1 | 102 | 0.96 (Standard Deviation 17.32) |
| CAPOX+ Placebo Visual Analog Scale C9D1 | 104 | 2.49 (Standard Deviation 18.01) |
| CAPOX+ Zolbetuximab Visual Analog Scale C10D1 | 85 | 2.88 (Standard Deviation 20.07) |
| CAPOX+ Placebo Visual Analog Scale C10D1 | 80 | 1.48 (Standard Deviation 17.73) |
| CAPOX+ Zolbetuximab Visual Analog Scale C11D1 | 81 | -1.12 (Standard Deviation 18.13) |
| CAPOX+ Placebo Visual Analog Scale C11D1 | 72 | 1.50 (Standard Deviation 18.57) |
| CAPOX+ Zolbetuximab Visual Analog Scale C12D1 | 75 | 2.89 (Standard Deviation 21.70) |
| CAPOX+ Placebo Visual Analog Scale C12D1 | 58 | 1.36 (Standard Deviation 24.31) |
| CAPOX+ Zolbetuximab Visual Analog Scale C13D1 | 60 | 4.30 (Standard Deviation 17.81) |
| CAPOX+ Placebo Visual Analog Scale C13D1 | 49 | 0.88 (Standard Deviation 20.52) |
| CAPOX+ Zolbetuximab Visual Analog Scale C14D1 | 56 | 5.68 (Standard Deviation 25.25) |
| CAPOX+ Placebo Visual Analog Scale C14D1 | 45 | 2.20 (Standard Deviation 23.17) |
| CAPOX+ Zolbetuximab Visual Analog Scale C15D1 | 51 | 4.61 (Standard Deviation 23.63) |
| CAPOX+ Placebo Visual Analog Scale C15D1 | 37 | -1.84 (Standard Deviation 19.58) |
| CAPOX+ Zolbetuximab Visual Analog Scale C16D1 | 48 | 2.40 (Standard Deviation 18.26) |
| CAPOX+ Placebo Visual Analog Scale C16D1 | 32 | 3.44 (Standard Deviation 25.37) |
| CAPOX+ Zolbetuximab Visual Analog Scale C17D1 | 43 | 6.07 (Standard Deviation 24.08) |
| CAPOX+ Placebo Visual Analog Scale C17D1 | 26 | 2.35 (Standard Deviation 13.65) |
| CAPOX+ Zolbetuximab Visual Analog Scale C18D1 | 41 | 8.49 (Standard Deviation 24.62) |
| CAPOX+ Placebo Visual Analog Scale C18D1 | 22 | 4.59 (Standard Deviation 12.68) |
| CAPOX+ Zolbetuximab Visual Analog Scale C19D1 | 40 | 5.08 (Standard Deviation 21.11) |
| CAPOX+ Placebo Visual Analog Scale C19D1 | 21 | 5.95 (Standard Deviation 10.28) |
| CAPOX+ Zolbetuximab Visual Analog Scale C20D1 | 39 | 2.97 (Standard Deviation 25.52) |
| CAPOX+ Placebo Visual Analog Scale C20D1 | 20 | 4.15 (Standard Deviation 14.14) |
| CAPOX+ Zolbetuximab Visual Analog Scale C21D1 | 36 | 0.69 (Standard Deviation 19.39) |
| CAPOX+ Placebo Visual Analog Scale C21D1 | 21 | 6.29 (Standard Deviation 10.93) |
| CAPOX+ Zolbetuximab Visual Analog Scale C22D1 | 31 | 3.55 (Standard Deviation 15.24) |
| CAPOX+ Placebo Visual Analog Scale C22D1 | 18 | 3.28 (Standard Deviation 13.40) |
| CAPOX+ Zolbetuximab Visual Analog Scale C23D1 | 31 | 3.55 (Standard Deviation 14.93) |
| CAPOX+ Placebo Visual Analog Scale C23D1 | 17 | 4.12 (Standard Deviation 16.03) |
| CAPOX+ Zolbetuximab Visual Analog Scale C24D1 | 29 | 5.17 (Standard Deviation 16.19) |
| CAPOX+ Placebo Visual Analog Scale C24D1 | 13 | 6.85 (Standard Deviation 14.15) |
| CAPOX+ Zolbetuximab Visual Analog Scale C25D1 | 28 | 1.43 (Standard Deviation 20.29) |
| CAPOX+ Placebo Visual Analog Scale C25D1 | 13 | 7.15 (Standard Deviation 12.08) |
| CAPOX+ Zolbetuximab Visual Analog Scale C26D1 | 26 | 4.15 (Standard Deviation 16.83) |
| CAPOX+ Placebo Visual Analog Scale C26D1 | 10 | 1.20 (Standard Deviation 12.84) |
| CAPOX+ Zolbetuximab Visual Analog Scale C27D1 | 25 | 0.20 (Standard Deviation 20.58) |
| CAPOX+ Placebo Visual Analog Scale C27D1 | 11 | 4.73 (Standard Deviation 4.82) |
| CAPOX+ Zolbetuximab Visual Analog Scale C28D1 | 21 | 2.90 (Standard Deviation 18.30) |
| CAPOX+ Placebo Visual Analog Scale C28D1 | 11 | 2.36 (Standard Deviation 6.02) |
| CAPOX+ Zolbetuximab Visual Analog Scale C29D1 | 22 | 3.73 (Standard Deviation 15.74) |
| CAPOX+ Placebo Visual Analog Scale C29D1 | 12 | 3.58 (Standard Deviation 5.95) |
| CAPOX+ Zolbetuximab Visual Analog Scale C30D1 | 20 | 0.75 (Standard Deviation 15.87) |
| CAPOX+ Zolbetuximab Visual Analog Scale C31D1 | 20 | 1.60 (Standard Deviation 16.83) |
| CAPOX+ Zolbetuximab Visual Analog Scale C32D1 | 18 | 2.00 (Standard Deviation 15.78) |
| CAPOX+ Zolbetuximab Visual Analog Scale C33D1 | 15 | 6.80 (Standard Deviation 17.07) |
| CAPOX+ Zolbetuximab Visual Analog Scale C34D1 | 12 | 8.33 (Standard Deviation 17.91) |
| CAPOX+ Zolbetuximab Visual Analog Scale C35D1 | 13 | 5.77 (Standard Deviation 16.63) |
| CAPOX+ Zolbetuximab Visual Analog Scale C36D1 | 12 | 4.17 (Standard Deviation 17.20) |
| CAPOX+ Zolbetuximab Visual Analog Scale C37D1 | 11 | 10.73 (Standard Deviation 14.55) |
| CAPOX+ Zolbetuximab Visual Analog Scale C38D1 | 10 | 7.10 (Standard Deviation 17.70) |
| CAPOX+ Zolbetuximab Visual Analog Scale C39D1 | 9 | 10.22 (Standard Deviation 11.42) |
| CAPOX+ Zolbetuximab Visual Analog Scale 30 day follow up | 58 | -7.79 (Standard Deviation 23.72) |
| CAPOX+ Placebo Visual Analog Scale 30 day follow up | 78 | -8.63 (Standard Deviation 20.32) |
| CAPOX+ Zolbetuximab Visual Analog Scale 90 day follow up | 63 | -5.24 (Standard Deviation 19.73) |
| CAPOX+ Placebo Visual Analog Scale 90 day follow up | 80 | -4.34 (Standard Deviation 19.79) |
Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)
Secondary outcome · Mean, micrograms/mililiter (ug/mL) · Predose on C2D1,C5D1,C9D1,C13D1,C17D1
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab C2D1 | 217 | 38.6 (Standard Deviation 31.3) |
| CAPOX+ Zolbetuximab C5D1 | 160 | 74.1 (Standard Deviation 51.6) |
| CAPOX+ Zolbetuximab C9D1 | 92 | 99.6 (Standard Deviation 58.2) |
| CAPOX+ Zolbetuximab C13D1 | 52 | 119.0 (Standard Deviation 55.6) |
| CAPOX+ Zolbetuximab C17D1 | 37 | 147.0 (Standard Deviation 70.5) |
Number of Anti-drug Antibody (ADA) Positive Participants
Secondary outcome · Number, Participants · Predose on C1D1,C2D1,C5D1,C9D1,C13D1,C17D1, 30-day follow up, 90-day Follow up
| Group | Analysed | Value |
|---|---|---|
| CAPOX+ Zolbetuximab C1D1 | 249 | 4 |
| CAPOX+ Zolbetuximab C2D2 | 212 | 8 |
| CAPOX+ Zolbetuximab C5D1 | 159 | 2 |
| CAPOX+ Zolbetuximab C9D1 | 92 | 1 |
| CAPOX+ Zolbetuximab C13D1 | 54 | 0 |
| CAPOX+ Zolbetuximab C17D1 | 38 | 0 |
| CAPOX+ Zolbetuximab 30 Day follow up | 64 | 5 |
| CAPOX+ Zolbetuximab 90 Day follow up | 46 | 1 |